Publications of
Green Lane Hospital
1942 – 2003
Editor: Nigel Wilson
CD ROM Compilation: Teena West
PCCS publications, Auckland, New Zealand, October 2003
Preface
Green Lane Hospital. The first healthcare institution on the Green Lane site was
the beautiful Costley “Refuge For The Aged Poor”, opened in 1890. Infirmary
Wards were added in 1907, and extended in 1925 and 1936. Later features were
the remarkable “shelters” in 1914 for TB patients, and the recycled USA South
Pacific Army Hospital of 1943. Green Lane Hospital first admitted patients in
1942. At the end of 2003 inpatient care will move to the Grafton site of hospitals.
The history of the evolution of Green Lane Hospital has been chronicled in
several books previously.
Not surprisingly there has been a rapid evolution of medical care and technology
over the decades at Green Lane Hospital. More remarkable is how often Green
Lane has been at the forefront of original medical research and development both
in New Zealand and internationally. It seemed appropriate to record the academic
output of the hospital in a single collection. Publications from Green Lane have
predominantly come from clinicians in whole or part-time hospital practice. That
there were few academic posts or links with the Auckland medical school makes
the contribution from Green Lane even more remarkable.
There were two main ideas for this book. The first aim was to produce a book
which is unashamedly a retrospective salute to the academic contribution of
Green Lane Hospital. Bound in a form which could be on the bookshelf or coffee
table, the book should be an easy reference to browse through, reminisce and
even show off to those interested.
The second aim was to provide a computer based template of publications for
departments or individuals to use prospectively with a reference manager or an
equivalent electronic indexing system. The microchip will enable use of the list of
publications in a variety of ways. For example a new registrar or fellow, on arrival
to the department, could be given the updated data base as an introduction to the
department. Too often trainees and even new consultants are unaware of
previous areas of research and development of their colleagues. Those new to
reference manager systems can build on this initial collection.
It was decided that books, chapters and refereed journal articles would be
included in the book but letters and non-refereed articles would not. After
discussion with various colleagues sections were chosen rather than recording
the list of journals chronologically or alphabetically by first author. Some articles
that have been allocated to a particular section could have appeared in one or
other alternate sections equally appropriately eg. many of the publications of the
“Heart Valve” section includes journal articles that could aptly fit in cardiac
surgery, pathology or cardiology. This is the strength of a computerised reference
system: an individual can arrange and rearrange the articles to suit oneself.
2
Many non-refereed articles are very useful monologues, for example Heart
Foundation Technical series and Patient Management publications. Whilst not
included in this book, such non-refereed articles can easily be included in a
department’s or individual’s indexing system.
The book could not have been completed as promptly without help from many: in
particular Barbara Semb, Kay O’Driscoll, Basil Hutchinson, John Kolbe, Peter
Ruygrok and Pat Clarkson. Finally I am indebted to Teena West for her time and
skills to bring the project to its culmination in electronic form.
Nigel Wilson
GLH
October, 2003
3
Contents
Books and Theses……………………………………………………………..….. 5
Early Years 1942-1960s ……………………………………………….……..…...7
Anaesthesia and Perfusion…………………….…………………………………13
Adult Cardiology
Arrhythmias, Electophysiology and Pacing…………….…………..……. 18
Cardiac transplantation…………………………………...……………….. 21
Coronary artery disease…………………………………………………… 22
General cardiology…………………………………………………………. 51
Inherited cardiac diseases (Includes surgery for HCM)……….………. 55
Interventional cardiac catheterisation …………………….……………... 56
Imaging (Includes echocardiography,
cineangiography, MRI, nuclear, CT)………………………………… 60
Drugs and therapeutics …………………………………………………… 63
Cardio-Thoracic Surgery………………………………….……………………... 65
General Medicine and General Surgery……………………………………… ...69
Heart Valves: Development from GLH…………......….………………………. 73
Otolaryngology……………………………….…….…………………………….. 79
Paediatric and Congenital Cardiac……………………………………………... 85
Pathology………………………………………………………………………….. 95
Physiology………………………………………….……………………………... 98
Politics, GLH History and Health Economics (Including the Harris/
Neutze/Merry/White advocacy letters)…………….…………………….101
Respiratory
Asthma……………………………………..…………………………… ….. 105
COPD…………………………………………………………………………… …. 110
Tuberculosis ………………………………..………………………… …… . 111
Cystic fibrosis/bronchiectasis/
diffuse parenchymal disease………………………………… …… 113
Lung Cancer/pleural/sleep…………………..……………………… ……… 115
General ………………………………………………………………… …. .. 117
Rheumatic Heart Disease (adult and paediatric)………………………… ……119
Subject headings key words for CD Rom……………………………………….121
4
Books and Theses
1.
Robb D. Medical Odyssey: An Autobiography. London: Collins, 1967.
2.
Harris EA, Neutze JM, Seelye ER, Simpson M, Rickard MP. Intensive care of the
heart and lungs: a text for nurses. Oxford: Blackwell Scientific Publications, 1972.
3.
Barratt-Boyes BG, Neutze JM, Harris EA. Heart disease in infancy: diagnosis and
surgical treatment. Edinburgh: Churchill Livingstone, 1973.
4.
Harris EA, Neutze JM, Seelye ER, Simpson M, Rickard MP. Intensive care of the
heart and lungs. Oxford: Blackwell Scientific Publications, 1975.
5.
Neutze JM, Moller J, Harris EA, Horsburgh MP. Intensive care of the heart and
lungs. Oxford: Blackwell Scientific Publications, 1982.
6.
Norris RM. Myocardial infarction: its presentation, pathogenesis and treatment.
Edinburgh: Churchill Livingstone, 1982.
7.
Roche EH, Roche AH. Green Lane Saga. Auckland: Richards, 1983.
8.
Kirklin JW, Barratt-Boyes BG. Textbook of Cardiac Surgery. New York: John
Wiley & Son, 1986.
9.
Greaves SC. Hypertrophic Cardiomyopathy. Auckland: University of Auckland,
1987:148.
10.
Neutze JM. The Green Lane Heart Book. Auckland: David Bateman, 1989.
11.
Hutchinson BR. Green Lane Hospital, the first hundred years. Auckland: Green
Lane Hospital Centennial Committee, 1990.
12.
Kolbe J, Reid IR. North-Nanson Clinical Manual. Auckland: University of
Auckland, 1992.
13.
Kirklin JW, Barratt-Boyes BG. Textbook of Cardiac Surgery. New York: Churchill
Livingstone, 1993.
14.
White HD. The prognostic importance of left ventricular end systolic volume and
infarct artery patency, and the effects of thrombolytic therapy. Dunedin: University
of Otago, 1995.
15.
Skinner JR, Alvarson D, Hunter S. Echocardiography for the Neonatologist:
Churchill Livingstome, 2000.
16.
Hancox RJ, Whyte KF. Interpreting lung function tests: explanations without
equations. Sydney: McGraw Hill, 2001.
17.
Merry AF, McCall Smith A. Errors, Medicine, and the Law: Cambridge University
Press, 2001.
18.
Spinetto H. The Auckland Rheumatic Fever Register 1993-1999: An Audit.
Department of Nursing. Auckland: University of Auckland, 2002.
19.
White H, de Feijter P, Meier B, Colombo A, Banning A, Schrader R. The year in
interventional cardiology 2002. Oxford: Clinical Publishing Services Limited, 2002.
20.
Williams BF. Informed consent for participation in clinical trials at hosptalisation
for acute myocardial infarction. Auckland: Auckland University of Technology,
2002.
21.
Kouchoukos NT, Blackstone E, Doty DB, Hanley FL, Karp RB. Kirklin/BarrattBoyes Cardiac Surgery. New York: Churchill Livingstone, 2003.
5
22.
Ruygrok PN. Clinical and Angiographic Outcome Following Percutaneous
Coronary Intervention. Auckland: University of Auckland, 2003.
23.
Sidebotham D, Merry A, Legget M. Practical Perioperative Transesophageal
Echocardiography. London: Elsevier, 2003.
24.
Webber B, Fleming JM, West T, White HD. The influence of clinical variables on
coronary artery blood flow, as assessed by frame counting, in patients with
normal coronary arteries and disease coronary arteries. Auckland: Auckland
University of Technology, 2003.
6
Early Years 1942-1960s
1.
McKechnie WR, Guthrie DW, Robb D. Peripheral aneurysms of traumatic origin:
Cases occurring in brachial, radial and ulna arteries. Aust N Z J Surg 1942;
12:147-148.
2.
Robb D. Wanted a precipitant. N Z Med J 1943:26-30.
3.
Robb D. heart disease due to thyrotoxicosis. N Z Med J 1943; 42:268-269.
4.
Roche E. Lobar pneumonia treated with penecillin. N Z Med J 1943; 42:283.
5.
Robb D. Empyema thoracis. N Z Med J 1944; 43:159-164.
6.
Robb D. Anaemia treated surgically. N Z Med J 1944; 43:198-199.
7.
Roche E. Agranulocytosis following phenacetin, phenazone and gold. N Z Med J
1944; 43:99-100.
8.
Robb D. Current thoughts on carcinoma of rectum. N Z Med J 1945; 44:296-303.
9.
Robb D. Health insurance in New Zealand. Can Med Assoc J 1945; 52:81-86.
10.
Robb D. A case of hydatid choloperitoneum. Med J Aust 1945; 1:504-394.
11.
Robb D. Resection of pulmonary tissue in tuberculosis. N Z Med J 1945; 44:197199.
12.
Roche E. Landry's paralysis. N Z Med J 1945; 44:200.
13.
Roche E. An obscure cerebral lesion with unusual sequel in a male aged 17. N Z
Med J 1945; 44:41.
14.
Lewis PJ, Hunt SR. Brachial plexus block. New Zealand Medical Journal 1946;
45:535-540.
15.
Robb D. Place of hospitals in medical affairs. N Z Med J 1946; 45:185-187.
16.
Robb D. Resection of pulmonary tissue in tuberculosis. Aust N Z J Surg 1946;
15:212-216.
17.
Robb D, MacDonald E. Advanced cardiospasm. Aust N Z J Surg 1946; 15:219222.
18.
Robb D. Group practice. N Z Med J 1946; 45:402-404.
19.
Roche E. Anterior mediastinal tumor with superior mediastinal obstruction. N Z
Med J 1946; 45:487-488.
20.
Roche E. The electrocardiogram in coronary disease. N Z Med J 1946; 45:331342.
21.
Anson GFV. Curare in Anaesthesia. N Z Med J 1947; 46:9-15.
22.
McDowell C. Dynamic postural drainage. An improved method in the treatment of
bronchiectasis. N Z Med J 1947; 46:410-412.
23.
Roche EH. A clinical study of congenital heart disease. N Z Med J 1947; 46:375385.
24.
Roche EH. Anticoagulants in medicine. N Z Med J 1947; 46:404.
25.
Robb D, R N. Advanced cardiospasm: 3 cases in which operation by thoracic
route was performed. Aust N Z J Surg 1948; 18:133-134.
7
26.
Robb D. Pulmonary resection for metastatic malignancy: 3 cases secondary to
hypernephroma. Br J Surg 1948; 36:200-202.
27.
Robb D. Point of technique in pulmonary lobectomy. Aust N Z J Surg 1948;
18:49-50.
28.
Robb D. Education for medicine. N Z Med J 1948; 47:151-155.
29.
Roche EH. A clinical study of congenital heart disease. N Z Med J 1948; 40.
30.
Klein N. Note on an improvised simultaneous bi-plane fluoroscopy. Brit J Radiol
1949; 22:346.
31.
Robb D. Cardiovascular surgery. N Z Med J 1949; 48:566-569.
32.
Robb D. Segmental pulmonary resection. Aust N Z J Surg 1949; 18:217-223.
33.
Robb D. Surgical aspects of congenital heart disease. N Z Med J 1949; 48:26-31.
34.
Roche E. Acute myocardial infarction in a boy aged 15 years. N Z Med J 1949;
48:602-603.
35.
Coombes AC, Roche EH. A fatal case of delayed hypersensitivity (anaphylactic)
reaction to a test dose of vasidone. Br Heart J 1950; 12:369-362.
36.
Hunt SR. Headache after spinal anaesthesia. New Zealand Medical Journal
1950; 49:414.
37.
Klein N. A prolapsed lipoma in the duodenal bulb. Brit J Radiol 1950; 23:233-235.
38.
Robb D. New Zealand health scheme. Postgrad Med J. 1950; 26:277-282.
39.
Roche E. Coronary spasm. N Z Med J 1950:584-585.
40.
Webster F. Gastro-jejuno-colic fistula. N Z Med J 1950; 49:590-592.
41.
Webster F. Interinnomino-abdominal amputation. N Z Med J 1950; 49:50-51.
42.
McDowell C, Robb D, Hinds JR, Nicks R. Case of intralobar sequestration of the
lung associated with an abnormal pulmonary artery. Br J Surg 1951; 39:87-89.
43.
Roche EH. Mitral valvotomy. N Z Med J 1951; 50:276.
44.
Webster FE. Carcinoma of thyroid. N Z Med J 1951; 59:393-394.
45.
Robb D, Nicks R. Surgical treatment of patent ductus arteriosus: report on 82
cases. N Z Med J 1952; 51:31-34.
46.
Robb D. Congenital tracheo-oesophageal fistula without atresia but with large
oesophageal diverticulum. Aust N Z J Surg 1952; 22:120-122.
47.
Roche EH. Some clinical observations on the apical systolic murmur. N Z Med J
1952; 51:390-393.
48.
Nicks R. The surgery of pulmonary tuberculosis. N Z Med J 1953; 52:366-371.
49.
Robb D. Malignant disease in association with hiatus hernia and thoracic
stomach. J Thorac Surg 1953; 25:493-494.
50.
Robb D. The doctor himself. Med J Aust 1953; 50:72-74.
51.
Robb D. Medical research in New zealand. NZ Sci Rev 1953; 11:39-41.
52.
Robb D. Hiatus hernia and oesophageal reflux. Med J Aust 1953; 1:824-825.
53.
Robb D. Surgical aspects of mitral stenosis. N Z Med J 1953; 52:168-170.
54.
Roche EH. Cyanotic heart disease with continuous murmur. Aust Ann Med 1953;
2:17-21.
8
55.
Fisher A. Early operation in acute cholecystitis. N Z Med J 1954; 53:267-270.
56.
Newman J. The physician and the potter. N Z Med J 1954; 53:347-352.
57.
Nicks R. Congenital pulmonary stenosis. N Z Med J 1954; 53:10-18.
58.
Robb D. Diaphragmatic hernia and the chest physician. N Z Med J 1954; 54:3135.
59.
Robb D. Mitral stenosis treated surgically: report of 35 further cases. N Z Med J
1954; 53:239-242.
60.
Roche EH. Arthur Guyon Purchas. A New Zealand pioneer. N Z Med J 1954;
53:203-209.
61.
Hinds JR. Agammaglobulinaemia: report of a case. N Z Med J 1955; 54:679-682.
62.
McDowell C, Robb D, Hinds JR. Two cases of intralobar sequestration of the
lung. Thorax 1955; 10:73-78.
63.
Molloy PJ. Pericardial hydatid cysts. N Z Med J 1955; 54:267-270.
64.
Nicks R. Hypothermia. Aust N Z J Surg 1955; 25:31-40.
65.
Nicks R, Caughey RH. Congenital oesphageal atresia. N Z Med J 1955; 54:682685.
66.
Nicks R. Experimental arterial grafting. N Z Med J 1955; 54:154-158.
67.
Nicks R, Watt J. Tracheal stenosis:report on one case of relief and reconstruction.
Brit J Radiol 1955; 42:398-400.
68.
Nicks R. Tracheal stenosis. Br J Surg 1955; 42:398-400.
69.
Robb D. Research in medical practice. N Z Med J 1955; 54:466-469.
70.
Roche EH. The clinical evaluation of systolic murmurs. N Z Med J 1955; 54:674678.
71.
Sinclair JD. The progress of pulmonary deficiency in emphysema. Brit J Tuberc
1955; 49:157-165.
72.
Sinclair JD. Spontaneous pneumothorax. A review of seventy cases. N Z Med J
1955; 54:51-57.
73.
Hunter AF. Co-existent seminoma and teratoma of the testis. Aust N Z J Surg
1956; 25:304-306.
74.
Molloy PJ, Nicks R. Surgery of persistent ductus arteriosus. Br.Med J 1956;
32:578-582.
75.
Nicks R, Molloy PJ, Whillans D. A freeze-dry method of arterial preservation and
the results of clinical trial. N Z Med J 1956; 55:390-395.
76.
Nicks R. Restoration and reconstruction of the trachea and main bronchi. J
Thorac Cardiovasc Surg 1956; 32:226-245.
77.
Robb D. Aortic stenosis: surgical aspects. N Z Med J 1956; 55:189-194.
78.
Anson G. Thoughts on the future of anaesthesia in New Zealand. N Z Med J
1957; 56:179-182.
79.
Newman J. Some scientific hoaxes. Med J Aust 1957; 44:350-353.
80.
Nicks R. Agenesis of the lung with persistent ductus arteriosus. Thorax 1957;
12:140-141.
9
81.
Nicks R. The surgery of major arterial obstruction and occlusion. Aust N Z J Surg
1957; 26:248-261.
82.
Robb D. Aortic surgery. N Z Med J 1957; 56:228-234.
83.
Robb D. Hiatus hernia in infants and children. N Z Med J 1957; 56:238-242.
84.
Hinds JR. Bronchiectasis in the Maori. N Z Med J 1958; 57:328-332.
85.
Newman J. Background to Harvey. N Z Med J 1958; 57:204-213.
86.
Nicks R. A surgical study of coarctation of the aorta. Br Heart J 1958; 20:351-356.
87.
Robb D. A case of neonatal fibrosarcoma of lung. Brit J Surg 1958; 46:173-174.
88.
Robb D. Outpatients: the proper scope and development of hospital out-patient
services in relation to other health services in the community. N Z Med J 1958;
57:346-350.
89.
Robb D. The changing world of medicine. N Z Med J 1958; 57:83-84.
90.
Cole DS. Thoracic space-occupying lesions in very young children. N Z Med J
1959; 58:148-154.
91.
Lowe JB, Williams JCP, Robb D, Cole DS. Congenital diverticulum of the lrft
ventricle. Br Heart J 1959; 21:101-106.
92.
WIlliams JCP, Barratt-Boyes BG. Atrial septal defect: the results of repair using
the atrial well method. N Z Med J 1959; 58:279-287.
93.
Barratt-Boyes B, Lowe JB, Cole DS, Watt WJ, Williams JCP. Initial experiences
with extracorporeal circulation in intracardiac surgery. British Medical Journal
1960; 2:1826.
94.
Cole DS. Cardiorespiratory resuscitation. N Z Med J 1960; 59:367-375.
95.
Cole DS. Progressive bacterial synergistic gangrene of skin. N Z Med J 1960:568.
96.
McMyn JK. Pulmonary hypertension. J Coll Radiol Australasia. 1960; 4:21.
97.
Newman J. A tonsillar autobiography. N Z Med J 1960; 59:316-319.
98.
Robb D. Repeat operations for mitral stenosis. N Z Med J 1960; 59:183-186.
99.
Robb D. The New Zealand medical service - an appraisal I. Can Med Assoc J
1960; 82:432-438.
100.
Robb D. The New Zealand medical service - an appraisal II. Can Med Assoc J
1960; 82:490-497.
101.
Robb D. Obstruction of popliteal artery by synovial cyst. Report of a case. Br J
Surg 1960; 48:221-222.
102.
Robb D. Maori and European: differential incidence of surgical and other
diseases. N Z Med J 1960; 59:271-279.
103.
Robb D. The cost of health services in New Zealand and other countries,. N Z
Med J 1960; 59:97-100.
104.
Barratt-Boyes BG, Yarrow S. A combined venous reservoir and defoaming
chamber for use in a heart-lung bypass circuit. Aust N Z J Surg 1961; 30:260264.
105.
Cole DS, Burcher S. Accidental rupture of the oesophagus and stomach. Lancet
1961; 1:24-25.
106.
Newman J. Geriatrics in New Zealand. N Z Med J 1961; 60:127-130.
10
107.
Robb D. The use of the jejunum in upper abdominal surgery and a comparison
with oesophago-gastrostomy. Aust N Z J Surg 1961; 30:252-259.
108.
Robb D. Medicine and health on a Commonwealth basis. 1961; Br Med J:375379.
109.
Roche EH. Doctors and clergy. N Z Med J 1961; 60:547-549.
110.
Rowe RD, Lowe JB, Barratt-Boyes BG. Heart malformation in infancy: initial
experience from a cardiosurgical unit. N Z Med J 1961; 60:549-555.
111.
Rowe RD. Congenital heart disease in the neonatal period. N Z Med J 1961;
60:469-473.
112.
WIlliams JCP, Barratt-Boyes BG, Lowe JB. Supravalvular aortic stenosis.
Circulation 1961; 24:1311-1318.
113.
Cole DS, Barratt-Boyes BG. Oesophageal atresia. N Z Med J 1962; 61:267-274.
114.
Kellaway GS, Ewen K. Magnesium deficiency complicating prolonged gastric
suction. N Z Med J 1962; 61:137-142.
115.
Kellaway GS, Ewen K. Magnesium deficiency. N Z Med J 1962; 61:369-370.
116.
Newman J. Old folk in wet beds. Br Med J 1962; 5295:1824-1827.
117.
Robb D. Surgical treatment of mycotic aneurysm. 1962; 52:847-850.
118.
Robb D. Medical training in New Zealand. N Z Med J 1962; 61:535-539.
119.
Robb D. The Doctor himself. Med J Aust 1962; 50:72-74.
120.
Rowe RD. Cardiac malformation in Mongolism. Am Heart J 1962; 64:567-569.
121.
Swinburn PD. Pulmonary hydatid disease. A review of 111 cases. N Z Med J
1962; 61:481-487.
122.
Williams S. A cytological survey of hospital patients for lung canceer. N Z Med J
1962; 61:401-404.
123.
Barratt-Boyes BG. The results of repair of atrial septal defect using the atrial well
method. Ann R Coll Surg Eng 1963; 33:209-225.
124.
Barratt-Boyes BG. Surgical correction of mitral incompetence resulting from
bacterial endocarditis. Br Heart J 1963; 25:415-420.
125.
Cole DS. Medicine: A life-long study. N Z Med J 1963; 62:301-302.
126.
Robb D. Traumatic diaphragmatic hernia into the pericaedium. Br J Surg 1963;
50:664-668.
127.
Rowe RD. Maternal rubella and pulmonary artery stenosis. Report of 11 cases.
Pediatrics 1963:180-185.
128.
Roydhouse N. Results of tonsillectomy and adenoidectomy. 1963; 62:589-583.
129.
WIlliams JCP, Barratt-Boyes BG, Lowe JB. Underdeveloped right ventricla and
pulmonary stenosis. Am J Cardiol 1963; 11:458-468.
130.
Windsor R. Strangulated diaphragmatic hernia with perforation of the stomach: A
case report. N Z Med J 1963:425-428.
131.
Windsor R. Cardiac damage after radiotherapy. Br Med J 1963:382-383.
132.
Cole DS, Yarrow S. Artificial Electrical Pacng for Heart Block. A review of 24
cases. N Z Med J 1964; 63:127.
11
133.
Gwynne J, Parrish V. A survey of pulmonary pathology. N Z Med J 1964; 63:1721.
134.
Robb D. Science, Humanism and medicine. N Z Med J 1964; 63:355-358.
135.
Rowe RD, Sinclair JD, Kerr AR, Gage PW. Duct flow and mitral regurgitation
during changes of oxygenation in newborn swine. J Appl. Physiol 1964; 19:11571163.
136.
Rowe RD, Lowe JB. Auscultation in the diagnosis of persistent ductus arteriosus
in infancy. A study of 50 patients. N Z Med J 1964; 63:185-189.
137.
Barratt-Boyes BG, Lowe JB, Cole DS, Kelly DT. Homograft valve replacement for
aortic valve disease. Thorax 1965; 20:495-504.
12
Anaesthesia and Perfusion
1.
Harris EA. Assisted respiration in tetanus. N Z Med J 1965; 64:Suppl-1.
2.
Seelye ER. Indications for tracheostomy and its complications. New Zealand
Medical Journal. 1965; 64:Suppl:86-7.
3.
Coulter RL. The use of the relaxant diallyltoxiferine in caesarean section. New
Zealand Medical Journal. 1966; 65:373-5.
4.
Hutchinson BR. Caudal analgesia in obstetrics. New Zealand Medical Journal.
1966; 65:224-6.
5.
Shaw HA, Hunt SR. The use of diallylnortoxiferine in anaesthesia. New Zealand
Medical Journal. 1966; 65:371-2.
6.
Hutchinson BR. Costs in paediatric anaesthesia. New Zealand Medical Journal.
1967; 66:520-2.
7.
Hutchinson BR. The vomiting hazard in obstetric anaesthesia. Australian & New
Zealand Journal of Obstetrics & Gynaecology. 1967; 7:104-7.
8.
Hutchinson BR. The cost of anaesthetic agents. New Zealand Medical Journal.
1967; 66:303-5.
9.
Hutchinson BR. Electrocardiographic changes in children following extubation.
Medical Journal of Australia. 1967; 1:151-4.
10.
Hutchinson BR. The performance of intravenous drip sets. New Zealand Medical
Journal. 1969; 70:91-3.
11.
Harris EA, Seelye ER, Barratt-Boyes BG. Respiratory and metabolic acid-base
changes during cardiopulmonary bypass in man. Br J Anaesth. 1970; 42:912-922.
12.
Seelye ER. Anaesthesia for children with congenital heart disease. Anaesthesia &
Intensive Care. 1973; 1:512-6.
13.
Barratt-Boyes BG. Type of heart-lung machine used in deep hypothermia. In:
Parezan L, Carcassone M, eds. Open Heart Surgery in Infancy. Marseille, 1974.
14.
Harris EA, Seelye ER, Barratt-Boyes BG. On the availability of oxygen to the
body during cardiopulmonary bypass in man. Br J Anaesth. 1974; 46:425-431.
15.
Hutchinson BR, Newson AJ. Pre-operative neutralization of gastric acidity.
Anaesthesia & Intensive Care. 1975; 3:198-203.
16.
Hutchinson BR. Intravenous anaesthesia--a modern technique? New Zealand
Medical Journal. 1975; 82:48-52.
17.
Barratt-Boyes BG, Harris EA, Kenyon AM, Lindop CA, Seelye ER. Coronary
perfusion and myocardial metabolism during open-heart surgery in man. J Thorac
Cardiovasc Surg 1976; 72:133-141.
18.
Boas RA, Hatangdi VS, Richards EG. Lumbar sympathectomy. In: Bonica JJ, ed.
Advances in Pain Research and Therapy. New York: Raven, 1976:685-689.
19.
Hatangdi VS, Boas RA, Richards EG. Postherpetic Neuralgia. In: Bonica JJ, ed.
Advances in Pain Research and Therapy. New York: Raven Press, 1976:583587.
20.
Hutchinson BR. Preoperative magnesium trisilicate in infants. Anaesthesia &
Intensive Care. 1976; 4:192-5.
13
21.
Kaye SE. The hypotensive effect of fresh lympholised plasma. Anaesthesia &
Intensive Care. 1976; 4:196-8.
22.
Davis FM, Parimelazhagan KN, Harris EA. Thermal balance during
cardiopulmonary bypass with moderate hypothermia in man. Br.J Anaesth. 1977;
49:1127-1132.
23.
Evans PJ, Ruygrok P, Seelye ER, Harris EA. Does sodium nitroprusside improve
tissue oxygenation during cardiopulmonary bypass? Br.J Anaesth. 1977; 49:799803.
24.
Davis FM. Radial artery cannulation: influence of catheter size and material on
arterial occlusion. Anaesthesia & Intensive Care. 1978; 6:49-53.
25.
Davis FM, Cornere B. Bacterial contamination of radial artery catheters. New
Zealand Medical Journal. 1979; 89:128-30.
26.
Harris EA, Parimelazhagan KN, Seelye ER, Barratt-Boyes BG. Optimization of
coronary perfusion rate during cardiac surgery in man. J Thorac Cardiovasc Surg
1979; 77:662-668.
27.
Davis FM, Stewart JM. Radial artery cannulation. A prospective study in patients
undergoing cardiothoracic surgery. British Journal of Anaesthesia 1980; 52:41-7.
28.
Hutchinson BR. Why I use preoperative magnesium trisilicate. Dissector 1980;
7:30-34.
29.
Lindop CR, Willcox TW, McKegg PM, Harris EA. Exposure of patients to ethylene
oxide during cardiopulmonary bypass using gas-sterilized pump components.
1980; 79:845-850.
30.
Kaye SE, Dimai W, Gattiker R. Intravenous nitroglycerin during surgery for
coronary artery disease. Anaesthesia & Intensive Care. 1981; 9:247-54.
31.
Newman J. Acupuncture, anaesthesia, and all that. N Z Med J 1982; 95:22.
32.
Hutchinson BR. The New Zealand anaesthetic training scheme, 1979-1982. New
Zealand Medical Journal. 1983; 96:938-9.
33.
Merry AF, Cross JA, Mayadeo SV, Wild CJ. Posture and the spread of extradural
analgesia in labour. Brit J Anaesth 1983; 55:303-7.
34.
Berry PR, St John SM. Percentage of anaesthetic fee refunded to patients by
schedule-using private medical insurers in New Zealand. New Zealand Medical
Journal. 1985; 98:593-5.
35.
Hutchinson BR, Merry AF, Wild CJ. The relationship of duration of fast to the
volume and pH of gastric contents. Anaesthesia & Intensive Care. 1986; 14:12830.
36.
Merry AF, Clapham GJ, Walker JS. The reversal of midazolam sedation with the
benzodiazepine antagonist flumazenil (Anexate). N Z Med J 1988; 101:571-572.
37.
Merry AF, Clapham GJ, Walker JS. Reversal of midazolam sedation with the
benzodiazepine antagonist flumazenil. New Zealand Medical Journal 1988;
101:571-2.
38.
Hutchinson BR. Early anaesthetics in New Zealand. New Zealand Medical
Journal. 1992; 105:343.
39.
Merry AF, Wardall GJ, Cameron RJ, Peskett MJ, Wild CJ. Prospective,
controlled, double-blind study of i.v. tenoxicam for analgesia after thoracotomy.
1992; 69:92-94.
14
40.
Merry AF. The place on non-steroidal anti-inflammatory drugs in perioperative
pain relief. In: Keneally J, Jones M, eds. Australasian Anaesthesia. Melbourne:
Australian and New Zealand College of Anaesthetists, 1994:149-157.
41.
Rutherford JS, Merry AF, Occleshaw CJ. Depth of central venous catheterization:
an audit of practice in a cardiac surgical unit. Anaesthesia & Intensive Care.
1994; 22:267-71.
42.
Peck D, Holland R. Anaesthesia in a patient with agoraphobia. Anaesthesia &
Intensive Care. 1995; 23:238-9.
43.
Garden AL, Merry AF, Holland RL, Petrie KJ. Anaesthesia information--what
patients want to know. Anaesthesia & Intensive Care. 1996; 24:594-8.
44.
Merry AF, Webster CS. Drug administration error in anaesthesia. In: Keneally J,
Jones BL, eds. Australasian Anaesthesia. Melbourne: Australian and New
Zealand College of Anaesthetists, 1996:53-61.
45.
Mitchell SJ, Willcox T, McDougal C, Gorman DF. Emboli generation by the
Medtronic Maxima hard-shell adult venous reservoir in cardiopulmonary bypass
circuits: a preliminary report. Perfusion. 1996; 11:145-55.
46.
Hempenstall K, Holland R. Regional anaesthesia for emergency caesarean
section in a patient with lepromatous leprosy. Anaesthesia & Intensive Care.
1997; 25:168-70.
47.
Merry AF, Holland RL, Middleton NG, Schug SA, Webster CS. Perioperative
tenoxicam - safety and efficay. A randomised controlled trial. Anaesthesia &
Intensive Care. 1997; 25:179.
48.
Merry AF, Judge M, Ready LB. Acute pain services in New Zealand - a survey.
New Zealand Medical Journal 1997; 110:233-5.
49.
Mitchell SJ, Willcox T, Gorman DF. Bubble generation and venous air filtration by
hard-shell venous reservoirs: a comparative study. Perfusion. 1997; 12:325-33.
50.
Christie IW, Ahkine PA, Holland RL. Central regional anaesthesia in a patient with
Klippel-Trenaunay syndrome. Anaesth.Intensive Care 1998; 26:319-321.
51.
Lorimer M, Hall R. Remifentanil and propofol total intravenous anaesthesia for
thymectomy in myasthenia gravis. Anaesth.Intensive Care 1998; 26:210-212.
52.
Merry AF, Swinburn PF, Middleton NG, Edwards JL, Calder MV. Tenoxicam and
paracetamol-codeine combination after oral surgery: a prospective, randomized,
double-blind, placebo-controlled study. 1998; 81:875-880.
53.
Milsom FP, Mitchell SJ. A dual-vent left heart deairing technique markedly
reduces carotid artery microemboli. Annals of Thoracic Surgery. 1998; 66:785-91.
54.
Merry AF, Webster CS, Van Cotthem IC, Holland RL, Beca JS, Middleton NG. A
prospective randomized clinical assessment of a new pigtail central venous
catheter in comparison with standard alternatives. 1999; 27:639-645.
55.
Neff SP, Merry AF, Anderson B. Airway management in Ludwig's angina. 1999;
27:659-661.
56.
Peskett MJ. Clinical indicators and other complications in the recovery room or
postanaesthetic care unit. Anaesthesia 1999; 54:1143-1149.
57.
Willcox TW, Mitchell SJ, Gorman DF. Venous air in the bypass circuit: a source of
arterial line emboli exacerbated by vacuum-assisted drainage. Annals of Thoracic
Surgery. 1999; 68:1285-9.
15
58.
Willcox T, Mitchell S, Gorman DF. Venous air in the bypass circuit: a source of
iatrogenic arterial gas embolism exacerbrated by vaccum assisted drainage.
Undersea Hyperbaric Medicine 1999; 26 (supp):63.
59.
Ducat CM, Merry AF, Webster CS. Attitudes and practices of New Zealand
anaesthetists with regard to emergency drugs. 2000; 28:692-697.
60.
Mitchell S, Willcox T, Gorman DF. Physical and pharmacological neuroprotection
in cardiac surgery. Seminars in Cardiothorasic and Vasc Anesthesia 2000; 4:805.
61.
Webster CS, Merry AF. British syringe label 'standards' are an accident waiting to
happen. 2000; 55:618.
62.
Hutchinson BR. Early cardiac anaesthesia at Green Lane Hospital. New Zealand
Medical Journal. 2001; 114:S12-4.
63.
Merry AF, Miller TE, Findon G, Webster CS, Neff SP. Touch contamination levels
during anaesthetic procedures and their relationship to hand hygiene procedures:
a clinical audit. 2001; 87:291-294.
64.
Merry AF, Webster CS, Mathew DJ. A new, safety-oriented, integrated drug
administration and automated anesthesia record system. 2001; 93:385-390.
65.
Webster CS. Transient fixation on a non-native language associated with
anaesthesia. Anaesthesia 2001; 56:906-924.
66.
Webster CS, Merry AF, Larsson L, McGrath KA, Weller J. The frequency and
nature of drug administration error during anaesthesia. 2001; 29:494-500.
67.
Webster CS, Merry AF, Ducat CM. Safety, cost and predrawn emergency drugs.
2001; 56:818-820.
68.
Merry AF, Sidebotham DA, Middleton NG, Calder MV, Webster CS. Tenoxicam
20 mg or 40 mg after thoracotomy: a prospective, randomized, double-blind,
placebo-controlled study. 2002; 30:160-166.
69.
Merry AF, Webster CS, Weller J, Henderson S, Robinson B. Evaluation in an
anaesthetic simulator of a prototype of a new drug administration system
designed to reduce error. 2002; 57:256-263.
70.
Webster CS, Mathew DJ, Merry AF. Effective labelling is difficult, but safety really
does matter. 2002; 57:201-202.
71.
Willcox TW, Mitchell SJ. The influence of vacuum assisted drainage on arterial
line emboli.[comment]. Journal of Extra-Corporeal Technology. 2002; 34:151-2.
72.
Willcox TW. Vacuum-assisted venous drainage: to air or not to air, that is the
question. Has the bubble burst? Journal of Extra-Corporeal Technology. 2002;
34:24-8.
73.
Willcox T, van Uden R. Best practice for cardiopulmonary bypass in the high-risk
elderly patient. Seminars in Cardiothorasic and Vasc Anesthesia 2002; 6:293300.
74.
Merry AF, Raudkivi PJ, Middleton NG, McDougall J, Nand P, Mills BP, Webber
BJ, Frampton CM, White HD. Bivalirudin versus heparin and protamine in off
pump coronary artery bypass surgery. Annals of Thoracic Surgery. 2003.
75.
Webster CS, Merry AF, Emmens DJ, Van Cotthem IC, Holland RL. A prospective
clinical audit of central venous catheter use and complications in 1000
consecutive patients. 2003; 31:80-86.
16
76.
Webster CS, Merry AF, Holland R, Van Cotthem IC. An audit of 1000 cases of
central venous catheter insertion at Green Lane Hospital. Anaesth Intensive Care
2003; 31:80-6.
77.
Webster CS, Merry AF, Gander PH, Mann NK. A prospective randomised clinical
evaluation of a new safety-orientated injectable drug administration system in
comparison with conventional methods. Anaesthesia 2003.
78.
Willcox T, Stone P, Milsom FP, Connell H. Cardiopulmonary bypass in
pregnancy: Possible new role for the intra aortic ballon pump. A case report.
Journal of Extra-Corporeal Technology. 2003; 2003.
17
Adult Cardiology
Arrhythmias, Electophysiology and Pacing
1.
Cole DS. Surgical management of complete heart block. N Z Med J 1965;
64:Suppl-5.
2.
O'Brien KP. Direct current countershock in the treatment of cardiac arrhythmias.
N Z Med J 1965; 64:Suppl-8.
3.
Neutze JM, Kerr AR, Whitlock RM. Epicardial mapping in a variant of type A
Wolff-Parkinson-White syndrome. Circulation 1973; 48:662-666.
4.
Heng MK, Singh BN, Roche AH, Norris RM, Mercer CJ. Effects of intravenous
verapamil on cardiac arrhythmias and on the electrocardiogram. Am Heart J
1975; 90:487-498.
5.
Singh BN. Verapamil and the heart. N Z Med J 1975; 82:339.
6.
Singh BN, Roche AH. Effects of intravenous verapamil on hemodynamics in
patients with heart disease. Am Heart J 1977; 94:593-599.
7.
Lubbe WF, Mercer CJ, Roche AH, Lowe JB. Amiodarone in long term
management of refractory cardiac tachyarrhythmias. N Z Med J 1981; 93:31-35.
8.
Agnew TM, Lauder IM, Fisher CA, Crawford GC. Sudden cardiac deaths:results
of resuscitation begun outside hospital. New Zealand Medical Journal 1983;
96:465-467.
9.
Lubbe WF, Nguyen T, Edwards MF. Antiarrhythmic action of labetalol and its
effect on adenine metabolism in the isolated rat heart. J Am Coll Cardiol 1983;
1:1296-1301.
10.
Smith W. Amiodarone--a drug for all seasons? Australian & New Zealand Journal
of Medicine. 1983; 13:229.
11.
Smith W. Permanent cardiac pacing--technology out of control? New Zealand
Medical Journal. 1984; 97:221-2.
12.
Brown MA, Smith WM, Lubbe WF, Norris RM. Amiodarone-induced torsades de
pointes. Eur Heart J 1986; 7:234-239.
13.
Lubbe WF, Holland RK, Gilchrist AI, Pybus J. Permissive action of potassium on
arrhythmogenesis in the rat heart. J Mol Cell Cardiol 1986; 18 Suppl 4:37-41.
14.
Smith WM, Lubbe WF, Whitlock RM, Mercer J, Rutherford JD, Roche AH. Longterm tolerance of amiodarone treatment for cardiac arrhythmias. Am J Cardiol
1986; 57:1288-1293.
15.
Smith WM, Wallace AG. Management of arrhythmias and conduction
abnormalities. In: Hurst JW, ed. The heart: McGraw-Hill, 1986:475-86.
16.
Smith WM. Durgs used to treat cardiac arrhythmias. In: Hurst JW, ed. The heart:
McGraw-Hill, 1986:1593-1605.
17.
Lubbe WF, Gilchrist AI, Holland RK, Pybus J. Adenine nucleotides and ventricular
fibrillation. J Mol Cell Cardiol 1987; 19 Suppl 5:23-33.
18.
Smeeton WM, Smith W. Sudden death due to a cardiomyopathy predominantly
affecting the right ventricle: right ventricular dysplasia. Med Sci Law 1987;
27:207-12.
18
19.
Anonymous. Multicentre randomized trial of sotalol vs amiodarone for chronic
malignant ventricular tachyarrhythmias. Amiodarone vs Sotalol Study Group.
European Heart Journal. 1989; 10:685-94.
20.
Hood MA, Smith WM, Robinson MC, Ashton N, Barber A. Catheter ablation of the
atrioventricular junction in patients with refractory atrial arrhythmias. New Zealand
Medical Journal. 1989; 102:344-7.
21.
Smith WM. Mechanisms of cardiac arrhythmias and conduction disturbances. In:
Hurst JW, ed. The heart: McGraw-Hill, 1989.
22.
McAlister HF, Luke RA, Whitlock RM, Smith WM. Intravenous amiodarone bolus
versus oral quinidine for atrial flutter and fibrillation after cardiac
operations.[comment]. Journal of Thoracic & Cardiovascular Surgery. 1990;
99:911-8.
23.
McAlister HF, Luke RA, Whitlock RM, Smith WM. Reply to: Amiodarone and
quinidine for postoperative atrial arrhythmias. Journal of Thoracic &
Cardiovascular Surgery. 1990; 100:630-1.
24.
Hood MA, Smith WM, Robinson MC, et al. Operations for Wolff-Parkinson-White
syndrome. Journal of Thoracic & Cardiovascular Surgery. 1991; 101:998-1003.
25.
Merry AF, Schug SA, Richards EG, Large RG. Opioids in the treatment of chronic
pain of non-malignant origin. New Zealand Medical Journal 1991; 104:520-1.
26.
Schug SA, Merry AF, Acland RH. Treatment principles for the use of opioids in
pain of non-malignant origin. Drugs 1991; 42:228-39.
27.
Smith WM, Robinson MC, Hood MA, et al. Surgical correction of the WolffParkinson-White syndrome. New Zealand Medical Journal. 1991; 104:327-9.
28.
Ellis CJ, Smith W. Giant T wave inversion. New Zealand Medical Journal. 1992;
105:246.
29.
Hood MA, Smith WM. Adenosine versus verapamil in the treatment of
supraventricular tachycardia: a randomized double-crossover trial.[comment].
American Heart Journal. 1992; 123:1543-9.
30.
Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic
adenosine monophosphate (AMP) and cytosolic calcium overload: implications
for prophylactic effects of beta-blockers in myocardial infarction and
proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 1992;
19:1622-1633.
31.
Merry AF, Schug SA, Richards EG, Large RG. Opioids in chronic pain of nonmalignant origin: state of the debate in New Zealand. European J Pain 1992;
13:39-44.
32.
Ho KY, Wilson NJ, Smith WM. Acute treatment of paroxysmal tachycardia by
adenosine. Aust N Z J Med 1994; 24:176-181.
33.
White HD. Aspirin or warfarin for non-rheumatic atrial fibrillation?[comment].
Lancet. 1994; 343:683-4.
34.
Smith W, McAlister H, Crozier I, Hood M, Easthope R, Low C. Management
decisions in survivors of cardiac arrest. New Zealand Medical Journal. 1997;
110:45-7.
35.
Smith W, Crozier I, McAlister H, O'Meeghan T, Stewart F. Guidelines for the use
of flecainide in patients with supraventricular arrhythmias. New Zealand Medical
Journal. 2000; 113:420-1.
19
36.
Mond HG, Whitlock RM. The Australian and New Zealand cardiac pacing and
implantable cardioverter-defibrillator survey: calendar year 1997. Internal
Medicine Journal. 2001; 31:267-71.
20
Adult Cardiology
Cardiac Transplantation
1.
Agnew TM, Coverdale HA, Graham KJ, Leathem P, McDougall JM, Middleton
NG, Rainer SP, Robinson MC, Whitfield CJ. Cardiac transplantation in New
Zealand: an initial report. New Zealand Medical Journal. 1989; 102:634-7.
2.
Powell KF, Bellamy AR, Catton MG, Cooper IP, Philip BA, Rainer S, Coverdale
HA, Croxson MC. Cytomegalovirus myocarditis in a heart transplant recipient:
sensitive monitoring of viral DNA by the polymerase chain reaction. Journal of
Heart Transplantation. 1989; 8:465-70.
3.
Ruygrok PN, Agnew TM, Coverdale HA, Whitfield C, Lambie NK. Survival after
heart transplantation without regular immunosuppression. Journal of Heart &
Lung Transplantation. 1994; 13:208-11.
4.
Lund M, Ellis CJ, Coverdale HA, Agnew TM, Haydock DA, Middleton NG,
Whitfield CJ, Whitlock RM. Cardiac transplantation in New Zealand: eight years
experience. New Zealand Medical Journal. 1997; 110:139-42.
5.
Ruygrok PN, Maddison R, Langlands JM, Haydock DA, Agnew TM, Coverdale
HA. Heart donation: the New Zealand experience, 1987-1996. New Zealand
Medical Journal. 1998; 111:206-8.
6.
Ruygrok P, Strickett MG, Aldersley PF, Dixon SJ, Coverdale HA, Agnew TM,
Whitlock RML, Graham KJ, Kerr AR. The recipient becomes a donor: utilization
of allograft aortic valves from the excised hearts of cardiac-transplant patients.
Asia Pacific Heart Journal 1998; 7:178-181.
7.
D'Costa R, Ruygrok PN, Coverdale HA, Agnew TM, Gibbs H, Reddy D, Haydock
DA, Kerr AR. Outcome following heart transplantation in Maori and Polynesian
patients: a comparison with European New Zealanders. New Zealand Medical
Journal. 2001; 114:44-6.
8.
Ruygrok PN, Gane EJ, McCall JL, Chen XZ, Haydock DA, Munn SR. Combined
heart and liver transplantation for familial amyloidosis. Internal Medicine Journal.
2001; 31:66-7.
9.
Wasywich CA, Ruygrok PN, Wilkinson L, Gibbs HC, Coverdale HA. Planned
pregnancy in a heart transplant patient. J Internal Med 2003.
10.
Ruygrok P, Farb A, Coverdale HA, Gibbs H, Virmani R. Histology of in-stent
restenosis in a transplanted heart. Journal of Heart lung and transplantation.
2003.
21
Adult Cardiology
Coronary Artery Disease
1.
Norris RM, Caughey DE, Scott PJ. Trial of propranolol in acute myocardial
infarction. Br Med J 1968; 2:398-400.
2.
Norris RM. Acute coronary care. N Z Med J 1968; 67:470-476.
3.
Norris RM, Bensley KE, Caughey DE, Scott PJ. Hospital mortality in acute
myocardial infarction. Br Med J 1968; 3:143-146.
4.
Norris RM. Long-term survival after cardiac arrest. N Z Med J 1969; 69:144-146.
5.
Norris RM, Brandt PW, Lee AJ. Mortality in a coronary-care unit analysed by a
new coronary prognostic index. Lancet 1969; 1:278-281.
6.
Norris RM. Bradyarrhythmia after myocardial infarction. Lancet 1969; 1:313-314.
7.
Norris RM. Heart block in posterior and anterior myocardial infarction. Br Heart J
1969; 31:352-356.
8.
Norris RM, Brandt PW, Caughey DE, Lee AJ, Scott PJ. A new coronary
prognostic index. Lancet 1969; 1:274-278.
9.
Briant RB, Norris RM. Alprenolol in acute myocardial infarction: Double-blind trial.
N Z Med J 1970; 71:135-138.
10.
Norris RM, Brandt PW, Caughey DE, Scott PJ. A new coronary prognostic index.
Am Heart J 1970; 79:428-431.
11.
Norris RM, Croxson MS. Bundle branch block in acute myocardial infarction. Am
Heart J 1970; 79:728-733.
12.
Norris RM, Caughey DE, Deeming LW, Mercer CJ, Scott PJ. Coronary prognostic
index for predicting survival after recovery from acute myocardial infarction.
Lancet 1970; 2:485-487.
13.
Norris RM, Mercer CJ, Yeates SE. Idioventricular rhythm complicating acute
myocardial infarction. Br Heart J 1970; 32:617-621.
14.
Norris RM, Caughey DE, Mercer CJ, Scott PJ, North KA. Coronary care units. N
Z Med J 1971; 74:412-414.
15.
Croxson MS, Neutze JM, John MB. Exchangeable potassium in heart disease:
long-term effects of potassium supplements and amiloride. Am Heart J 1972;
84:53-60.
16.
Norris RM, Mercer CJ, Croxson MS. Conduction disturbances due to anteroseptal
myocardial infarction and their treatment by endocardial pacing. Am Heart J 1972;
84:560-566.
17.
Norris RM, Mercer CJ, Yeates SE. Sinus rate in acute myocardial infarction. Br
Heart J 1972; 34:901-904.
18.
Reynolds JL, Whitlock RM. Effects of a beta-adrenergic receptor blocker in
myocardial infarction treated for one year from onset. British Heart Journal. 1972;
34:252-9.
19.
Agnew TM. Coronary artery surgery. New Zealand Medical Journal 1973:40-41.
22
20.
Norris RM, Mercer CJ. Long term prognosis following treatment in coronary-care
unit. Aust N Z J Med 1973; 3:31-37.
21.
Norris RM. Factors affecting long-term prognosis after myocardial infarction. Med
J Aust 1973; 2:Suppl-7.
22.
Norris RM, Caunt VS. Delay in admission to a coronary-care unit. N Z Med J
1973; 78:342-346.
23.
Norris RM. Prognosis in acute myocardial infarction. Singapore Med J 1973;
14:271-272.
24.
Norris RM. Bundle-branch block after acute myocardial infarction. Med J Aust
1973; 2:Suppl-50.
25.
Norris RM, Caughey DE, Deeming LW, Mercer CJ, Scott PJ. Prognosis following
acute myocardial infarction. N Z Med J 1973; 77:12-18.
26.
Norris RM. Bundle-branch block and myocardial infarction. Lancet 1973; 2:439440.
27.
Norris RM, Mercer CJ. Significance of idioventricular rhythms in acute myocardial
infarction. Prog.Cardiovasc Dis 1974; 16:455-468.
28.
Norris RM, Caughey DE, Mercer CJ, Scott PJ. Prognosis after myocardial
infarction. Six-year follow-up. Br Heart J 1974; 36:786-790.
29.
Singh BN. Mortality in ischaemic heart disease: a biased view point. N Z Med J
1974; 79:1071-1072.
30.
Norris RM, Whitlock RM, Barratt-Boyes C, Small CW. Clinical measurement of
myocardial infarct size. Modification of a method for the estimation of total
creatine phosphokinase release after myocardial infarction. Circulation. 1975;
51:614-20.
31.
Norris RM. Prognosis in myocardial infarction. Heart Lung 1975; 4:75-80.
32.
Norris RM, Smith HJ, Singh BN, Nisbet H, John MB, Hurley PJ. The effects of
isoprenaline on epicardial ST-segment elevation, lactate production, and
myocardial blood flow following coronary artery ligation. Cardiovasc Res 1975;
9:770-778.
33.
Pritchard DA, Singh BN, Hurley PJ. Effects of amiodarone on thyroid function in
patients with ischaemic heart disease. Br.Heart J 1975; 37:856-860.
34.
Sharpe DN, Norris RM, McL WB. Treatment with digoxin and measurement of
serum digoxin levels after myocardial infarction. 1975; 37:530-533.
35.
Singh BN, Smith HJ, Norris RM. Reduction in infarct size following experimental
coronary occlusion by administration of verapamil. Proceedings of the 7th Annual
Meeting of the International Study Group in Cardiac Research and Metabolism.
Baltimore: University Park Press, 1975:435-452.
36.
Singh BN, Smith HJ, Norris RM. Reduction in infarct size following experimental
coronary occlusion by administration of verapamil. Recent
Adv.Stud.Cardiac.Struct.Metab 1975; 10:435-452.
37.
Smith HJ, Singh BN, Nisbet HD, Norris RM. Effects of verapamil on infarct size
following experimental coronary occlusion. Cardiovasc Res 1975; 9:569-578.
38.
Smith HJ, Singh BN, Norris RM, John MB, Hurley PJ. Changes in myocardial
blood flow and S-T segment elevation following coronary artery occlusion in dogs.
Circ.Res 1975; 36:697-705.
23
39.
Agnew TM, Roche A, Brandt PW, Kerr AR. Coronary artery disease:recent
developments. New Zealand Medical Journal 1976; 83:556.
40.
Heng MK, Norris RM, Singh BM, Partridge JB. Prognosis in unstable angina. Br
Heart J 1976; 38:921-925.
41.
Heng MK, Singh BN, Norris RM, John MB, Elliot R. Relationship between
epicardial ST-segment elevation and myocardial ischemic damage after
experimental coronary artery occlusion in dogs. J Clin Invest 1976; 58:1317-1326.
42.
Norris RM, Howell D, Whitlock RM, Heng MK, Peter T. Enzyme release after
myocardial infarction: comparison of serial serum alpha-hydroxybutyrate
dehydrogenase with creatine phosphokinase levels. European Journal of
Cardiology. 1976; 4:461-8.
43.
Norris RM, Barratt-Boyes C, Heng MK, Singh BN. Failure of ST segment
elevation to predict severity of acute myocardial infarction. Br Heart J 1976;
38:85-92.
44.
Rutherford JD, Singh BN, Ambler PK, Norris RM. Plasma propranolol
concentration in patients with angina and acute myocardial infarction. Clin
Exp.Pharmacol.Physiol 1976; 3:297-304.
45.
Smith HJ, Norris RM, Singh BN, Heng MK, Harris EA. Regional differences in
lactate concentration in experimental myocardial infarction. Aust N Z J Med 1976;
6:15-22.
46.
Woo KS, Agnew TM, Graham KJ. Cardiac rupture with false aneurism after
myocardial infarction. New Zealand Medical Journal 1976; 83:230.
47.
Coombes AC. Myocardial infarct in the home. N Z Med J 1977; 86:391-394.
48.
Heng MK, Norris RM, Singh BN, Barratt-Boyes C. Effects of glucose and glucoseinsulin-potassium on haemodynamics and enzyme release after acute myocardial
infarction. Br Heart J 1977; 39:748-757.
49.
Smith HJ, Singh BN, Norris RM, Nisbet HD, John MB, Hurley PJ. The effect of
verapamil on experimental myocardial ischaemia with a particular reference to
regional myocardial blood flow and metabolism. Aust N Z J Med 1977; 7:114-121.
50.
Heng MK, Norris RM, Peter T, Nisbet HD, Singh BN. The effect of glucoseinsulin-potassium on experimental myocardial infarction in the dog. Cardiovasc
Res 1978; 12:429-435.
51.
Norris RM, Agnew TM, Brandt PW, et al. Prognostic factors after myocardial
infarction:progress report of a study involving coronary angiography and coronary
artery surgery. In: Wilhelmson L, Hjalmarson A, eds. Acute and long term
management of myocardial ischemia. Stockholm: Astra Lts, 1978:98-105.
52.
Norris RM. Infarct size quantitation:present and future. In: Hearse DJ, de Leiris J,
eds. Enzymes in Cardiology: diagnosis and research. London: John Wiley and
Sons, 1978:355-378.
53.
Norris RM, Woo KS. Bundle-branch block in acute myocardial infarction:acute
and long-term effects. In: Kelly DT, ed. Advances in the Management of
Arrhythmias. Sydney, 1978:364-373.
54.
Norris RM. Myocardial damage following infarction. Compr.Ther 1978; 4:18-24.
55.
Norris RM, Clarke ED, Sammel NL, Smith WM, Williams B. Protective effect of
propranolol in threatened myocardial infarction. Lancet 1978; 2:907-909.
24
56.
Peter T, Norris RM, Clarke ED, Heng MK, Singh BN, Williams B. Reduction of
enzyme levels by propranolol after acute myocardial infarction. Circulation 1978;
57:1091-1095.
57.
Peter T, Heng MK, Singh BN, Ambler P, Nisbet H, Elliot R, Norris RM. Failure of
high doses of propranolol to reduce experimental myocardial ischemic damage.
Circulation 1978; 57:534-540.
58.
Nicholson MR, Whitlock RM. Sulphinpyrazone (Anturan) after myocardial
infarction. New Zealand Medical Journal. 1979; 90:263.
59.
Peter T, Norris RM, Heng MK, Sammel NL. Regional 99m technetium
diphosphonate uptake in experimental dog heart infarct: relation to duration and
severity of ischaemia. Cardiovasc Res 1979; 13:635-641.
60.
Woo KS, Norris RM. Bundle branch block after myocardial infarction--a long term
follow-up. Australian & New Zealand Journal of Medicine. 1979; 9:411-6.
61.
Norris RM. Beta adrenoceptor blockade in acute myocardial infarction. Am Heart
J 1980; 99:683-685.
62.
Norris RM, Sammel NL, Clarke ED, Brandt PW. Treatment of acute myocardial
infarction with propranolol. Further studies on enzyme appearance and
subsequent left ventricular function in treated and control patients with developing
infarcts. Br Heart J 1980; 43:617-622.
63.
Norris RM, Sammel NL. Predictors of late hospital death in acute myocardial
infarction. Prog.Cardiovasc Dis 1980; 23:129-140.
64.
Norris RM. Rest and the acutely ischaemic heart. N Z Med J 1980; 92:53-56.
65.
Sammel NL, Stuckey JG, Brandt PW, Norris RM. Comparison of enzymic with
cineangiocardiographic estimations of myocardial infarct size. Br Heart J 1980;
43:609-616.
66.
Sammel NL, Wilson RL, Norris RM, Brandt PW, Stuckey JG. Angiocardiography
and exercise testing at one month after a first myocardial infarction. Aust N Z J
Med 1980; 10:182-187.
67.
Hines BA, Brandt PW, Agnew TM. Unusal intercoronary artery communications:a
case report. Cardiovasc Intervent Radiol 1981; 4:259-263.
68.
Johnson RN, Sammel NL, Norris RM. Depletion of myocardial creatine kinase,
lactate dehydrogenase, myoglobin and K+ after coronary artery ligation in dogs.
Cardiovasc Res 1981; 15:529-537.
69.
O'Rourke MF, Norris RM, Campbell TJ, Chang VP, Sammel NL. Randomized
controlled trial of intraaortic balloon counterpulsation in early myocardial infarction
with acute heart failure. Am J Cardiol 1981; 47:815-820.
70.
Williams B. Admissions to a coronary-care unit over the past seven years (197379). N Z Med J 1981; 93:158-160.
71.
Johnson RN, Lubbe WF, Mercer CJ, Sammel NL, Norris RM. Serum myoglobin,
creatine kinase and creatine kinase-MB as mutually supportive indices of
myocardial infarction and infarct size. Aust N Z J Med 1982; 12:160-165.
72.
Kerr A. The place of cardiac surgery in myocardial infarction and acute
myocardial ischaemia. In: Norris RM, ed. Myocardial infarction: Churchill
Lvingstone, 1982.
73.
Lubbe WF. Metabolic derangements in the genesis of arrthythmias in
experimental myocardial ischemia. In: Norris RM, Livingstone C, eds. Myocardial
Infarction: It's Presentation, Pathogenesis and Treatment, 1982:259-267.
25
74.
Norris RM. Rationale for the long-term use of beta blockers after myocardial
infarction. In: Alfonso VT, ed. Proceedings of a Symposium Acute and Long-term
Management of Myocardial Infarction. New York: Biomedical Inforamtion Corp,
1982:81-90.
75.
Norris RM, Barnaby PF, Geary GG. Intravenous beta-blockers during unstable
angina and threatened infarction. Br J Clin Pharmacol. 1982; 14 Suppl 1:29S35S.
76.
Lubbe WF, McLean JA, Nguyen T. Antiarrhythmic actions of nifedipine in acute
myocardial ischemia. Am Heart J 1983; 105:331-333.
77.
Lubbe WF, White DA. Beneficial effect of labetalol in hypertensive patients with
angina pectoris. South African Medical Journal 1983; 63:67-71.
78.
Matangi MF, Norris RM, Hill DG. Subacute cardiac rupture: a surgical emergency.
N Z Med J 1983; 96:1003-1005.
79.
Sammel NL, Norris RM, Hughes CF, Johnson RN, Ashton NG, Elliott RL. Severity
of canine myocardial infarcts in relation to indices of oxygen demand:
preservation of myocardial creatine kinase activity by vagal stimulation and
propranolol. Cardiovasc Res 1983; 17:50-60.
80.
Merrilees MA, Scott PJ, Norris RM. Prognosis after myocardial infarction: results
of 15 year follow up. Br Med J 1984; 288:356-359.
81.
Norris RM, Barnaby PF, Brandt PW, et al. Prognosis after recovery from first
acute myocardial infarction: determinants of reinfarction and sudden death. Am J
Cardiol 1984; 53:408-413.
82.
Norris RM. The medical management of cardiogenic shock. In: Califf R, Wagner
GS, eds. Coronary Care. Boston: Martinus Nijhoff Co, 1984:427-437.
83.
Norris RM, Barnaby PF, Brown MA, et al. Prevention of ventricular fibrillation
during acute myocardial infarction by intravenous propranolol. Lancet 1984;
2:883-886.
84.
Norris RM. Status of beta blocker therapy in acute myocardial infarction. Methods
Find.Exp.Clin Pharmacol. 1984; 6:219-224.
85.
Paxton JW, Norris RM. Propranolol disposition after acute myocardial infarction.
Clin Pharmacol.Ther 1984; 36:337-342.
86.
Abraham KA, Brown MA, Norris RM. Right ventricular infarction,
bradyarrhythmias, and cardiogenic shock: importance of atrial or atrioventricular
sequential pacing. Aust N Z J Med 1985; 15:52-54.
87.
Brown MA, Norris RM, Barnaby PF, Geary GG, Brandt PW. Effect of early
treatment with propranolol on left ventricular function four weeks after myocardial
infarction. Br Heart J 1985; 54:351-356.
88.
White HD, Brown MA, Norris RM. Treatment of myocardial infarction by early lysis
of intracoronary thrombi. N Z Med J 1985; 98:692-693.
89.
Neutze JM, Starling MB. Fish oils and coronary heart disease. N Z Med J 1986;
99:581-583.
90.
Norris RM. Intravenous beta blocker therapy for acute myocardial infarction. In:
Califf R, Wagner GS, eds. Acute Coronary Care. Boston: Martinus Nijhoff,
1986:61-72.
91.
Norris RM. Beta blockers and infarct size. J Mol.Cell Cardiol 1986; 18 Suppl 4:99103.
26
92.
White HD, Norris RM, Brown MA. Early reperfusion of the ischaemic myocardium
by thrombolytic agents. Atherosclerosis. Amsterdam: Elsevier Science publishers,
1986:543-8.
93.
White HD, Norris RM. Thrombolysis: an effective therapy in acute coronary
thrombosis. Australian & New Zealand Journal of Medicine. 1986; 16:441-3.
94.
Brown MA, Norris RM, Takayama M, White HD. Post-systolic shortening: a
marker of potential for early recovery of acutely ischaemic myocardium in the
dog. Cardiovasc Res 1987; 21:703-716.
95.
Jackson R, Scragg R, Marshall R, White H, O'Brien K, Small C. Changes in
serum lipid concentrations during first 24 hours after myocardial infarction. British
Medical Journal Clinical Research Ed. 1987; 294:1588-9.
96.
Lubbe WF, Opie LH. Metabolic basis of increased vulnerability to fibrillation in
myocardial ischaemia. J Mol.Cell Cardiol 1987; 19 Suppl 5:1-3.
97.
Norris RM. Hospital and post-hospital mortality after myocardial infarction. In:
Kappagoda C, Greenwood PV, eds. Long-term Management of Patients after
Myocardial Infarction. Boston: Martinus Nijhoff, 1987:47-65.
98.
Norris RM, White HD, Brown MA, et al. Improved left ventricular function and
survival after acute myocardial infarction with intravenous streptokinase: a
double-blind trial with and without concomitant intravenous propanolol. British
Heart Journal 1987; 57:576.
99.
White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, Ormiston
JA, Whitlock T. Effect of intravenous streptokinase on left ventricular function and
early survival after acute myocardial infarction. New England Journal of Medicine.
1987; 317:850-5.
100.
White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left
ventricular end-systolic volume as the major determinant of survival after recovery
from myocardial infarction. Circulation. 1987; 76:44-51.
101.
White HD. Angioplasty in acute myocardial infarction. Australian & New Zealand
Journal of Medicine. 1987; 17:189-91.
102.
Chan NS, White H, Maslowski A, Cleland J. Plasmacytosis and renal failure after
readministration of streptokinase for threatened myocardial reinfarction. British
Medical Journal. 1988; 297:717-8.
103.
Geary GG, Norris RM. Propranolol and vagal nerve stimulation do not affect
postsystolic shortening during acute myocardial ischaemia in the dog. Cardiovasc
Res 1988; 22:527-536.
104.
Norris RM, White HD. Therapeutic trials in coronary thrombosis should measure
left ventricular function as primary end-point of treatment. Lancet. 1988; 1:104-6.
105.
Stewart AW, Fraser J, Norris RM, Beaglehole R. Changes in severity of
myocardial infarction and three year survival rates after myocardial infarction in
Auckland, 1966-7 and 1981-2. BMJ 1988; 297:517-519.
106.
Takayama M, Norris RM, Brown MA, Armiger LC, Rivers JT, White HD. Postsystolic shortening of acutely ischemic canine myocardium perdicts early and late
recovery of function following coronarly artery reperfusion. Circulation 1988;
78:994-1007.
107.
Takayama M, Norris RM, Brown MA, Armiger LC, Rivers JT, White HD.
Postsystolic shortening of acutely ischemic canine myocardium predicts early and
late recovery of function after coronary artery reperfusion. Circulation 1988;
78:994-1007.
27
108.
White HD, Rivers JT, Norris RM, et al. Is rt-Pa or streptokinase superior for
preservation of left ventricular function after acute coronary occlusion? Circulation
1988; 78:1207.
109.
Norris RM. Pathophysiology of myocardial ischaemia. In: Foex P, ed. Anaethesia
for the compromised heart. London: Balliere Tindall, 1989:1-25.
110.
White HD, Norris RM. Left ventricular function in patients with myocardial
infarction treated with intracoronary or systemic thrombolysis. In: Verstraete M,
ed. Thrombolysis in Cardiovasular Disease. New York: Marcel Dekker, 1989:129139.
111.
White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH,
Sharpe DN, Whitlock RML, Norris RM. Effect of intravenous streptokinase as
compared with that of tissue plasminogen activator on left ventricular function
after first myocardial infarction.[comment]. New England Journal of Medicine.
1989; 320:817-21.
112.
White HD, Rivers JT, Norris RM, et al. Comparison of rt-PA and strptokinase for
preservation of left ventricular function after myocardial infarction. British Heart
Journal 1989; 61:72.
113.
White HD. The effects of streptokinase on left ventricular function and early
survival. Thrombolysis. Kent: Royal Wells Medical Press, 1989.
114.
White HD. Comparison of tissue plasminogen activator and streptokinase in the
management of acute myocardial infarction. Chest. 1989; 95:265S-269S.
115.
White HD. Acute myocardial infarction: a true medical emergency. New Zealand
Medical Journal. 1989; 102:281-3.
116.
White HD, Norris RM. Left-ventricular function as an end-point. Lancet 1989;
2:676.
117.
Anonymous. In-hospital mortality and clinical course of 20,891 patients with
suspected acute myocardial infarction randomised between alteplase and
streptokinase with or without heparin. The International Study Group.[comment].
Lancet. 1990; 336:71-5.
118.
French JK, White HD, Greaves SC. Simvastatin therapy for
hypercholesterolaemia in patients with coronary heart disease. New Zealand
Medical Journal 1990; 103:41-43.
119.
Norris RM. The changing natural history and prognosis of acute myocardial
infarction. In: Gersh BG, Rahimtoola SH, eds. Acute Myocardial Infarction. New
York: Elsevier, 1990:87-97.
120.
Norris RM. Infarct extenstion and expansion. In: Chamberlain DA, Julian DG,
Sleight P, eds. The Managment of Acute Myocardial Ischemia. London: Chapman
and Hall, 1990:59-65.
121.
Norris RM. Effect of thrombolysis on left ventricular function. In: Chamberlain DA,
Julian DG, Sleight P, eds. The Management of Acute Myocardial Ischaemia.
London: Chapman and Hall, 1990:76-79.
122.
Norris RM, White HD. Left ventricular function as an end-point of thrombolytic
therapy. European Heart Journal. 1990; 11:5-9.
123.
Rivers JT, White HD, Cross DB, Williams BF, Norris RM. Reinfarction after
thrombolytic therapy for acute myocardial infarction followed by conservative
management: incidence and effect of smoking. Journal of the American College
of Cardiology. 1990; 16:340-8.
28
124.
White HD, Cross DB, Williams BF, Norris RM. Safety and efficacy of repeat
thrombolytic treatment after acute myocardial infarction. British Heart Journal.
1990; 64:177-81.
125.
White HD. Comparison of intravenous streptokinase and tissue plasminogen
activator on left ventricular function. Fibrinogen, Thrombosis, Coagulation and
Fibrinolysis: Advances in Experimental Medicine and Biology. New York: Plenum
Press, 1990:383-7.
126.
White HD, Cross DB, Norris RM. Thrombolytic therapy and recurrent myocardial
infarction. New Zealand Medical Journal. 1990; 103:163-4.
127.
White HD. Relation of thrombolysis during acute myocardial infarction to left
ventricular function and mortality. American Journal of Cardiology. 1990; 66:92-5.
128.
Anonymous. Fourth International Study of Infarct Survival: protocol for a large
simple study of the effects of oral mononitrate, of oral captopril, and of
intravenous magnesium. ISIS-4 collaborative group. American Journal of
Cardiology. 1991; 68:87D-100D.
129.
Cross DB, Ashton NG, Norris RM, White HD. Comparison of the effects of
streptokinase and tissue plasminogen activator on regional wall motion after first
myocardial infarction: analysis by the centerline method with correction for area at
risk. Journal of the American College of Cardiology. 1991; 17:1039-46.
130.
Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and
treatment of coronary artery disease: a workshop consensus statement.
American Heart Journal. 1991; 121:1244-63.
131.
Elliott JM, White HD. Regression of atherosclerosis: fact or fiction? New Zealand
Medical Journal. 1991; 104:510-2.
132.
White HD. Comparative safety of thrombolytic agents. American Journal of
Cardiology. 1991; 68:30E-37E.
133.
White H. Thrombolytic treatment for recurrent myocardial infarction.[comment].
BMJ 1991; 302:429-30.
134.
White H, Cross D, Scott M, Norris R. Comparison of effects of thrombolytic
therapy on left ventricular function in patients over with those under 60 years of
age. American Journal of Cardiology. 1991; 67:913-8.
135.
White HD. Introduction 'From patency to mortality'. American Journal of
Cardiology 1991; 68:1E-2E.
136.
Agnew TM, French JK, Neutze JM, Whitlock RM, Brandt PW, Kerr AR, Webber
BJ, Rutherford JD. The role of dipyridamole in addition to aspirin in the prevention
of occlusion of coronary artery bypass grafts. Australian and New Zealand
Journal of Medicine 1992; 22:665-670.
137.
Anonymous. ISIS-3: a randomised comparison of streptokinase vs tissue
plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone
among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third
International Study of Infarct Survival) Collaborative Group, includes White
H.[comment]. Lancet. 1992; 339:753-70.
138.
Anonymous. Six-month survival in 20,891 patients with acute myocardial
infarction randomized between alteplase and streptokinase with or without
heparin. GISSI-2 and International Study Group. Gruppo Italiano per lo Studio
della Sopravvivenza nell'Infarto. European Heart Journal. 1992; 13:1692-7.
29
139.
Barbash GI, White HD, Modan M, Van de Werf F. Antecedent angina pectoris
predicts worse outcome after myocardial infarction in patients receiving
thrombolytic therapy: experience gleaned from the International Tissue
Plasminogen Activator/Streptokinase Mortality Trial. Journal of the American
College of Cardiology. 1992; 20:36-41.
140.
Elliott JM, Williams BF, White HD. Streptokinase and lifestyle outcome in
survivors of myocardial infarction. New Zealand Medical Journal. 1992; 105:1634.
141.
Gustavson CM, Norris RM. Clinical applications for decision support systems.
Healthc.Inf.Manage. 1992; 6:8-11.
142.
Haydock DA. Stretching the limits on cardiac allograft utilization. Coronary Artery
Disease 1992; 3:792-97.
143.
Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G. The
risk of stroke in patients with acute myocardial infarction after thrombolytic and
antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza
nell'Infarto Miocardico II (GISSI-2), and The International Study Group.[comment].
New England Journal of Medicine. 1992; 327:1-6.
144.
Neutze J, Cormack B, Kerr B, Pepper L, Ramage C. Contribution of a risk factor
clinic to lipid management in patients with coronary artery disease. N Z Med J
1992; 105:97-99.
145.
Norris RM, White HD, Cross DB, Wild CJ, Whitlock RM. Prognosis after recovery
from myocardial infarction: the relative importance of cardiac dilatation and
coronary stenoses. European Heart Journal. 1992; 13:1611-8.
146.
Norris RM, Ockelford PA, Cross DB, et al. Reduced synthesis of tissue
plasminogen activator by vascular endothelium during acute myocardial
infarction. Australian & New Zealand Journal of Medicine. 1992; 22:261-4.
147.
Stewart FM, Neutze JM, Newsome-White R. The addition of oatbran to a low fat
diet has no effect on lipid values in hypercholesterolaemic subjects. N Z Med J
1992; 105:398-400.
148.
Topol EJ, Armstrong P, Van de Werf F, Kleiman N, Lee K, Morris D, Simoons M,
Barbash G, White H, Califf RM. Confronting the issues of patient safety and
investigator conflict of interest in an international clinical trial of myocardial
reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator
for Occluded Coronary Arteries (GUSTO) Steering Committee. Journal of the
American College of Cardiology. 1992; 19:1123-8.
149.
White HD. Rationale for late thrombolytic therapy in acue myocardial infarction.
The major clinical trials of thrombolysis for acute myocardial infarction. New York:
Raven Press, 1992.
150.
White HD. Remodelling of the heart after myocardial infarction. Australian & New
Zealand Journal of Medicine. 1992; 22:601-6.
151.
White HD. Left ventricular function after thrombolysis. Interventional Cardiology
1992; 5:111-6.
152.
White HD. Thrombolytic therapy for patients with myocardial infarction presenting
after six hours. Lancet. 1992; 340:221-2.
153.
Anonymous. An international randomized trial comparing four thrombolytic
strategies for acute myocardial infarction. The GUSTO investigators.[comment].
New England Journal of Medicine. 1993; 329:673-82.
30
154.
Barbash GI, White HD, Modan M, Van de Werf F. Significance of diabetes
mellitus in patients with acute myocardial infarction receiving thrombolytic
therapy. Investigators of the International Tissue Plasminogen
Activator/Streptokinase Mortality Trial. Journal of the American College of
Cardiology. 1993; 22:707-13.
155.
Barbash GI, Modan M, Goldbourt U, White HD, Van de Werf F. Comparative case
fatality analysis of the International Tissue Plasminogen Activator/Streptokinase
Mortality Trial: variation by country beyond predictive profile. The Investigators of
the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Journal of the American College of Cardiology. 1993; 21:281-6.
156.
Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A,
Moulopoulos S, Paolasso EA, Van der Werf T, et al. Significance of smoking in
patients receiving thrombolytic therapy for acute myocardial infarction.
Experience gleaned from the International Tissue Plasminogen
Activator/Streptokinase Mortality Trial.[comment]. Circulation. 1993; 87:53-8.
157.
Baxter-Jones CS, White HD, Anderson JL. An overview of the patency and stroke
rates following thrombolysis with streptokinase, alteplase, and anistreplase used
to treat an acute myocardial infarction. Journal of Interventional Cardiology. 1993;
6:15-23.
158.
Bradley A, Elliott J, White H. Attitudes and practice of New Zealand doctors in the
management of patients with dyslipidaemia. New Zealand Medical Journal. 1993;
106:243-7.
159.
Elliott JM, Cross DB, Cederholm-Williams SA, White HD. Neutralizing antibodies
to streptokinase four years after intravenous thrombolytic therapy. American
Journal of Cardiology. 1993; 71:640-5.
160.
Ellis CJ, Van de Merwe W, Caruana M. Cholesterol emboli-induced renal failure
following cardiac angiography. European Journal of Medicine. 1993; 2:181-2.
161.
French JK, Elliott JM, Williams BF, Nixon DJ, Denton MA, White HD. Association
of angiographically detected coronary artery disease with low levels of highdensity lipoprotein cholesterol and systemic hypertension. American Journal of
Cardiology 1993; 71:505-510.
162.
Hamer AW, White HD. Women and coronary heart disease. New Zealand
Medical Journal. 1993; 106:176-7.
163.
Norris RM. Prognosis and risk assessment of patients with myocardial infarction.
In: Kapoor AS, Singh BN, eds. Prognosis and Risk Assessment in Cardiovascualr
Disease. New York: Churchill Livingstone, 1993:161-171.
164.
Norris RM, Twigden DG, Williams BF, Johnson RN, White HD. Use of creatine
kinase isoforms for diagnosis of infarct artery patency after thrombolytic therapy
with streptokinase. Coronary Artery Disease. 1993; 4:201-5.
165.
Norris RM, White HD, Cross DB, Woo KS, Elliott JM, Twigden D, Williams B,
Johnson RN. Non-invasive diagnosis of arterial patency after thrombolytic therapy
and its relationship to prognosis. British Heart Journal 1993; 69:485-91.
166.
Norris RM, White HD, Cross DB, Woo KS, Maslowski AH, Caruana MP, Hart HH,
Williams B. Aspirin does not improve early arterial patency after streptokinase
therapy for acute myocardial infarction. British Heart Journal 1993; 69:492-5.
167.
Scott WG, White HD, Scott HM. Cost of coronary heart disease in New
Zealand.[comment]. New Zealand Medical Journal. 1993; 106:347-9.
31
168.
Thompson PL, Tonkin AM, Aylward P, White H. Thrombolysis '93--overview and
conclusions. Australian & New Zealand Journal of Medicine. 1993; 23:774-7.
169.
White HD. Myocardial infarction: post thrombolytic risk assessment and
prognosis. In: Kapoor AS, Singh BN, eds. Prognosis and Risk Assessment in
Cardiovascular Disease. New York: Churchill Livingstone Inc, 1993:173-9.
170.
White HD, Barbash GI, Modan M, Simes J, Diaz R, Hampton JR, Heikkila J,
Kristinsson A, Moulopoulos S, Paolasso EA, et al. After correcting for worse
baseline characteristics, women treated with thrombolytic therapy for acute
myocardial infarction have the same mortality and morbidity as men except for a
higher incidence of hemorrhagic stroke. The Investigators of the International
Tissue Plasminogen Activator/Streptokinase Mortality Study. Circulation. 1993;
88:2097-103.
171.
White H. Issues raised by GUSTO. Australian & New Zealand Journal of
Medicine. 1993; 23:739-41.
172.
White H. Strokes and net clinical benefit. Australian & New Zealand Journal of
Medicine. 1993; 23:737-8.
173.
Woo KS, White HD. Pharmacoeconomic aspects of treatment of acute myocardial
infarction with thrombolytic agents. Pharmacoeconomics. 1993; 3:192-204.
174.
Woo KS, White HD. Comparative tolerability profiles of thrombolytic agents. A
review. Drug Safety. 1993; 8:19-29.
175.
Anonymous. Indications for fibrinolytic therapy in suspected acute myocardial
infarction: collaborative overview of early mortality and major morbidity results
from all randomised trials of more than 1000 patients. Fibrinolytic Therapy
Trialists' (FTT) Collaborative Group.[comment][erratum appears in Lancet 1994
Mar 19;343(8899):742]. Lancet. 1994; 343:311-22.
176.
Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A,
Moulopoulos S, Paolasso EA, Van der Werf T, et al. Outcome of thrombolytic
therapy in relation to hospital size and invasive cardiac services. The
Investigators of the International Tissue Plasminogen Activator/Streptokinase
Mortality Trial. Archives of Internal Medicine. 1994; 154:2237-42.
177.
Cross DB, White HD. Allergic reactions to streptokinase; does antibody formation
prevent reuse in a second myocardial infarction? Clinical Immunotherapeutics
1994:415-20.
178.
Ellis CJ, Wallis WE, Caruana M. Peripheral neuropathy with bezafibrate. BMJ
1994; 309:929.
179.
Granger CB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis of
coronary arterial patency and left ventricular function after intravenous
thrombolysis for acute myocardial infarction. American Journal of Cardiology.
1994; 74:1220-8.
180.
Hamer AW, Takayama M, Abraham KA, Roche AH, Kerr AR, Williams BF,
Ramage MC, White HD. End-systolic volume and long-term survival after
coronary artery bypass graft surgery in patients with impaired left ventricular
function. Circulation. 1994; 90:2899-904.
181.
Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, Holmes
DR Jr, Bates E, Pfisterer M, Vahanian A, et al. Mortality within 24 hours of
thrombolysis for myocardial infarction. The importance of early reperfusion. The
GUSTO Investigators, Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries.[comment]. Circulation.
1994; 90:2658-65.
32
182.
Norris RM, Singh BN. Pathogenesis and pharacologic management of myocardial
infarction. In: Singh BN, ed. Cardiovascular Pharmaceutial and Therapeutics.
New York: Churchill Livingstone, 1994:467-479.
183.
White HD, Cross DB, Elliott JM, Norris RM, Yee TW. Long-term prognostic
importance of patency of the infarct-related coronary artery after thrombolytic
therapy for acute myocardial infarction.[comment]. Circulation. 1994; 89:61-7.
184.
White HD. Scandinavian simvastatin study (4S)[comment]. Lancet. 1994;
344:1766; author reply 1767-8.
185.
White HD. Management of myocardial infarction.[comment]. New Zealand
Medical Journal. 1994; 107:184-5.
186.
White HD, Cross DB, Elliott JM, Norris RM, Yee TW. Long-term prognostic
importance of patency of the infarct-related coronary artery after thrombolytic
therapy for acute myocardial infarction. Circulation 1994; 89:61-67.
187.
Woo KS, White HD. Thrombolytic therapy in acute myocardial infarction. Current
Opinion in Cardiology 1994; 9:471-82.
188.
Woo KS, White HD. Factors affecting outcome after recovery from myocardial
infarction. Annual Review of Medicine. 1994; 45:325-39.
189.
Anonymous. ISIS-4: a randomised factorial trial assessing early oral captopril,
oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with
suspected acute myocardial infarction. ISIS-4 (Fourth International Study of
Infarct Survival) Collaborative Group.[comment]. Lancet. 1995; 345:669-85.
190.
Armiger LC, Woo KS, Norris RM. Can streptokinase improve the microcirculation
in the "no-reflow" zone of reperfused infarcts? Progr Microcirc Res 1995; 8:7-8.
191.
Armiger LC, Headrick JP, Jordan LR, Willis RJ. Bound inorganic phosphate and
early contractile failure in global ischaemia. Basic Res Cardiol 1995; 90:482-488.
192.
Barbash GI, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z, Morris
D, Aylward P, Woodlief LH, Topol EJ. Evaluation of paradoxic beneficial effects of
smoking in patients receiving thrombolytic therapy for acute myocardial infarction:
mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic
insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for
Occluded Coronary Arteries.[comment]. Journal of the American College of
Cardiology. 1995; 26:1222-9.
193.
Barbash GI, White HD, Modan M, et al. Acute myocardial infarction in the young-the role of smoking. The Investigators of the International Tissue Plasminogen
Activator/Streptokinase Mortality Trial.[comment]. European Heart Journal. 1995;
16:313-6.
194.
Ellis CJ, Parkinson GF, Jaffe WM, Campbell MJ, Kerr AR. Good long-term
outcome following surgical repair of post-infarction ventricular septal defect.
Australian & New Zealand Journal of Medicine. 1995; 25:330-6.
195.
French JK, White HD. Left ventricular function following thrombolytic therapy for
myocardial infarction. Clinical and Experimental Pharmacology and Physiology
1995; 22:173-179.
196.
Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash
GI, Van de Werf F, Aylward PE, Topol EJ, et al. Stroke after thrombolysis.
Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies
to Open Occluded Coronary Arteries.[comment]. Circulation. 1995; 92:2811-8.
33
197.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4:
a randomised factorial trial assessing early oral captopril, oral mononitrate, and
intravenous magnesium sulphate in 58,050 patients with suspected acute
myocardial infarction. Lancet 1995; 345:669-685.
198.
Karnash SL, Granger CB, White HD, Woodlief LH, Topol EJ, Califf RM. Treating
menstruating women with thrombolytic therapy: insights from the global utilization
of streptokinase and tissue plasminogen activator for occluded coronary arteries
(GUSTO-I) trial. Journal of the American College of Cardiology. 1995; 26:1651-6.
199.
Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G,
White H, Simoons ML, Nelson CL. Cost effectiveness of thrombolytic therapy with
tissue plasminogen activator as compared with streptokinase for acute
myocardial infarction.[comment][erratum appears in N Engl J Med 1995 Jul
27;333(4):267]. New England Journal of Medicine. 1995; 332:1418-24.
200.
White HD, French JK, Hamer AW, Brown MA, Williams BF, Ormiston JA, Cross
DB. Frequent reocclusion of patent infarct-related arteries between 4 weeks and
1 year: effects of antiplatelet therapy. Journal of the American College of
Cardiology 1995; 25:218-223.
201.
White HD, Cross DB, Williams BF, Norris RM, Woo KS, Hamer AW, Elliott JM,
Ormiston JA. "Rescue" thrombolysis with intracoronary tissue plasminogen
activator for failed intravenous thrombolysis with streptokinase for acute
myocardial infarction. American Journal of Cardiology. 1995; 75:172-4.
202.
White HD, Marder VJ. Streptokinase and anistreplase. In: Califf R, Mark DB,
Wagner GS, eds. Acute Coronary Care. St Louis: Mosby-Year Book Inc,
1995:297-303.
203.
White HD. Prognosis after myocardial infarction. In: Ball SG, ed. Myocardial
infarction: from trials to practice. Petersfield: Wrightson Biomedical Publishing
Limited, 1995:1-14.
204.
White HD, French JK, Norris RM, Williams BF, Hart HH, Cross DB. Effects of
streptokinase in patients presenting within 6 hours of prolonged chest pain with
ST segment depression.[comment]. British Heart Journal. 1995; 73:500-5.
205.
White HD. Angioplasty versus bypass surgery.[comment]. Lancet. 1995;
346:1174-5.
206.
White HD. Selecting a thrombolytic agent. Cardiology Clinics. 1995; 13:347-54.
207.
White HD. Thrombolytic therapy for acute myocardial infarction: where are we
now? Where should we go? Chinese Medical Journal. 1995; 108:462-5.
208.
White HD. Effects of thrombolytic therapy on left ventricular function and the
importance of long-term patency of the infarct-related artery. Clinical Science.
1995; 88:21-4.
209.
White HD. Lifting the smoke-screen: the enigma of better outcome in smokers
after myocardial infarction.[comment]. American Journal of Cardiology. 1995;
75:278-9.
210.
White HD, Yusuf S. Issues regarding the use of heparin following streptokinase
therapy. Journal of Thrombosis & Thrombolysis. 1995; 2:5-10.
211.
White HD, French JK, Norris RM, Williams BF, Hart HH, Cross DB. Effects of
streptokinase in patients presenting within 6 hours of prolonged chest pain with
ST segment depression. Br Heart J 1995; 73:500-505.
34
212.
Amos DJ, Tonkin AM, White HD. New insights into the pathogenesis, prevention
and management of acute coronary syndromes. Australian & New Zealand
Journal of Medicine. 1996; 26:344-8.
213.
Califf RM, White HD, Van de Werf F, et al. One-year results from the Global
Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I)
trial. GUSTO-I Investigators.[comment]. Circulation. 1996; 94:1233-8.
214.
French JK, Williams BF, Hart HH, Wyatt S, Poole JE, Ingram C, Ellis CJ, Williams
MG, White HD. Prospective evaluation of eligibility for thrombolytic therapy in
acute myocardial infarction.[comment]. British Medical Journal. 1996; 312:163741.
215.
French JK, Neutze JM, Webster MWI, White HD. Evidence-based assessment of
the benefit of revascularisation in coronary disease: beyond the randomised trials.
Australian and New Zealand Journal of Medicine 1996; 26:490-495.
216.
French J, Williams B, Hart H, Woo K, Wang L, Grant J, Ingram C, O’Brien P,
Poole J, Sharpe N, Williams M, White H. Management of acute myocardial
infarction in Auckland. New Zealand Medical Journal 1996; 109:248-251.
217.
Gallo R, Webster MW, Chesebro JH, Fuster V. Antithrombotic therapy in acute
myocardial infarction: enhancement of thrombolysis, reduction of occlusion and
prevention of thromboembolism. In: Gersh BJ, Rahimtoola SH, eds. Management
of acute myocardial infarction: Elsevier, 1996:472-501.
218.
Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL,
Bovill EG, Simes RJ, Topol EJ. Activated partial thromboplastin time and outcome
after thrombolytic therapy for acute myocardial infarction: results from the
GUSTO-I trial. Circulation. 1996; 93:870-8.
219.
Mruk JS, Zoldhelyi P, Webster MW, Heras M, Grill DE, Holmes DR Jr, Fuster V,
Chesebro JH. Does antithrombotic therapy influence residual thrombus after
thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or
aspirin. Circulation. 1996; 93:792-9.
220.
Norris RM, White HD, Hart HH, Williams BF. Comparison of aspirin with a
thromboxane antagonist for patients with prolonged chest pain and ST segment
depression. New Zealand Medical Journal. 1996; 109:278-80.
221.
Norris RM, Johnson RN, White HD, Robinson DR. Non-invasive diagnosis of
infarct artery patency after acute myocardial infarction by use of serial plasma
troponin T concentrations: importance of measurement of peak levels. Heart
1996; 75:481-485.
222.
Ramanathan K, Ellis CJ, White HD. Thrombolytic therapy in the elderly.
Pharmacoeconomic considerations. Drugs & Aging. 1996; 8:237-44.
223 .
Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM,
Bargash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM. Comparisons of
characteristics and outcomes among women and men with acute myocardial
infarction treated with thrombolytic therapy. GUSTO-I investigators.[comment].
Jama. 1996; 275:777-82.
225.
White HD. Myocardial infarction. In: Julian D, Camm AJ, Fox KM, Hall RJ, Poole
PA, eds. Diseases of the heart. London: WB Saunders Company Ltd, 1996:104275.
226.
White HD. Thrombolytic therapy. In: Thompson PL, ed. Coronary care manual.
London: Churchill Livingstone, 1996:285-97.
35
227.
White HD. Topics in preventive cardiology: the importance of early reperfusion
with thrombolytic treatment of acute myocardial infarction. Amsterdam: Experpta
Medica, 1996.
228.
White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, Kleiman
NS, Aylward PE, Gore JM, Vahanian A, Lee KL, Ross AM, Topol EJ. Age and
outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial.
Global Utilization of Streptokinase and TPA for Occluded coronary arteries
trial.[comment]. Circulation. 1996; 94:1826-33.
229.
Amos DJ, White HD. Remodeling after myocardial infarction: an opportunity for
early intervention. Basic Research in Cardiology. 1997; 92:69-71.
230.
Anonymous. A clinical trial comparing primary coronary angioplasty with tissue
plasminogen activator for acute myocardial infarction. The Global Use of
Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes
(GUSTO IIb) Angioplasty Substudy Investigators.[comment][erratum appears in N
Engl J Med 1997 Jul 24;337(4):287]. New England Journal of Medicine. 1997;
336:1621-8.
231.
Anonymous. A comparison of continuous infusion of alteplase with double-bolus
administration for acute myocardial infarction. The Continuous Infusion versus
Double-Bolus Administration of Alteplase (COBALT) Investigators.[comment].
New England Journal of Medicine. 1997; 337:1124-30.
232.
Califf RM, Woodlief LH, Harrell FE, Jr., Lee KL, White HD, Guerci A, Barbash GI,
Simes RJ, Weaver WD, Simoons ML, Topol EJ. Selection of thrombolytic therapy
for individual patients: development of a clinical model. GUSTO-I Investigators.
American Heart Journal. 1997; 133:630-9.
233.
Ellis CJ, White HD. New antiplatelet strategies in the adjunctive treatment of
acute myocardial infarction. In: Becker R, ed. textbook of Coronary Thrombosis
and Thrombolysis. Massachusetts: Kluwer Academic Publishers, 1997.
234.
Ellis CJ, French JK, White HD. Coronary Artery Patency and Survival in Clinical
Trials. 1997; 4:239-250.
235.
Holmes DR, Jr., Califf RM, Van de Werf F, Berger PB, Bates ER, Simoons ML,
White HD, Thompson TD, Topol EJ. Difference in countries' use of resources and
clinical outcome for patients with cardiogenic shock after myocardial infarction:
results from the GUSTO trial.[comment]. Lancet. 1997; 349:75-8.
236.
Gusto III Investigators (includes White H) .A comparison of reteplase with
alteplase for acute myocardial infarction. New England Journal of Medicine 1997;
337:1118-1123.
237.
Mahaffey KW, Granger CB, Toth CA, White HD, Stebbins AL, Barbash GI,
Vahanian A, Topol EJ, Califf RM. Diabetic retinopathy should not be a
contraindication to thrombolytic therapy for acute myocardial infarction: review of
ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization
of Streptokinase and t-PA for Occluded Coronary Arteries. Journal of the
American College of Cardiology. 1997; 30:1606-10.
238.
Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM,
Topol EJ. Influence of diabetes mellitus on clinical outcome in the thrombolytic
era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Journal of the American College of Cardiology. 1997; 30:171-9.
36
239.
Migrino RQ, Young JB, Ellis SG, White HD, Lundergan CF, Miller DP, Granger
CB, Ross AM, Califf RM, Topol EJ. End-systolic volume index at 90 to 180
minutes into reperfusion therapy for acute myocardial infarction is a strong
predictor of early and late mortality. The Global Utilization of Streptokinase and tPA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators.
Circulation. 1997; 96:116-21.
240.
Moen EK, Asher CR, Miller DP, Weaver WD, White HD, Califf RM, Topol EJ.
Long-term follow-up of gender-specific outcomes after thrombolytic therapy for
acute myocardial infarction from the GUSTO-I trial. Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Journal of Women's Health. 1997; 6:285-93.
241.
Ng WK, Vedder M, Whitlock RML, Milsom FP, Nisbet HD, Smith WM, Kerr AR,
French JK. Coronary revascularisation in young adults. European Journal of
Cardio-Thoracic Surgery 1997; 11:732-738.
242.
Scott L, Kerr A, Haydock D, Merrilees M. Subendothelial proteoglycan synthesis
and transforming growth factor beta distribution correlate with susceptibility to
atherosclerosis. Journal of Vascular Research. 1997; 34:365-77.
243.
Sonke GS, Stewart AW, Beaglehole R, Jackson R, White HD. Comparison of
case fatality in smokers and non-smokers after acute cardiac event. BMJ 1997;
315:992-3.
244.
Topol EJ, Califf RM, Van de Werf F, Simmoons M, Hampton J, Lee KL,White H,
Simes J, Armstrong PW. Perspectives on large-scale cardiovascular clinical trials
for the new millennium. The Virtual Coordinating Center for Global Collaborative
Cardiovascular Research (VIGOUR) Group. Circulation. 1997; 95:1072-82.
245.
White HD, Rapold HJ. Adjunctive antihrombotic strategies. In: DBecker RC, ed.
Textbook of coronary thrombosis and thrombolysis. Boston: Kluwer Academic
Publishers, 1997:355.
246.
White HD. Thrombolysis. In: Pitt B, Julian D, Pocock S, eds. Clinical trials in
cardiology. London: WB Saunders Company Ltd, 1997.
247.
White HD. Should all occluded infarct-related arteries be opened?[comment].
European Heart Journal. 1997; 18:1207-9.
248.
White HD, Aylward PE, Frey MJ, Adgey AA, Nair R, Hillis WS, Shalev Y, Brown
MA, French JK, Collins R, Maraganore J, Adelman B. Randomized, double-blind
comparison of hirulog versus heparin in patients receiving streptokinase and
aspirin for acute myocardial infarction (HERO). Hirulog Early
Reperfusion/Occlusion (HERO) Trial Investigators.[comment]. Circulation. 1997;
96:2155-61.
249.
White HD. Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor
inhibitors in acute ischemic coronary syndromes. American Journal of Cardiology.
1997; 80:44B-48B.
250.
White HD. Unmet therapeutic needs in the management of acute ischemia.
American Journal of Cardiology. 1997; 80:2B-10B.
251.
White HD. Clinical trials of direct thrombin inhibitors in acute ischaemic
syndromes. Thrombosis & Haemostasis. 1997; 78:364-6.
252.
White HD. Is heparin of value in the management of acute myocardial
infarction?[comment]. Cardiovascular Drugs & Therapy. 1997; 11:111-9.
253.
White HD. What is the standard for antithrombotic therapy? Perspectives in
Cardiology 1997; 13:29-37.
37
254.
White HD. Hirudin is modestly more effective than heparin in the treatment of
acute coronary syndromes. Evidence-Based Cardiovascular Medicine 1997; 1:19.
255.
White HD. Thrombin hypothesis: the MI 9B and GUSTO IIB trials have
successfully disproven/proven the thrombin hypothesis. Journal of Thrombosis &
Thrombolysis. 1997; 4:317-9.
256.
Woodfield SL, Lundergan CF, Reiner JS, Thompson MA, Rohrbeck SC, Deychak
Y, Smith JO, Burton JR, McCarthy WF, Califf RM, White HD, Weaver WD, Topol
EJ, Ross AM. Gender and acute myocardial infarction: is there a different
response to thrombolysis? Journal of the American College of Cardiology. 1997;
29:35-42.
257.
Anonymous. International, randomized, controlled trial of lamifiban (a platelet
glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON
Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary
syndrome events in a Global Organization Network. Circulation. 1998; 97:238695.
258.
Anonymous. Prevention of cardiovascular events and death with pravastatin in
patients with coronary heart disease and a broad range of initial cholesterol
levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Study Group.[comment]. New England Journal of Medicine. 1998; 339:1349-57.
259.
Brieger DB, Mak K-H, White HD, Kleiman NS, Miller DP, Vahanian A, Ross AM,
Califf RM, Topol EJ, for the GUSTO-I Investigators. Benefit of early sustained
reperfusion in patients with prior myocardial infarction (the GUSTO-I trial).
American Journal of Cardiology 1998; 81: 282-7.
el Gaylani N, Weston CF, Griffith K, Wong PS, Norris RM, Penny WJ. Acute
myocardial infarction: are there missed opportunities for reperfusion? UK Heart
Attack Study Investigators. Coron.Artery Dis 1998; 9:753-758.
Ellis CJ, French JK, White HD. Thrombolytic eligibility. Australian and New
Zealand Journal of Medicine 1998; 28: 518-24.
260.
261.
262.
Ellis CJ, Zambanini A, French JK, Denton M, Johnson R, Patel H, White HD.
Inadequate control of lipid levels in patients with a previous myocardial infarction.
New Zealand Medical Journal 1998; 111: 464-7.
263.
French JK, Ellis CJ, Webber BJ, Williams BF, Amos DJ, Ramanathan K, Whitlock
RML, White HD. Abnormal coronary flow in infarct arteries 1 year after myocardial
infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial
Infarction (TIMI) frame count and stenosis severity. American Journal of
Cardiology 1998; 81: 665-71.
264.
French JK, White HD. Adjunctive antithrombotic therapy for acute myocardial
infarction. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, editors.
Evidence based cardiology. London: BMJ Books; 1998. p. 460-78.
265.
Gebel JM, Sila CA, Sloan MA, Granger CB, Mahaffey KW, Weisenberger J,
Green CL, White HD, Gore JM, Weaver WD, Califf RM, Topol EJ. Thrombolysisrelated intracranial hemorrhage: a radiographic analysis of 244 cases from the
GUSTO-I trial with clinical correlation. Stroke 1998; 29: 563-9.
266.
Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng
JE, Lincoff AM, Hasselblad V, Topol EJ. Clinical outcomes of therapeutic agents
that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.
Circulation 1998; 98: 2829-35.
267.
MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, White H, on behalf
of the LIPID Trial Research Group. Effects of lowering average or below-average
38
cholesterol levels on the progression of carotid atherosclerosis: results of the
LIPID Atherosclerosis Substudy. Circulation 1998; 97: 1784-90.
268.
Mahaffey KW, Granger CB, Sloan MA, Thompson TD, Gore JM, Weaver WD,
White HD, Simoons ML, Barbash GI, Topol EJ, Califf RM, for the GUSTO-I
Investigators. Risk factors for in-hospital nonhemorrhagic stroke in patients with
acute myocardial infarction treated with thrombolysis: results from GUSTO-I.
Circulation 1998; 97: 757-64.
269.
Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, Fuster V,
MacAulay CM, Califf RM, Topol EJ, for the Global Use of Strategies to Open
Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb)
Investigators. Randomized comparison of direct thrombin inhibition versus
heparin in conjunction with fibrinolytic therapy for acute myocardial infarction:
results from the GUSTO-IIb trial. Journal of the American College of Cardiology
1998; 31: 1493-8.
270.
Neuhaus K-L, Zeymer U, White HD. CCU treatment of acute myocardial
infarction. In: Verstraete M, Fuster V, Topol EJ, editors. Cardiovascular
thrombosis: thrombocardiology and thromboneurology. 2nd ed. Philadelphia:
Lippincott-Raven Publishers; 1998. p. 499-510.
271.
Sloan MA, Sila CA, Mahaffey KW, Granger CB, Longstreth WT Jr, Koudstaal P,
White HD, Gore JM, Simoons ML, Weaver WD, Green CL, Topol EJ, Califf RM,
for the GUSTO-I Investigators. Prediction of 30-day mortality among patients with
thrombolysis-related intracranial hemorrhage. Circulation 1998; 98: 1376-82.
272.
Stewart JT, French JK, Théroux P, Ramanathan K, Solymoss BC, Johnson R,
White HD. Early noninvasive identification of failed reperfusion after intravenous
thrombolytic therapy in acute myocardial infarction. Journal of the American
College of Cardiology 1998; 31: 1499-505.
273.
Straznicky IT, White HD. Thrombolysis in elderly patients. In: Califf RM, editor.
Thrombolytic therapy: new standards of AMI care: part IV: patients with
complicating cardiac conditions. Belle Mead: American Journal of Cardiology;
1998. p. 23-8.
274.
White HD, French JK, Ellis CJ. New antiplatelet agents. Australian and New
Zealand Journal of Medicine 1998; 28: 558-64.
275.
White HD, Ellis CJ, French JK. Low molecular weight heparins in acute ischaemic
syndromes. Australian and New Zealand Journal of Medicine 1998; 28: 555-7.
276.
White HD, French JK, Ellis CJ, Aylward P. Hirudin (desirudin) and Hirulog
(bivalirudin) in acute ischaemic syndromes and the rationale for the Hirulog/Early
Reperfusion Occlusion (HERO 2) study. Australian and New Zealand Journal of
Medicine 1998; 28: 551-4.
277.
White HD. Unstable angina: ischemic syndromes. In: Topol EJ, editor.
Cardiovascular medicine. Philadelphia: Lippincott-Raven Publishers; 1998. p 35987. Also in: Topol EJ, editor. Comprehensive cardiovascular medicine.
Philadelphia: Lippincott-Raven Publishers; 1998. p. 395-423. Also in: Topol EJ,
editor. Cardiovascular medicine: enhanced multimedia CD-ROM. Philadelphia:
Lippincott-Raven Publishers, 1998.
278.
White HD. Direct thrombin inhibition and thrombolytic therapy: rationale for the
Hirulog and Early Reperfusion/Occlusion (HERO-2) trial. American Journal of
Cardiology 1998; 82: 57P-62P.
279.
White HD, Braunwald E. Applying the open artery theory: use of predictive
survival markers. European Heart Journal 1998; 19: 1132-9.
39
280.
White HD, Van de Werf FJJ. Thrombolysis for acute myocardial infarction.
Circulation 1998; 97: 1632-46.
281.
White HD. Thrombolytic therapy and equivalence trials [editorial]. Journal of the
American College of Cardiology 1998; 31: 494-6.
282.
White HD. Targeting therapy in unstable angina. Journal of Invasive Cardiology
1998; 10 Supplement D: 12D-21D.
283.
White HD. The therapy of myocardial infarction: streptokinase or tissue
plasminogen activator (tPA)? Die Gelben Hefte 1988; 3: 101-6.
284.
Zambanini A, French JK, Webster MWI, White HD. The roles for coronary surgery
and angioplasty in the management of patients with stable angina: evidence and
decision making. Journal of Evaluation in Clinical Practice 1998; 4: 93-102.
285.
Alexander JH, Granger CB, Sadowski ZP, Aylward PE, White HD, Thompson TD,
Califf RM, Topol EJ, for the GUSTO-I and GUSTO-IIb Investigators. Prophylactic
lidocaine use in acute myocardial infarction: incidence and outcomes from two
international trials. American Heart Journal 1999; 137: 799-805.
286.
Cohen M, Théroux P, Weber S, Laramée P, Huynh T, Borzak S, Diodati JG,
Squire IB, Deckelbaum LI, Thornton AR, Harris KE, Sax FL, Lo M-W, White HD.
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
International Journal of Cardiology 1999; 71: 273-81.
287.
French JK, White HD. Direct thrombin inhibitors as adjuncts to thrombolytic
therapy. Current Cardiology Reports 1999; 1(3): 184-91.
288.
French JK, White HD. Generalization of trial and registry cohort results to
individual patients with cardiogenic shock. ACC Current Journal Review 1999; 8
(6): 27-30.
289.
French JK, White HD. Glycoprotein IIb/IIIa antagonists in acute coronary
syndromes: clinical trials. Cardiology Review 1999; 16 (10): 43-53.
290.
French JK, White HD. Hirudin was superior to heparin in preventing CV death, MI
and refractory angina, in patients with unstable angina or MI without ST elevation
[commentary]. Evidence-Based Cardiovascular Medicine 1999; 3: 68-9.
291.
French JK, Hyde TA, White HD. Left ventricular function following thrombolytic
therapy for myocardial infarction. In: Timmis GC, editor. Thrombolytic therapy.
New York: Futura Publishing Company Inc; 1999. p. 293-304.
292.
French JK, Hyde TA, Patel H, Amos DJ, McLaughlin SC, Webber BJ, White HD.
Survival 12 years after randomization to streptokinase: the influence of
Thrombolysis in Myocardial Infarction flow at three to four weeks. Journal of the
American College of Cardiology 1999; 34: 62-9.
293.
French JK, Straznicky IT, Webber BJ, Aylward PE, Frey MJ, Adgey AAJ, Williams
BF, McLaughlin SC, White HD, for the HERO-1 Investigators. Angiographic frame
counts 90 minutes after streptokinase predict left ventricular function at 48 hours
following myocardial infarction. Heart 1999; 81: 128-33.
294.
French JK, Amos DJ, Williams BF, Cross DB, Elliott JM, Hart HH, Williams MG,
Norris RM, Ashton NG, Whitlock RML, McLaughlin SC, White HD. Effects of early
captopril administration after thrombolysis on regional wall motion in relation to
infarct artery blood flow. Journal of the American College of Cardiology 1999; 33:
139-45.
295.
French JK, White HD. Antithrombin agents as adjuncts to thrombolytic therapy.
Journal of Thrombosis and Thrombolysis 1999; 8: 159-66.
40
296.
Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD, for the
PRISM Study Investigators. Troponin concentrations for stratification of patients
with acute coronary syndromes in relation to therapeutic efficacy of tirofiban.
Lancet 1999; 354: 1757-62.
297.
Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller
CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH, for the SHOCK
Investigators. Early revascularization in acute myocardial infarction complicated
by cardiogenic shock. New England Journal of Medicine 1999; 341: 625-34.
298.
Hochman JS, Tamis JE, Thompson TD, Weaver WD, White HD, Van de Werf F,
Aylward P, Topol EJ, Califf RM, for the Global Use of Strategies to Open
Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. Sex,
clinical presentation, and outcome in patients with acute coronary syndromes.
New England Journal of Medicine 1999; 341: 226-32.
299.
Holmes DR Jr, White HD, Pieper KS, Ellis SG, Califf RM, Topol EJ. Effect of age
on outcome with primary angioplasty versus thrombolysis. Journal of the
American College of Cardiology 1999; 33: 412-9.
300.
Hyde TA, French JK, Wong C-K, Straznicky IT, Whitlock RML, White HD. Fouryear survival of patients with acute coronary syndromes without ST-segment
elevation and prognostic significance of 0.5-mm ST-segment depression.
American Journal of Cardiology 1999; 84: 379-85.
301.
Kleiman NS, Granger CB, White HD, Armstrong P, Ardissino D, Van de Werf F,
Zoldhelyi P, Thompson TD, Califf RM, Topol EJ. Death and nonfatal reinfarction
within the first 24 hours after presentation with an acute coronary syndrome:
experience from GUSTO-IIb. American Heart Journal 1999; 137: 12-23.
302.
Kong DF, Topol EJ, Bittl JA, White HD, Théroux P, Hasselblad V, Califf RM.
Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999; 100:
2049-53.
303.
Mahaffey KW, Granger CB, Sloan MA, Green CL, Gore JM, Weaver WD, White
HD, Simoons ML, Barbash GI, Topol EJ, Califf RM, and the GUSTO-I
Investigators. Neurosurgical evacuation of intracranial hemorrhage after
thrombolytic therapy for acute myocardial infarction: experience from the GUSTOI Trial. American Heart Journal 1999; 138: 493-9.
304.
Moliterno DJ, White HD. Unstable angina: PARAGON, PURSUIT, PRISM, and
PRISM-Plus. In: Lincoff AM, Topol EJ, editors. Contemporary cardiology: platelet
glycoprotein IIb/IIIa inhibitors in cardiovascular disease. Totowa: Humana Press
Inc; 1999. p. 201-27.
305.
Ohman EM, Armstrong PW, White HD, Granger CB, Wilcox RG, Weaver WD,
Gibler WB, Stebbins AL, Cianciolo C, Califf RM, Topol EJ, for the GUSTO-III
Investigators. Risk stratification with a point-of-care cardiac troponin T test in
acute myocardial infarction. American Journal of Cardiology 1999; 84: 1281-6.
306.
Puma JA, Sketch MH Jr, Thompson TD, Simes RJ, Morris DC, White HD, Topol
EJ, Califf RM. Support for the open-artery hypothesis in survivors of acute
myocardial infarction: analysis of 11,228 patients treated with thrombolytic
therapy. American Journal of Cardiology 1999; 83: 482-7.
307.
Timmis GC, White HD. Acute coronary syndromes: the clot is there. American
Journal of Cardiology 1999; 83: 1556-8.
308.
Tung CY, Granger CB, Sloan MA, Topol EJ, Knight JD, Weaver WD, Mahaffey
KW, White H, Clapp-Channing N, Simoons ML, Gore JM, Califf RM, Mark DB, for
41
the GUSTO II Investigators. Effects of stroke on medical resource use and costs
in acute myocardial infarction. Circulation 1999; 99: 370-6.
309.
White HD. Future of reperfusion therapy for acute myocardial infarction [editorial].
Lancet 1999: 354: 695-7.
310.
White HD. Optimal treatment of patients with acute coronary syndromes and nonST-elevation myocardial infarction. American Heart Journal 1999; 138: S105S114.
311.
White HD. Relationship between late infarct artery patency and outcome in the
reperfusion era: is there a role for percutaneous revascularisation? International
Journal of Cardiology 1999; 68 Supplement I: S15-22.
312.
White HD. Is thrombin a pharmacological target during reperfusion? Blood
Coagulation and Fibrinolysis 1999; 10 Supplement 1: S55-S57.
313.
White HD. Newer antiplatelet agents in acute coronary syndromes. American
Heart Journal 1999; 138: S570-6.
314.
Wong C-K, French JK, Aylward PE, Frey MJ, Adgey AAJ, White HD. Usefulness
of the presenting electrocardiogram in predicting successful reperfusion with
streptokinase in acute myocardial infarction. American Journal of Cardiology
1999; 83: 164-8.
315.
Andrews J, French JK, Manda SOM, White HD. New Q waves on the presenting
electrocardiogram independently predict increased cardiac mortality following a
first myocardial infarction. European Heart Journal 2000; 21: 647-53.
316.
Andrews J, Straznicky IT, French JK, Green CL, Maas ACP, Lund M, Krucoff
MW, White HD, for the HERO-1 Investigators. ST-segment recovery adds to the
assessment of TIMI 2 and 3 flow in predicting infarct wall motion after
thrombolytic therapy. Circulation 2000; 101: 2138-43.
317.
Braunwald E, Califf RM, Cannon CP, Fox KAA, Fuster V, Gibler WB, Harrington
RA, King SB III, Kleiman NS, Théroux P, Topol EJ, Van de Werf F, White HD,
Willerson JT. Redefining medical treatment in the management of unstable
angina. American Journal of Medicine 2000; 108: 41-53.
318.
Cohen M, Maritz F, Gensini GF, Danchin N, Timerman A, Huber K, Gurfinkel EP,
White H, Fox KAA, Vittori L, le-Louer V, Bigonzi F. The TETAMI Trial: the safety
and efficacy of subcutaneous enoxaparin versus intravenous unfractionated
heparin and of tirofiban versus placebo in the treatment of acute myocardial
infarction for patients not thrombolyzed: methods and design. Journal of
Thrombosis and Thrombolysis 2000; 10: 241-6.
319.
Dixon SR, Legget M, Wong SP. Ventricular septal aneurysm:a complication of
myocardial infarction. Echocardiography 2000; 17:439-42.
320.
Edwards CC, White HD. Door-to-needle times: room for improvement and need
for continuous audit [editorial]. Emergency Medicine 2000; 12: 91-4.
321.
French JK, Hyde TA, Straznicky IT, Andrews J, Lund M, Amos DJ, Zambanini A,
Ellis CJ, Webber BJ, McLaughlin SC, Whitlock RML, Patel H, White HD.
Relationship between corrected TIMI frame counts at three weeks and late
survival after myocardial infarction. Journal of the American College of Cardiology
2000; 35: 1516-24.
322.
Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, Godfrey E,
White HD, Lim J, LeJemtel T, for the SHOCK Investigators. Cardiogenic shock
complicating acute myocardial infarction – etiologies, management and outcome:
42
a report from the SHOCK Trial Registry. Journal of the American College of
Cardiology 2000; 36: 1063-70.
323.
Jacobs AK, French JK, Col J, Sleeper LA, Slater JN, Carnendran L, Boland J,
Jiang X, LeJemtel TH, Hochman JS. Cardiogenic shock with non-ST-segment
elevation myocardial infarction: a report from the SHOCK Trial Registry. Journal
of the American College of Cardiology 2000; 36:1091-1096.
324.
Lund M, French JK, White HD. Occluded infarct-related arteries and clinical
events. Progress in Cardiovascular Diseases 2000; 42: 405-18.
325.
MacMahon S, Sharpe N, Gamble G, Clague A, Ni Mhurchu C, Clark T, Hart H,
Scott J, White H. Randomised, placebo-controlled trial of the angiotensin
converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive
arterial disease. Journal of the American College of Cardiology 2000; 36: 438-43.
326.
McGuire DK, Emanuelsson H, Granger CB, Ohman EM, Moliterno DJ, White HD,
Ardissino D, Box JW, Califf RM, Topol EJ, for the GUSTO-IIb Investigators.
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute
coronary syndromes: findings from the GUSTO-IIb Study. European Heart
Journal 2000; 21: 1750-8.
327.
Menon V, Slater JN, White HD, Sleeper LA, Cocke T, Hochman JS. Acute
myocardial infarction complicated by systemic hypoperfusion without
hypotension: report of the SHOCK Trial Registry. American Journal of Medicine
2000; 108: 374-80.
328.
Menon V, White H, LeJemtel T, Webb JG, Sleeper LA, Hochman JS, for the
SHOCK Investigators. The clinical profile of patients with suspected cardiogenic
shock due to predominant left ventricular failure: a report from the SHOCK Trial
Registry. Journal of the American College of Cardiology 2000; 36: 1071-6.
329.
Mruk JS, Webster MW, Heras M, Reid JM, Grill DE, Chesebro JH. Flavone-8acetic acid (Flavonoid) profoundly reduces platelet-dependent thrombosis and
vasoconstriction after deep arterial injury In vivo.[comment]. Circulation. 2000;
101:324-8.
330.
Newby LK, Eisenstein EL, Califf RM, Thompson TD, Nelson CL, Peterson ED,
Armstrong PW, Van de Werf F, White HD, Topol EJ, Mark DB. Cost effectiveness
of early discharge after uncomplicated acute myocardial infarction. New England
Journal of Medicine 2000; 342: 749-55.
331.
Sanborn TA, Sleeper LA, Bates ER, Jacobs AK, Boland J, French JK, Dens J,
Dzavik V, Palmeri ST, Webb JG, Goldberger M, Hochman JS, for the SHOCK
Investigators. Impact of thrombolysis, intra-aortic balloon pump counterpulsation,
and their combination in cardiogenic shock complicating acute myocardial
infarction: a report from the SHOCK Trial Registry. Should we emergently
revascularize Occluded Coronaries for cardiogenic shock? Journal of the
American College of Cardiology. 2000; 36:1123-9.
332.
Stewart RA, Kittelson J, Kay IP. Statistical methods to improve the precision of
the treadmill exercise test. Journal of the American College of Cardiology. 2000;
36:1274-9.
333.
Straznicky IT, White HD. Thrombolytic therapy for acute myocardial infarction in
the elderly. Coronary Artery Disease 2000; 11: 299-304.
334.
Théroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS,
Tognoni G, White HD, Willerson JT, Jessel A, for the Guard During Ischemia
Against Necrosis (GUARDIAN) Investigators. Inhibition of the sodium-hydrogen
43
exchanger with cariporide to prevent myocardial infarction in high-risk ischemic
situations: main results of the GUARDIAN Trial. Circulation 2000; 102: 3032-8.
335.
Tonkin AM, Colquhoun D, Emberson J, Hague W, Keech A, Simes RJ, Lane G,
MacMahon S, Shaw J, Thompson PL, White HD, Hunt D, for the LIPID Study
Group. Effects of pravastatin in 3260 patients with unstable angina: results from
the LIPID Study. Lancet 2000; 356: 1871-5.
336.
Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, Aylward P, Simes J,
Dalby A, Betriu A, Bode C, White HD, Hochman JS, Emanuelson H, Vahanian A,
Sapp S, Stebbins A, Moliterno DJ, Califf RM, on behalf of the GUSTO III
Investigators. Survival outcomes 1 year after reperfusion therapy with either
alteplase or reteplase for acute myocardial infarction: results from the Global
Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III
Trial. Circulation 2000; 102: 1761-5.
337.
Van de Water NS, French JK, Lund M, Hyde TA, White HD, Browett PJ.
Prevalence of factor V Leiden and prothrombin variant G20210A in patients age
<50 years with no significant stenoses at angiography three to four weeks after
myocardial infarction. Journal of the American College of Cardiology 2000; 36:
717-22.
338.
Webb JG, Sleeper LA, Buller CE, Boland J, Palazzo A, Buller E, White HD,
Hochman JS, for the SHOCK Investigators. Implications of the timing of onset of
cardiogenic shock after acute myocardial infarction: a report from the SHOCK
Trial Registry. Journal of the American College of Cardiology 2000; 36: 1084-90.
339.
White HD. Thrombolytic therapy in the elderly [editorial]. Lancet 2000; 356: 202830.
340.
White HD. Cardiogenic shock: a more aggressive approach is now warranted
[editorial]. European Heart Journal 2000; 21: 1897-901.
341.
White HD. Low molecular weight heparin and platelet glycoprotein IIb/IIIa receptor
blockade in the treatment of acute coronary syndromes: complementary or
competing therapies? Journal of Invasive Cardiology 2000; 12 Supplement A: 6A13A.
342.
White HD. International differences: selection, noise, or real? [editorial] European
Heart Journal 2000; 21: 339-42.
343.
White HD. Single bolus tenecteplase was equivalent to front-loaded alteplase for
30-day mortality after acute MI [editorial]. Evidence-Based Cardiovascular
Medicine 2000; 4: 16.
344.
Wong SC, Sanborn T, Sleeper LA,Webb JG, Pilchik R, Hart D, Mejnartowicz S,
Antonelli TA, Lange R, French JK, Bergman G, LeJemtel T, Hochman JS.
Angiographic findings and clinical correlates in patients with cardiogenic shock
complicating acute myocardial infarction: a report from the SHOCK Trial Registry.
Should we emergently revascularize Occluded Coronaries for cardiogenic shock?
Journal of the American College of Cardiology 2000; 36:1077-1083.
345.
Wong C-K, Amos DJ, White HD. Does infection have a role in the pathogenesis
of coronary artery disease? New Zealand Medical Journal 2000; 113: 190-2.
346.
Wong CK, White HD. Medical treatment for acute coronary syndromes. Current
Opinion in Cardiology 2000; 15: 441-62.
347.
Wong C-K, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM, for
the GUSTO-III Investigators. New atrial fibrillation after acute myocardial
infarction independently predicts death: the GUSTO-III experience. American
Heart Journal 2000; 140: 878-85.
44
348.
Woo KS, Armiger LC, White HD, Norris RM. Can streptokinase produce beneficial
effects additional to coronary recanalization? Quantitative microvascular analysis
of critically injured reperfused myocardium. Microvascular Research 2000; 60: 820.
349.
Amos DJ, French JK, Andrews J, Ashton NG, Williams BF, Whitlock RML, Manda
SOM, White HD. Corrected TIMI frame counts correlate with stenosis severity
and infarct zone wall motion after thrombolytic therapy. American Heart Journal
2001; 41: 586-91.
350.
Direct Thrombin Inhibitor Trialists’ Collaborative Group [including White HD].
Direct thrombin inhibitors in acute coronary syndromes: design of a meta-analysis
based on individual patient data. American Heart Journal 2001; 141: e2.
351.
Aroney C, Boyden AN, Jelinek MV, Thompson P, Tonkin AM, White H. Current
guidelines for the management of unstable angina: a new diagnostic and
management paradigm. Internal Medicine Journal 2001; 31: 104-11.
352.
Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, Webb JG,
Steingart R, Picard MH, Menegus MA, Boland J, Sanborn T, Buller CE, Modur S,
Forman R, Desvigne-Nickens P, Jacobs AK, Slater JN, LeJemtel TH, for the
SHOCK Investigators. One-year survival following early revascularization for
cardiogenic shock. Journal of the American Medical Association 2001; 285: 1902.
353.
The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators
[including White HD]. Thrombin-specific anticoagulation with bivalirudin versus
heparin in patients receiving fibrinolytic therapy for acute myocardial infarction:
the HERO-2 randomised trial. Lancet 2001; 358: 1855-63.
354.
Kutryk M, White H. Acute coronary syndromes. In: Curzen N, Rothman MT.
Coronary artery stenting: a case-oriented approach. London: Martin Dunitz; 2001.
p. 117-132.
355.
Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, Singh BB,
Friedlander D, White H, Thompson P, Tonkin A, on behalf of the LIPID Study
Investigators. Long-term risk stratification for survivors of acute coronary
syndromes: results from the Long-Term Intervention with Pravastatin in Ischemic
Disease (LIPID) Study. Journal of the American College of Cardiology 2001; 38:
56-63.
356.
Merry AF, Smith WM, Anderson DJ, Emmens DJ, Choong CK. Cost-effectiveness
of spinal cord stimulation in patients with intractable angina. 2001; 114:179-181.
357.
Merry AF, Smith W, Emmens DJ, Anderson D, Choong CK. Spinal cord
stimulation for angina - an analysis of resource utilisation. New Zealand Medical
Journal 2001; 114:179-181.
358.
Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD,
Armstrong PW, Van de Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ,
for the PARAGON-B Investigators. Benefit of glycoprotein IIb/IIIa inhibition in
patients with acute coronary syndromes troponin T-positive status: the
PARAGON-B Troponin T Substudy. Circulation 2001; 103: 2891-6.
359.
Peters RJG, Spickler W, Theroux P, White H, Gibson M, Molhoek PG, Anderson
HV, Weitz JI, Hirsh J, Weaver WD. Randomized comparison of a novel
anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for
acute myocardial infarction: results of the VITAL Study (Vasoflux International
Trial for Acute Myocardial Infarction Lysis). American Heart Journal 2001; 142:
237-43.
45
360.
Roe MT, Granger CB, Puma JA, Hellkamp AS, Hochman JS, Ohman EM, White
HD, Van de Werf F, Armstrong PW, Ellis SG, Califf RM, Topol EJ. Comparison of
benefits and complications of hirudin versus heparin for patients with acute
coronary syndromes undergoing early percutaneous coronary intervention.
American Journal of Cardiology 2001; 88: 1403-6.
361.
Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW,
Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ. Platelet
glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-STsegment elevation acute coronary syndromes. Circulation 2001; 104: 2767-71.
362.
Second SYMPHONY Investigators [including White HD]. Randomized trial of
aspirin, sibrafiban, or both for secondary prevention after acute coronary
syndromes. Circulation 2001; 103: 1727-33.
363.
Van de Water NS, French JK, McDowell J, Browett PJ. The endothelial protein C
receptor (EPCR) 23bp insert in patients with myocardial infarction. Thrombosis
and Haemostasis 2001; 85:749-751.
364.
White HD. Defining the limits of acute coronary syndromes. In: Opie LH, Yellon
DM, editors. Cardiology at the limits IV. Cape Town: Stanford Writers; 2001. p.
33-59.
365.
White H; Hirulog and early reperfusion or occlusion (HERO)-2 Trial
investigatoors. Thrombin-specific anticoagulation with bivalirudin versus heparin
in patients receiving fibrinolytic therapy for acute myocardial infarction: the Hero-2
randomised trial (comment) Lancet 2001;358:1855-63.
366.
White HD. Prehospital thrombolysis [editorial]. New Zealand Medical Journal
2001; 114: 195-6.
367.
Wong C-K, French JK, Zambanini A, Andrews J, Aylward PEG, Adgey AAJ, Frey
MJ, White HD. Relation of pathologic Q waves at presentation and time to
streptokinase therapy with early changes in infarct-related artery flow and
ventricular wall motion. American Journal of Cardiology 2001; 88: 558-61.
368.
Al-Khatib SM, Granger CB, Huang Y, Lee KL, Califf RM, Simoons ML, Armstrong
PW, Van de Werf F, White HD, Simes RJ, Moliterno DJ, Topol EJ, Harrington RA.
Sustained ventricular arrhythmias among patients with acute coronary syndromes
with no ST-segment elevation: incidence, predictors, and outcomes. Circulation
2002; 106: 309-12.
369.
Anderson RD, White HD, Ohman EM, Wagner GS, Krucoff MW, Armstrong PW,
Weaver WD, Gibler WB, Stebbins AL, Califf RM, Topol EJ. Predicting outcome
after thrombolysis in acute myocardial infarction according to ST-segment
resolution at 90 minutes: a substudy of the GUSTO-III Trial. American Heart
Journal 2002; 144: 81-8.
370.
Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, de
Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ,
Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes:
a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-98.
371.
Cohen M, Théroux P, Borzak S, Frey MJ, White HD, van Mieghem W, Senatore
F, Lis J, Mukherjee R, Harris K, Bigonzi F, on behalf of the ACUTE II
Investigators. Randomized double-blind safety study of enoxaparin versus
unfractionated heparin in patients with non-ST-segment elevation acute coronary
syndromes treated with tirofiban and aspirin: the ACUTE II study. American Heart
Journal 2002; 144: 470-7.
46
372.
Edmond JJ, French JK, Henny H, Belz LM, West T, Stewart R, White HD.
Prospective evaluation of a chest pain pathway at Green Lane Hospital. New
Zealand Medical Journal [serial online] 2002 July 26 [cited 2002 July
29];115(1158):[9 screens]. Available from URL:
http://www.nzma.org.nz/journal/115-1158/103/content.pdf
373.
Edwards C, Stewart RAH, Ramanathan K, West TM, French JK, White HD.
Increased myocardial ischemia after food is not explained by endothelial
dysfunction. American Heart Journal 2002; 144: e8.
374.
Eikelboom JW, French J. Management of patients with acute coronary
syndromes: what is the clinical role of direct thrombin inhibitors? Drugs 2002;
62:1839-1852.
375.
French JK, Andrews J, Manda SOM, Stewart RAH, McTigue JJC, White HD.
Early ST-segment recovery, infarct artery blood flow, and long-term outcome after
acute myocardial infarction. American Journal of Cardiology 2002; 143: 265-71.
376.
Glasziou PP, Eckermann SD, Mulray SE, Simes RJ, Martin AJ, Kirby AC, Hall JP,
Caleo S, White HD, Tonkin AM. Cholesterol-lowering therapy with pravastatin in
patients with average cholesterol levels and established ischaemic heart disease:
is it cost-effective? Medical Journal of Australia 2002; 177: 428-34.
377.
Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD, on behalf of
the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM)
Investigators. Withdrawal of statins increases event rates in patients with acute
coronary syndromes. Circulation 2002; 105: 1446-52.
378.
Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW,
Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D,
Savonitto S, Bar F, Sadowsky Z, Betriu A, Booth JE, Wolski K, Waller M, Topol
EJ, for the GUSTO V Investigators. Mortality at 1 year with combination platelet
glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy versus
conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V
randomized trial. Journal of the American Medical Association 2002; 288: 2130-5.
379.
Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS,
Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf
RM, Topol EJ. Promise of combined low-molecular-weight heparin and platelet
glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the
Reduction of Acute Coronary Events in a Global Organization Network B
(PARAGON B). American Heart Journal 2002; 144: 995-1002.
380.
PACIFIC Study Group [including White H]. Dose-dependent effects of folic acid
on plasma homocysteine in a randomized trial conducted among 723 individuals
with coronary heart disease. European Heart Journal 2002; 23: 1509-15.
381.
Newby LK, Califf RM, White HD, Harrington RA, Van de Werf F, Granger CB,
Simes RJ, Hasselblad V, Armstrong PW. The failure of orally administered
glycoprotein IIb/IIIa inhibitors to preent recurrent cardiac events. American
Journal of Medicine 2002; 112: 647-58.
382.
Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heeschen C,
Hamm CW, Robbins MA, Kleiman NS, Théroux P, White HD, Topol EJ. Platelet
glycoprotein IIb/IIIa inhibition in acute coronary syndromes: gradient of benefit
related to the revascularization strategy. European Heart Journal 2002; 23: 14418.
383.
Savonitto S, Granger CB, Ardissino D, Gardner L, Cavallini C, Galvani M, Ottani
F, White HD, Armstrong PW, Ohman EM, Pieper KS, Califf RM, Topol EJ, on
47
behalf of the GUSTO-IIb Investigators. The prognostic value of creatine kinase
elevations extends across the whole spectrum of acute coronary syndromes.
Journal of the American College of Cardiology 2002; 39: 22-9.
384.
Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RAH, Hague
W, Keech A, Thompson P, White H, Shaw J, Tonkin A, on behalf of the LIPID
Study Investigators. Relationship between lipid levels and clinical outcomes in the
Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: to
what extent is the reduction in coronary events with pravastatin explained by onstudy lipid levels? Circulation 2002; 105: 1162-9.
385.
West MJ, White HD, Simes RJ, Kirby A, Watson JD, Anderson NE, Hankey GJ,
Wonders S, Hunt D, Tonkin AM. Risk factors for non-haemorrhagic stroke in
patients with coronary heart disease and the effect of lipid-modifying therapy with
pravastatin. Journal of Hypertension 2002; 20: 2513-7.
386.
White H, Hochman JS. Emergency revascularization in acute myocardial
infarction complicated by cardiogenic shock  results of the SHOCK Trial. In:
Braunwald E, editor. Harrison’s advances in cardiology. McGraw-Hill Companies
Inc; 2002. p. 185-7.
387.
White HD. Non-ST-elevation acute coronary syndromes: unstable angina and
non-ST-elevation myocardial infarction. In: Topol EJ, editor. Textbook of
cardiovascular medicine. 2nd edition. Philadelphia: Lippincott Williams & Wilkins;
2002. p. 351-84.
388.
White HD, Chew DP. Bivalirudin: an anticoagulant for acute coronary syndromes
and coronary interventions. Expert Opinion on Pharmacotherapy 2002; 3: 777-88.
389.
White HD. Things ain’t what they used to be: impact of a new definition of
myocardial infarction [editorial]. American Heart Journal 2002; 144: 933-7.
390.
White HD. Improved efficacy and less bleeding: further evidence of a unique
uncoupling of benefit and risk with bivalirudin [editorial]. American Heart Journal
2002; 143: 189-92.
391.
White HD, Wong CK. Risk stratification and treatment benefits in patients with
non-ST-elevation acute coronary syndromes [editorial]. European Heart Journal
2002; 23: 187-91.
392.
White HD. Further evidence that antithrombotic therapy is beneficial with
streptokinase: improved early ST resolution and late patency with enoxaparin
[editorial]. European Heart Journal 2002; 23: 1233-7.
393.
Williams M, Stewart R. Inflammation, atherosclerosis and predicting
cardiovascular risk. New Zealand Medical Journal. 2002; 115:U196.
394.
Wong CK, French JK, Gao W, White HD. Relation of initial platelet counts to
Thrombolysis in Myocardial Infarction-3 flow rates at 90 minutes after
commencing fibrinolytic therapy in patients with acute myocardial infarction.
American Journal of Cardiology 2002; 90: 54-7.
395.
Wong C-K, French JK, Krucoff MW, Gao W, Aylward PE, White HD. Slowed ST
segment recovery despite early infarct artery patency in patients with Q waves at
presentation with a first acute myocardial infarction: implications of initial Q waves
on myocyte reperfusion. European Heart Journal 2002; 23: 1449-55.
396.
Wong C-K, French JK, Andrews J, Frey MJ, Adgey AAJ, Aylward PE, White HD.
Usefulness of the presenting electrocardiogram in predicting myocardial salvage
with thrombolytic therapy in patients with a first acute myocardial infarction.
European Heart Journal 2002; 23: 399-404.
48
397.
Wong C-K, White HD. Risk stratification of patients with right ventricular
infarction: is there a need for a specific risk score? [editorial] European Heart
Journal 2002; 23: 1642-5.
398.
Wong C-K, White HD. Relation between blood pressure after an acute coronary
event and subsequent cardiovascular risk [editorial]. Heart 2002; 88: 555-8.
399.
Wong C-K, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM, for
the GUSTO-III Investigators. Management and outcome of patients with atrial
fibrillation during acute myocardial infarction: the GUSTO-III experience. Heart
2002; 88: 357-62.
400.
Wong C-K, White HD. Has the mortality rate from acute myocardial infarction
fallen substantially in recent years? [editorial] European Heart Journal 2002; 23:
689-92.
401.
Wong C-K, White HD. Recognising “painless” heart attacks [editorial] [published
erratum available from URL:
http://heart.bmjjournals.com/cgi/content/full/87/1/3/DC1]. Heart 2002; 87: 3-5.
402.
Al-Khatib SM, Stebbins AL, Califf RM, Lee KL, Granger CB, White HD, Armstrong
PW, Topol EJ, Ohman EM. Sustained ventricular arrhythmias and mortality
among patients with acute myocardial infarction: results from the GUSTO-III Trial.
American Heart Journal 2003; 145: 515-21.
403.
Bittl JA, White HD, Antman EM. Clinical trials of direct thrombin inhibitors. In:
Manson JAE, Buring JE, Ridker PM, Gaziano JM, editors. Clinical trials in
cardiovascular disease. 2nd edition. WB Saunders Company. In press 2004.
404.
Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A,
Krzeminska-Pakula M, Danchin N, White HD, Santopinto J, Bigonzi F, Hecquet C,
Vittori L, on behalf of the TETAMI Investigators. The safety and efficacy of
subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban
versus placebo in the treatment of acute ST-segment elevation myocardial
infarction patients ineligible for reperfusion (TETAMI): a randomized trial. Journal
of the American College of Cardiology. In press 2016.
405.
Eikelboom J, White H, Yusuf S. The evolving role of direct thrombin inhibitors in
acute coronary syndromes. Journal of the American College of Cardiology 2003;
41 Supplement S: 70S-78S.
406.
French JK, White HD. Adjunctive antithrombotic therapy for ST-elevation acute
myocardial infarction. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ,
editors. Evidence-based cardiology. 2nd edition. London: BMJ Books; 2003. p.
456-476.
407.
French JK, Van de Water NS, Sutton TM, Lund M, Gao W, McDowell J, LiuStratton Y, Pohorence J, Szymanski D, Goldschmidt-Clermont P, White HD,
Browett PJ, Cooke G. Potential thrombophilic mutations/polymorphisms in
patients with no flow-limiting stenosis after myocardial infarction. American Heart
Journal 2003; 145: 118-24.
408.
French JK, Ramanathan K, Stewart JT, Gao W, Théroux P, White HD. A score
predicts failure of reperfusion after fibrinolytic therapy for acute myocardial
infarction. American Heart Journal 2003; 145: 508-14.
409.
French JK, White HD. Tirofiban: a paradigm for “small molecule” glycoprotein
IIb/IIIa receptor antagonists? In: Sasahara AA, Loscalzo J, editors. New
therapeutic agents in thrombosis and thrombolysis. New York: Marcel Dekker Inc;
2003. p. 389-400.
49
410.
Hyde TA, French JK, Wong C-K, Edwards C, Whitlock RML, White HD.
Associations between ST depression, four year mortality, and in-hospital
revascularisation in unselected patients with non-ST elevation acute coronary
syndromes. Heart 2003; 89: 490-5.
411.
Newby LK, Hasselblad V, Armstrong PW, Van de Werf F, Mark DB, White HD,
Topol EJ, Califf RM. Time-based risk assessment after myocardial infarction:
implications for timing of discharge and applications to medical decision-making.
European Heart Journal 2003; 24: 182-9.
412.
Newby LK, Bhapkar MV, White HD, Topol EJ, Dougherty FC, Harrington RA,
Smith MC, Asarch LF, Califf RM, for the SYMPHONY and 2nd SYMPHONY
Investigators. Predictors of 90-day outcome in patients stabilized after acute
coronary syndromes. European Heart Journal 2003; 24: 172-82.
413.
French JK, White HD. Acute myocardial infarction with ST elevation. In: Falk E, et
al, editors. Colour handbook of ischaemic heart disease. London: Manson
Publishing. In press 2016.
414.
White HD. AMI reperfusion therapy: thrombolytic therapy remains best for most.
In: Stone GW, Leon MB, editors. Textbook of coronary stenting. New York: CRF
Publications. In press 2016.
415.
White HD. Risk assessment of patients with acute coronary syndromes. In:
Tonkin A, editor. Atherosclerosis and heart disease. London: Martin Dunitz. In
press 2016.
416.
White HD. Use of brain natriuretic peptide levels for risk assessment in non-STelevation acute coronary syndromes [editorial]. Journal of the American College
of Cardiology. In press 2016.
417.
Wong C-K, French JK, Gao W, White HD. Relationship between initial white
blood cell counts, stage of acute myocardial infarction evolution at presentation
and incidence of Thrombolysis in Myocardial Infarction-3 flow after streptokinase.
American Heart Journal 2003; 145: 95-102.
418.
Wong CK, White HD. Risk assessment in acute coronary syndromes. In: Becker
RC, Harrington RA, editors. The practice of clinical, interventional, and
investigational thrombocardiology. In press 2016.
419.
Wong C-K, White HD. Myocardial infarction: why can’t we get the diagnosis right?
[editorial] European Heart Journal 2003; 24: 1177-9.
420.
Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM.
Significance of atrial fibrillation during acute myocardial infarction, and its current
management: insights from the GUSTO-3 trial. Cardiac Electrophysiology
Review. In press 2016.
421.
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP,
Solomon SD, Swedberg K, Van de Werf F, White HD, Leimberger JD, Henis M,
Edwards S, Zelenkofske S, Sellers MA, Califf RM for the VALIANT Investigators.
Effects of valsartan relative to captopril in patients with myocardial infarction
complicated by heart failure and or left ventricular dysfunction. New England
Medical Journal. In press 2003.
422.
Savonitto S, Armstrong PW, Lincoff AM, Jia G, Sila CA, Booth J, Terrosu P,
Cavallini C, White HD, Ardission D, Califf RM, Topol EJ, for the Gusto V
Investigators. Risk of intracranial haemorrhage with combined fibrinolytic and
glycoprotein llB/llla inhibitor therapy in acute myocardial infarction. Dichotomous
response as a function of age in the GUSTO V trial. European Heart Journal
2003; 24: 1807-14
50
Adult Cardiology
General Cardiology
1.
O'Brien KP. Mitral incompetence due to ruptured chordae. N Z Med J 1965;
64:Suppl-4.
2.
Norris RM, Jamison DL. Resuscitation from cardiac arrest. N Z Med J 1967;
66:68-76.
3.
Agnew TM. Premature valve closure in patients with a Starr-Edwards mitral
prosthesis and aortic incompetence. British Heart Journal 1970; 32:436.
4.
Croxson MS, Altmann MM, O'Brien KP. Dental status and recurrence of
Streptococcus viridans endocarditis. Lancet 1971; 1:1205-1207.
5.
Croxson MS, O'Brien KP, Lowe JB. Traumatic tricuspid regurgitation. Long-term
survival. Br Heart J 1971; 33:750-755.
6.
Neutze JM, Arter WJ. Bacterial endocarditis and the dentist. N Z Dent.J 1971;
67:79-84.
7.
Smith HJ, Roche AH, Jagusch MF, Herdson PB. Cardiomyopathy associated with
amphetamine administration. Am Heart J 1976; 91:792-797.
8.
MacCulloch D, Menzies R, Cornere BM. Endocarditis due to Citrobacter diversus
developing resistance to cephalothin. New Zealand Medical Journal. 1977;
85:182-3.
9.
Nicholson MR, Roche AH, Kerr AR, Long S. Mitral valve vegetations in bacterial
endocarditis resembling left atrial myxoma. Australian & New Zealand Journal of
Medicine. 1980; 10:327-9.
10.
Hay DR, Ellis-Pegler RB, Faoagali J, Leslie PN, Neutze JM. Prevention of
infective endocarditis associated with dental treatment and dental disease: a
report by a committee of the National Heart Foundation of New Zealand, January
1981. N Z Dent.J 1981; 77:67-69.
11.
Hay DR, Ellis-Pegler RB, Faoagali J, Leslie PN, Neutze JM. Prevention of
infective endocarditis associated with dental treatment and dental disease. N Z
Med J 1981; 93:275-277.
12.
Ormiston JA, Neutze JM, Agnew TM, Lowe JB, Kerr AR. Infective endocarditis: a
lethal disease. Aust N Z J Med 1981; 11:620-629.
13.
Rutherford JD, Agnew TM, Neutze JM, Roche AA, Smith WM, Lowe JB. Infective
endocarditis: prudent treatment for a lethal disease. 1982; 95:852-853.
14.
Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Fetal survival after prednisone
suppression of maternal lupus-anticoagulant. Lancet 1983; 1:1361-1363.
15.
Sage MJ, Maslowski AH, MacCulloch D. Bacterial endocarditis due to Kingella
kingae. New Zealand Medical Journal. 1983; 96:795-6.
16.
Abraham AK, Neutze JM, MacCulloch D, Cornere B. Culture negative infective
endocarditis. Aust N Z J Med 1984; 14:223-226.
17.
Lubbe WF. Hypertension in pregnancy. Pathophysiology and management.
Drugs 1984; 28:170-188.
51
18.
Hay DR, Ellis-Pegler RB, Faoagali J, Leslie PN, Neutze JM. Prevention of
infective endocarditis associated with dental treatment: a report by a committee of
the National Heart Foundation of New Zealand. N Z Dent.J 1985; 81:120-123.
19.
Hay DR, Ellis-Pegler RB, Faoagali J, Leslie PN, Neutze JM. Prevention of
infective endocarditis associated with dental treatment and other medical
intervention. N Z Med J 1985; 98:1046-1049.
20.
White HD, Ribeiro JP, Hartley LH, Colucci WS. Immediate effects of milrinone on
metabolic and sympathetic responses to exercise in severe congestive heart
failure. American Journal of Cardiology. 1985; 56:93-8.
21.
Isaacs RD, Roche AH, Smeeton WM, Ali MR, Croxson MC. Idiopathic giant cell
myocarditis: case report. N Z Med J 1986; 99:360-361.
22.
Kellaway GS, Lubbe WF. A community-based trial of transdermal
antihypertensive therapy with clonidine (Catapres-TTS). N Z Med J 1986; 99:711714.
23.
Wilsher ML, Roche AH, Neutze JM, Synek BJ, Holdaway IM, Nicholson GI. A
familial syndrome of cardiac myxomas, myxoid neurofibromata, cutaneous
pigmented lesions, and endocrine abnormalities. Aust N Z J Med 1986; 16:393396.
24.
Haydock D, Barratt-Boyes B. Aortic Valve Endocarditis: A follow up study of 108
patients. New Zealand Medical Journal. 1989; 102:509-10.
25.
Lubbe WF, Pattison NS. Corticosteroid treatment of pregnant women with
antiphospholipid antibodies and previous fetal loss. Am J Obstet Gynecol 1990;
162:1341-1343.
26.
Lubbe WF. Treatment of hypertension in pregnancy. J Cardiovasc Pharmacol
1990; 16 Suppl 7:S110-S113.
27.
Lubbe WF. Antihypertension treatment in pregnancy. In: Buhler FR, Laragh JH,
eds. Handbook of Hypertension, vol 13: The Management of Hypertension.
Amsterdam: Elsevier Science Publishers, 1990.
28.
Lintott CJ, Scott RS, Sharpe DN, Nye ER,Charleson H, French JK, White HD,
Reuben S, Maling TJ, Lewis GR, et al. Treatment of primary
hypercholesterolaemia with simvastatin: New Zealand multicentre evaluation.
Medical Journal of Australia 1991; 155:433-436.
29.
Menzies R, MacCulloch D, Cornere B. Investigation of nosocomial prosthetic
valve endocarditis due to antibiotic-resistant Staphylococcus epidermidis. Journal
of Hospital Infection. 1991; 19:107-14.
30.
Hay DR, Chambers ST, Ellis-Pegler RB, Jones MR, Leslie PN, Neutze JM.
Prevention of infective endocarditis associated with dental treatment and other
medical interventions. N Z Med J 1992; 105:192-194.
31.
White HD. Heart failure: to digitalise or not? The view against. Australian & New
Zealand Journal of Medicine. 1992; 22:626-30.
32.
Hamer AW, Weeks PA. Diagnosis of left atrial myxoma at routine coronary
angiography in an asymptomatic patient. Cathet.Cardiovasc Diagn 1993; 30:233235.
33.
Mann JI, Crooke M, Fear H, Hay DR, Jackson RT, Neutze JM, White HD.
Guidelines for detection and management of dyslipidaemia. Scientific Committee
of the National Heart Foundation of New Zealand. N Z Med J 1993; 106:133-141.
52
34.
Ellis CJ, Waite ST, Coverdale HA, Jaffe WM. Transoesophageal
echocardiography in patients with prosthetic heart valves and systemic emboli: is
it a useful investigation? New Zealand Medical Journal. 1995; 108:376-7.
35.
Gallo R, Webster MW, Chesebro JH, Fuster V. Acute thromboembolism. In:
Messerli FH, ed. Cardiovascular drug therapy: WB Saunders, 1996.
36.
Patel H, Neutze JM, Kerr B, White HD. Failure of implementation of the National
Heart Foundation of New Zealand guidelines for the management of
dyslipidaemia. N Z Med J 1996; 109:24-26.
37.
Sanderson JE, Woo KS, Chung HK, Chan WW, Tse LK, White HD. The effect of
transcutaneous electrical nerve stimulation on coronary and systemic
haemodynamics in syndrome X. Coronary Artery Disease. 1996; 7:547-52.
38.
Webster MW, Scott RS. What cardiologists need to know about
diabetes.[comment]. Lancet. 1997; 350:SI23-8.
39.
Ellis-Pegler RB, Hay KD, Lang SD, Neutze JM, Swinburn BA. Prevention of
infective endocarditis associated with dental treatment and other medical
interventions. National Heart Foundation. N Z Dent.J 1999; 95:85-88.
40.
Ellis-Pegler R, Hay KD, Lang SD, Neutze JM, Swinburn B. Prevention of infective
endocarditis associated with dental treatment and other medical interventions. N
Z Med J 2000; 113:289-292.
41.
French JK, White HD. Smoking: back to the future - again? [editorial]. European
Heart Journal 2000; 21:1570-1571.
42.
Lund M, French JK, Johnson RN, Williams BF, White HD. Serum troponins T and
I after elective cardioversion.[comment]. European Heart Journal. 2000; 21:24553.
43.
White HD. Moving cardiology to the front of the hospital.[comment]. Heart 2000;
84:573-4.
44.
Edmond JJ, Eykyn SJ, Smith LD. Community acquired staphylococcal pulmonary
valve endocarditis in non-drug users: case report and review of the literature.
Heart 2001; 86:E17.
45.
Rowan JA, McCowan LM, Raudkivi PJ, North RA. Enoxaparin treatment in
women with mechanical heart valves during pregnancy. American Journal of
Obstetrics & Gynecology. 2001; 185:633-7.
46.
French JK, Wong CK, White HD. Medical treatment for cardiogenic shock. In:
Hasdai D, Berger PB, Battler A, Holmes DR, Jr., eds. Cardiogenic shock:
diagnosis and treatment. Totowa: Humana Press Inc, 2002:59-71.
47.
Kingston N, Ruygrok PN, Taylor G, O'Malley SI, Gibbs HC, Oldfield R. Cardiac
sarcoidosis: an elusive diagnosis. Heart Lung and Circulation 2002; 11:189-192.
48.
Drinkovic D, Morris A, Pottumarthy S, MacCulloch D, West TM. Bacteriological
outcome of combination versus single agent treatment for staphylococcal
endocaditis. Journal of Antimicrobial Chemotherapy. 2003.
49.
Gerber IL, Stewart RA, Legget ME, West TM, French RL, Sutton TM, Yandle TG,
French JK, Richards AM, White HD. Increased plasma natriuretic peptide levels
reflect symptom onset in aortic stenosis. Circulation. 2003; 107:1884-90.
50.
Gerber IL, Stewart RA, French JK, Legget M, Greaves SC, West TM, Kerr AJ,
Richards AM, White HD. Associations between plasma natriuretic peptide levels,
symptoms and left ventricular function in aortic regurgitation. The American
Journal of Cardiology 2003; 92:755-8.
53
51.
Gerber IL, Stewart RAH, Hammett CJ, et al. Effect of aortic valve replaement for
non-rheumatic aortic stenosis onC-Reactive protein. American Journal of
Cardiology 2003.
52.
Gerber IL, Ruygrok P, Calder L, Greaves SC, Coverdale HA, Long S. Association
of a double orifice mitral valve and bicuspid aortic valve in an explanted heart with
dilated cardiomyopathy. Journal of Heart Lung and Circulation 2003.
53.
Jacobs AK, Leopold JA, Bates E, Mendes LA, Sleeper LA, White H, Davidoff R,
Boland J, Modur S, Forman R, Hochman JS. Cardiogenic shock caused by right
ventricular infarction: a report from the SHOCK registry.[comment]. Journal of the
American College of Cardiology. 2003; 41:1273-9.
54.
Morris AJ, Drinkovic D, Pottumarthy S, Strickett MG, MacCulloch D, Lambie N,
Kerr AR. Gram stain, culture, and histopathological examination findings for heart
valves removed because of infective endocarditis. Clinical Infectious Diseases.
2003; 36:697-704.
55.
Sutton TM, Stewart RA, Gerber IL, West TM, Richards AM, Yandle TG, Kerr AJ.
Plasma natriuretic peptide levels increase with symptoms and severity of mitral
regurgitation. Journal of the American College of Cardiology. 2003; 41:2280-7.
56.
Wasywich CA, Ruygrok PN, West TM, Haydock DA. Extended follow up after
isolated aortic valve replacement in the elderly. Heart and Lung Circulation 2003;
12:103-107.
54
Adult Cardiology
Inherited Diseases
1.
Kelly DT. Haemodynamic observations and results of surgery in muscular
subaortic stenosis. N Z Med J 1965; 64:Suppl-5.
2.
Kelly DT, Barratt-Boyes BG, Lowe JB. Results of surgery and hemodynamic
observations in muscular subaortic stenosis. J Thorac Cardiovasc Surg 1966;
51:353-365.
3.
Barratt-Boyes BG, O'Brien KP. Surgical treatment of idiopathic hypertrophic
subaortic stenosis. In: Wolstenholme G, O'Connor M, eds. Hypertrophic
obstructive cardiopyopathy. London: J & A Churchill, 1971.
4.
Agnew TM, Barratt-Boyes BG, Brandt PW, Roche AH, Lowe JB, O'Brien KP.
Surgical resection in idiopathic hypertrophic subaortic stenosis with a combined
approach through aorta and left ventricle. J Thorac Cardiovasc Surg 1977;
74:307-316.
5.
Hill DG, Barratt-Boyes BG, Agnew TM, Brandt PW. Surgical treatment of
idiopathic hypertrophic subaortic stenosis using a combined left ventricular aortic
approach. In: Sekiguchi M, Olsen EGJ, eds. Cardiomyopathy. Clinical
Pathological and Theoretic Aspects. Proceedings Symposium on Clinial and
Experimental Aspects of Cardiomyopathy. Tokyo: University of Tokyo Press,
1980.
6.
Smith W. The long Q-T syndrome. Australian & New Zealand Journal of
Medicine. 1984; 14:700-4.
7.
Barratt-Boyes BG. Operative management. In: Cate FJ, ed. Basic and Clinical
Cardiology, Vol 4: Hypertrophic Cardiomyopathy. Clinical Recognition and
Management. New York: Marcel Dekker Inc, 1985.
8.
Brett W, Brandt PW, Bierre AR, Roche AH. Progression of hypertrophic
cardiomyopathy to congestive cardiomyopathy: case report. N Z Med J 1985;
98:994-998.
9.
Greaves SC, Roche AH, Neutze JM, Whitlock RM, Veale AM. Inheritance of
hypertrophic cardiomyopathy: a cross sectional and M mode echocardiographic
study of 50 families. Br Heart J 1987; 58:259-266.
10.
Greaves S, Roche A. Hypertrophic cardiomyopathy: patterns of inheritance.
Cardiology Board Review 1988; 5:49-65.
11.
French JK. Molecular cardiology: Potential for diagnosis and treatment. Vol. 64.
Auckland: National Heart Foundation of New Zealand, 1994.
12.
Ameratunga R, McKee J, French J, et al. Molecular pathology of the X-linked
hyper immunoglobulin M syndrome: the detection of wild type transcripts in a
patient with a complex splicing defect of the CD40 ligand. Journal of Clinical and
Diagnostic Laboratory Immunology 1996; 3:722-726.
13.
Ameratunga R, Lederman HM, Sullivan KE, et al. Defective antigen-induced
lymphocyte proliferation in the X-linked hyper-IgM syndrome. 1997; 131:147-150.
14.
Ponoth P, Kerr A, Raudkivi PJ, Grahm K, Hydock D, Milson P. Surgical correction
of hypertrophic obstructive cardiomyopathy: seventeen-year Green Lane
experience. Journal of Cardiac Surgery. 1997; 12:294-9.
55
Adult Cardiology
Interventional Cardiac Catherisation
1.
Lee J, Wattie J. Balloon angioplasty of a superior mesenteric artery occlusion in a
patient with angiodysplasia of the caecum. Australasian Radiology. 1984; 28:2403.
2.
Ormiston JA, Stewart FM, Roche AH, Webber BJ, Whitlock RM, Webster MW.
Late regression of the dilated site after coronary angioplasty: a 5-year quantitative
angiographic study. Circulation. 1997 Jul 15;96(2):468-74
3.
Ormiston JA, Roche AH, Webster MW. Directional coronary atherectomy in
lesions unfavourable for balloon angioplasty: initial Green Lane and Mercy
Hospitals experience. New Zealand Medical Journal. 1992; 105:391-3.
5.
Ormiston JA, Smith WM. Interventional cardiology in New Zealand. Journal of
Interventional Cardiology. 1995; 8:33-7.
6.
Ormiston JA, Webster MW. Simultaneous inflation of tandem (sequential)
angioplasty balloons: a means of simultaneously treating multiple lesions in one
coronary artery.[comment]. Catheterization & Cardiovascular Diagnosis. 1995;
34:365-7.
7.
Webster MW, Ormiston JA. Directional coronary atherectomy in the era of stents.
Australian & New Zealand Journal of Medicine. 1995; 25:661-2.
8.
Ormiston JA, Ng K, Webster MW. Enhanced manipulation of directional coronary
atherectomy and coronary angioplasty guide catheters. Catheterization &
Cardiovascular Diagnosis. 1996; 37:425-7.
9.
Porter GF, Ormiston JA, Webster MW. Percutaneous rotational coronary
atherectomy: initial Green Lane and Mercy hospitals' experience. New Zealand
Medical Journal. 1996; 109:203-5.
10.
Ormiston JA, Stewart FM, Roche AH, Webber BJ, Whitlock RM, Webster MW.
Late regression of the dilated site after coronary angioplasty: a 5-year quantitative
angiographic study. Circulation. 1997; 96:468-74.
11.
Dixon SR, Ormiston JA, Webster MW. Long lesion length assessment.
Catheterization & Cardiovascular Diagnosis. 1998; 45:299-300.
12.
Ellis CJ, French JK, White HD, Ormiston JA, Whitlock RM, Webster MW. Results
of percutaneous coronary angioplasty in patients <40 years of age. American
Journal of Cardiology. 1998; 82:135-9.
13.
Ormiston J, Ruygrok PN, Webster MW, Stewart JT, White HD. Mechanical
properties of five long stents compared. Journal of Invasive Cardiology 1998;
10:35B.
14.
Ruygrok P, Barron G, Ormiston J, Meredith I, Webster M, Harper R, Saltups A,
O’Shaughnessy B, Stewart J. Introduction of the Multilink stent into routine
angioplasty practice: early angiographic and clinical outcome. Catheterization &
Cardiovascular Diagnosis. 1998; 43:147-52.
15.
Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E,
van der Giessen W, Colombo A, Seabra-Gomes R, Kiemeneij F, Ruygrok P,
Ormiston J, Emanuelsson H, Fajadet J, Haude M, Klugmann S, Morel MA.
56
Randomised comparison of implantation of heparin-coated stents with balloon
angioplasty in selected patients with coronary artery disease (Benestent
II)[erratum appears in Lancet 1998 Oct 31;352(9138):1478]. Lancet. 1998;
352:673-81.
16.
Serruys PW, van der Giessen W, Garcia E, Macaya C, Colombo A, Rutsch W,
Vrints C, Bonnier H, Mudra H, Fleck E, Ormiston J, Figulla H, Seabra-Gomes R,
Veldhof S, Morel MA. Clinical and angiographic results with the Multi-Link stent
impantation under intravascular guidence (West-2 Study). Journal of Invasive
Cardiology 1998; 10:20B.
17.
Hasdai D, Lerman A, Rihal CS, Criger DA, Garratt KN, Betriu A, White HD, Topol
EJ, Granger CB, Ellis SG, Califf RM, Holmes DR. Smoking status and outcome
after primary coronary angioplasty for acute myocardial infarction. American
Heart Journal. 1999; 137:612-20.
18.
Ormiston JA, Webster MW, Ruygrok PN, Stewart JT, White HD, Scott DS. Stent
deformation following simulated side-branch dilatation: a comparison of five stent
designs. Catheterization & Cardiovascular Interventions. 1999; 47:258-64.
19.
Rhydwen GR, Webster MW, Ruygrok PN, Ormiston JA, O'Shaughnessy B,
Stewart JT. Preliminary experience with the V-flex plus coronary stent: immediate
and one-month clinical outcome. Catheterization & Cardiovascular Interventions.
1999; 47:504-8.
20.
Ruygrok PN, Melkert R, Morel MA, Ormiston JA, Bar FW, Fernandez-Aviles F,
Suryapranata H, Dawkins KD, Hanet C, Serruys PW. Does angiography six
months after coronary intervention influence management and outcome?
Benestent II Investigators. Journal of the American College of Cardiology. 1999;
34:1507-11.
21.
Dixon SR, Webster MW, Ormiston JA, Wattie WJ, Hammett CJ. Gelfoam
embolization of a distal coronary artery guidewire perforation. Catheterization &
Cardiovascular Interventions. 2000; 49:214-7.
22.
Ormiston JA, Webster MW, Ruygrok PN, Elliott JM, Simmonds MB, Meredith IT,
Devlin GP, Stewart JT, Dixon SR, Price S, Ellis CJ, West TM. A randomized
study of direct coronary stent delivery compared with stenting after predilatation:
the NIR future trial. On behalf of the NIR Future Trial Investigators.
Catheterization & Cardiovascular Interventions. 2000; 50:377-81; discussion 3823.
23.
Ormiston JA, Dixon SR, Webster MW, Ruygrok PN, Stewart JT, Minchington I,
West T. Stent longitudinal flexibility: a comparison of 13 stent designs before and
after balloon expansion. Catheterization & Cardiovascular Interventions. 2000;
50:120-4.
24.
Ruygrok PN, Ormiston JA, O'Shaughnessy B. Coronary angioplasty in New
Zealand 1995-1998: a report from the National Coronary Angioplasty
Registry.[comment]. New Zealand Medical Journal. 2000; 113:381-4.
25.
Webster MW, Dixon SR, Ormiston JA, Ruygrok PN, Stewart JT. Optimal stent
positioning in coronary arteries: partial balloon inflation to overcome cardiac
cycle-related motion of the stent/delivery system.[comment]. Catheterization &
Cardiovascular Interventions. 2000; 49:102-4.
26.
Chan C, Mak KH, Ho DSW, Ormiston JA, Lim YL. Current strategies in treating
long diffuse coronary lesions, 2001.
57
27.
Ormiston JA, Dixon B, Webster MW, Ruygrok PN. 5 French guide catheters for
percutaneous coronary intervention: a feasibility study in 100 consecutive
patients. Catheterization & Cardiovascular Interventions. 2001; 52:45-8.
28.
Ormiston JA, Webster MW. Late restenosis after percutaneous intervention.
Cardiology International 2001; 2:41.
29.
Ruygrok PN, Webster MW, de Valk V, van Es GA, Ormiston JA, Morel MA,
Serruys PW. Clinical and angiographic factors associated with asymptomatic
restenosis after percutaneous coronary intervention. Circulation. 2001; 104:228994.
30.
Blake JW, Webster MW, Butler R, Edmond JJ, Ruygrok PN. Stent deployment
with distal vascular protection for the culprit vein graft stenosis in a patient with an
acute infarct and cardiogenic shock. Catheterization & Cardiovascular
Interventions. 2002; 57:234-8.
31.
Juergens CP, White HD, Belardi JA, et al. A multicenter study of the tolerability of
tirofiban versus placebo in patients undergoing planned intracoronary stent
placement. Clinical Therapeutics. 2002; 24:1332-44.
32.
Leclerc G, Ormiston JA. The Duraflex coronary stent system. In: Serruys PW,
Rensing BJ, Dunitz M, eds. Handbook of Coronary Stents. United Kingdom,
2002.
33.
Ormiston JA, Webster MW, Ruygrok PN, Meredith IT, Ardill JP, Buller CE, Ricci
DR, Chan C, Devlin GP, Stewart JT, Penn IM, Price S, Webber B, West T; Stella
Trial Investigators. Six-month angiographic and 12-month clinical follow-up of
MultiLink long (25 to 35 mm) stents for long coronary narrowings in patients with
angina pectoris. American Journal of Cardiology. 2002; 90:222-6.
34.
Ormiston JA, Shaw BL, Panther MJ, Ruygrok PN, Devlin GP, Stewart RA,
Webster MW. Percutaneous coronary intervention with bivalirudin
anticoagulation, immediate sheath removal, and early ambulation: a feasibility
study with implications for day-stay procedures. Catheterization & Cardiovascular
Interventions. 2002; 55:289-93.
35.
Webster MW. Drug management post percutaneous coronary intervention. In:
White HD, de Feijter P, Meier B, Colombo A, Banning A, Schrader R, eds. The
year in interventional cardiology 2002: Clinical Publishing Services, 2002:49-56.
36.
Ormiston J, Webster MW. Stent Design: How much does it really matter?
Cardiology International 2003; 4:5.
37.
Ruygrok PN, Sim KH, Chan C, Rachman OJ, Adipranoto JD, Trisnohadi HB,
Stewart JT, Ahmad N, Mak KH, Yusak M, Boestan I, Santoso T, Suryapranata H.
Coronary intervention with a heparin-coated stent and aspirin only. J Invasive
Cardiol 2003; 15:439-441.
38.
Ruygrok PN, Webster MW, Ardill JJ, Chan CC, Mak KH, Meredith IT, Stewart JT,
Ormiston JA, Price S. Vessel caliber and restonsis: a perspective clinical
angiographic study of NIR stent deployment in small and large coronary artries in
the same patient. Cathet Cardiovasc Intervent 2003; 59:165-171.
39.
Ruygrok P, Ardill JP, Chan C, et al. Stenting of lesion in small and large diameter
coronary arteries in the same patient: 6 month clinical and angiographic results of
the prospective STANZA study. Cathet Cardiovasc Intervent 2003; 59:165-171.
40.
Tolleson TR, Newby LK, Harrington RA, Bhapkar MV, Verheugt FW, Berger PB,
Moliterno DJ, White HD, Ohman EM, Van de Werf E, Topol EJECTION
58
41.
Califf RM. Frequency of stent thrombosis after acute coronary syndromes (from
the SYMPHONY and 2nd SYMPHONY trials). American Journal of Cardiology.
2003; 92:330-3.
42.
Webster MW. Percutaneous coronary intervention and stents. In: Banning A, de
Feijter P, eds. The year in interventional cardiology 2003: Clinical Publishing
Services, 2003.
43.
West NEJ, Ruygrok PN, C.M.C. D, et al. Clinical and angiographic predictors of
restenosis following stent implantation in diabetic patients. Circulation 2003.
44.
Wong P, Manalo CM, Lingamanaiker J, Ormiston J, Chan C. Percutaneous
intervention of diffuse coronary artery disease: an end to a 'long' problem. 2003.
45.
Ruygrok P. Spiral dissection managed conservatively. In: Rothman M, ed. One
hundred cases in interventional cardiology: Martin Dunitz Publishers.
59
Adult Cardiology
Imaging
1.
McMyn JK. Report of overseas tour, 1964. Australas.Radiol 1966; 10:190206.
2.
McMyn JK. Pulmonary stenosis. Plain films and fluoroscopy. 1967; 11:2329.
3.
Langbein IE, Brandt PW. Traumatic rupture of the aorta. Australas.Radiol
1968; 12:102-108.
4.
Brandt PW, O'Brien KP, Glancy DL. Cardiac catheterization. 3.
Angiocardiography. Australas.Radiol 1970; 14:398-408.
5.
Glancy DL, O'Brien KP, Brandt PW. Cardiac catheterization. II. Detection
and assessment of common cardio-vascular abnormalities. 1970; 14:387397.
6.
O'Brien KP, Glancy DL, Brandt PW. Cardiac catheterization. I. Indications,
current techniques, and complications. 1970; 14:378-386.
7.
McMyn JK. Planning of an X-ray department. Australas.Radiol 1974;
18:223-228.
8.
Schwartz SE, Fischer HW, House AJ. Studies in adherence of contrast
media to mucosal surfaces. Methods and preliminary investigations.
Radiology 1974; 112:727-731.
9.
Bass NM, Whitlock RM. Computer analysis of echocardiograms. Medical
Journal of Australia. 1977; 1:5.
10.
Brandt PW, Partridge JB, Wattie WJ. Coronary arteriography; method of
presentation of the arteriogram report and a scoring system. Clin Radiol
1977; 28:361-365.
11.
Thomson KR, House AJ, Gothlin JH, Dolin TE. Percutaneous lymph node
aspiration biopsy: experience with a new technique. Clin Radiol 1978;
29:329-332.
12.
De Martini WJ, House AJ. Partial Bochdalek's herniation; computerized
tomographic evaluation. Chest 1980; 77:702-704.
13.
Rea HH, Shevland JE, House AJ. Accuracy of computed tomographic
scanning in assessment of the mediastinum in bronchial carcinoma. 1981;
81:825-829.
14.
Nicholson MR, Ferner RE, White H, Ranasinghe H, Julian DG. Fatal
atheromatous embolization during coronary angiography. Cardiovascular &
Interventional Radiology. 1982; 5:174-6.
15.
Sahn DJ, Barratt-Boyes BG, Graham K, Kerr A, Roche A, Hill D, Brandt
PW, Copeland JG, Mammana R,Temkin LP, Glenn W. Ultrasonic imaging
of the coronary arteries in open-chest humans: evaluation of coronary
atherosclerotic lesions during cardiac surgery. 1982; 66:1034-1044.
60
16.
Brandt PW. Axially angled angiocardiography. 1984; 7:166-169.
17.
Partridge JB, Brandt PW. Accuracy of angiographic appearances of the
coronary arteries. 1985; 53:235-236.
18.
Wattie WJ. Digital subtraction angiography. N Z Med J 1987; 100:238-239.
19.
Jaffe WM, Roche AH, Coverdale HA, McAlister HF, Ormiston JA, Greene
ER. Clinical evaluation versus Doppler echocardiography in the
quantitative assessment of valvular heart disease. Circulation. 1988;
78:267-75.
20.
Jaffe WM, Roche AH. Doppler echocardiographic assessment of atrial
filling fraction in severe mitral stenosis. Am J Cardiol 1988; 61:1354-1355.
21.
Wattie WJ, Marshall RG. The value of pulmonary angiograms when lung
scans disagree with clinical impressions about emboli. Australas.Radiol
1993; 37:50-53.
22.
Doughty RN, Haydock DA, Wattie J, Stewart JT, Webster MW. Images in
cardiovascular medicine. Systemic embolism from a large ascending aortic
thrombus. Circulation. 1998; 97:1421-2.
23.
French JK, Ellis CJ, White HD. The corrected TIMI frame count. The new
gold standard? Australian & New Zealand Journal of Medicine. 1998;
28:569-73.
24.
Wells AU. Computed tomographic imaging of bronchiolar disorders. Curr
Opin Pulm.Med 1998; 4:85-92.
25.
Legget M. Usefulness of parameters of left ventricular wall stress and
systolic function in the evaluation of patients with aortic stenosis.
Echocardiography 1999; 16:701-710.
26.
Dixon SR, Legget ME, Wong SP. Ventricular septal aneurysm: a
complication of myocardial infarction. Echocardiography. 2000; 17:439-42.
27.
Greaves SC. Assessment of left ventricular systolic function in research
and in clinical practice. Heart 2000; 83:493-4.
28.
Ruygrok PN, Occleshaw CJ, Legget ME, Kerr AR. Images in cardiology.
Myocardial Haemangioma: echocardiographic, MRI, and anatomical
correlation. Heart 2000; 84:117.
29.
Agnew TM. The early days of cardiac catheterisation at Green Lane
Hospital. New Zealand Medical Journal 2001;114:S2-4
30
Greaves SC. Role of echocardiography in acute coronary syndromes.
Heart 2002; 88:419-25.
31.
Thomson LE, Hachamovitch R. Coronary artery calcium scoring using
electron-beam computed tomography: where does this test fit into a clinical
practice? Rev Cardiovasc Med 2002; 3:121-128.
32.
Fonseca CG, Oxenham HC, Cowan BR, Occleshaw CJ, Young AA. Aging
alters patterns of regional nonuniformity in LV strain relaxation: a 3-D MR
tissue tagging study. American Journal of Physiology - Heart & Circulatory
Physiology. 2003; 285:H621-30.
61
33.
Legget M, Sidebotham D. The aortic valve and left ventricular outflow tract.
In: Sidebotham D, Merry A, Legget M, eds. Practical Perioperative
Transesophageal Echocardiography. London: Elsevier, 2003.
34.
Mckee A. Transplantation and Mechanical cardiac support. In: Sidebotham
D, Merry A, Legget M, eds. Practical Perioperative Transesophageal
Echocardiography. London: Elsevier, 2003.
35.
Merry A. Aspects of quantitative and semi-quantitative echocardiography.
In: Sidebotham D, Merry A, Legget M, eds. Practical Perioperative
Transesophageal Echocardiography. London: Elsevier, 2003.
36.
Oxenham HC, Young AA, Cowan BR, Gentles TL, Occleshaw CJ,
Fonseca CG, Doughty RN, Sharpe N. Age-related changes in myocardial
relaxation using three-dimensional tagged magnetic resonance imaging. J
Cardiovasc Magn Reson. 2003; 5:421-430.
37.
Picard MH, Davidoff R, Sleeper LA, Mendes LA, Thompson CR, Dzavik V,
Steingart R, Gin K, White HD, Hochman JS, SHOCK Trial.
Echocardiographic predictors of survival and response to early
revascularization in cardiogenic shock. Circulation. 2003; 107:279-84.
38.
Scott D, Sidebotham D, Merry A. The role of perioperative
transoesophageal echocardiography. In: Sidebotham D, Merry A, Legget
M, eds. Practical Perioperative Transesophageal Echocardiography.
London: Elsevier, 2003.
39.
Sidebotham D, Mckee A. The evaluation of haemodynamic instability. In:
Sidebotham D, Merry A, Legget M, eds. Practical Perioperative
Transesophageal Echocardiography. London: Elsevier, 2003.
40.
Sidebotham D, Hussey M. Diastolic Dysfunction. In: Sidebotham D, Merry
A, Legget M, eds. Practical Perioperative Transesophageal
Echocardiography. London: Elsevier, 2003.
41.
Sidebotham D, Legget M. The mitral valve. In: Sidebotham D, Merry A,
Legget M, eds. Practical Perioperative Transesophageal
Echocardiography. London: Elsevier, 2003.
42.
Wong SP. The right ventricule, tricuspid valve and pulmonary valve. In:
Sidebotham D, Merry A, Legget M, eds. Practical Perioperative
Transesophageal Echocardiography. London: Elsevier, 2003.
62
Adult Cardiology
Drugs and Therapeutics
1.
Agnew TM, Neutze JM, Whitlock RM. A comparative assessment of B-adrenergic
blocking drugs in sheep, Symposium of Beta adrenergic blockade, Sydney, 1970.
2.
Singh BN, Till MR, Kelly DT. The effects of oxprenolol (Trasicor, Ciba 39089-Ba)
on patterns of urinary sodium excretion in man. Am J Cardiol 1971; 27:372-375.
3.
Jones BL, Eastgate NO, Downey PG, Davies LJ. A comparison of doxepin with
diazepam and amitriptyline in general practice. New Zealand Medical Journal.
1972; 76:174-9.
4.
Singh BN, Nisbet HE, Harris EA, Whitlock RM. A comparison of the actions of
ICI66082 and propranolol on cardiac and peripheral beta-adrenoceptors. Eur J
Pharmacol. 1975; 34:75-86.
5.
Singh BN, Whitlock RM, Comber RH, Williams FH, Harris EA. Effects of
cardioselective beta adrenoceptor blockade on specific airways resistance in
normal subjects and in patients with bronchial asthma. 1976; 19:493-501.
6.
Singh BN, Williams FM, Whitlock RM, Collett J, Chew C. Plasma timolol levels
and systolic time intervals. Clinical Pharmacology & Therapeutics. 1980; 28:15966.
7.
Lubbe WF, Hodge JV. Combined alpha- and beta-adrenoceptor antagonism with
prazozin and Oxyprenalol in control of severe hypertension in pregnancy. N Z
Med J 1981; 94:169-172.
8.
Lubbe WF, Hodge JV, Kellaway GS. Antihypertensive treatment and fetal welfare
in essential hypertension in pregnancy: a retrospective survey of experience with
various regimes at National Women's Hospital, Auckland, 1970-80. N Z Med J
1982; 95:1-5.
9.
Lubbe WF, Mercer CJ. Amiodarone: its side effects, adverse reactions and
dosage schedules. N Z Med J 1982; 95:502-504.
10.
White HD, Lowe JB. Antianginal efficacy of perhexiline maleate in patients
refractory to beta-adrenoreceptor blockade. 1983; 3:145-155.
11.
Lubbe WF. Cardiac actions of adenosine. Methods Find.Exp.Clin Pharmacol.
1984; 6:171-177.
12.
Paton DM, Webster DR, Neutze JM. A review of the clinical pharmacokinetics of
amiodarone. Methods Find.Exp.Clin Pharmacol. 1984; 6:41-49.
13.
Ribeiro JP, White HD, Hartley LH, Colucci WS. Acute increase in exercise
capacity with milrinone: lack of correlation with resting hemodynamic responses.
Brazilian Journal of Medical & Biological Research. 1990; 23:1069-78.
14.
White H. Hirudin and Hirulog. Australian & New Zealand Journal of Medicine.
1993; 23:769-70.
15.
Woo KS, Norris RM, Nicholls G. Racial difference in incidence of cough with
angiotensin-converting enzyme inhibitors (a tale of two cities). American Journal
of Cardiology. 1995; 75:967-8.
16.
Gallo R, Webster MW, Chesebro JH, Fuster V. Dipyridamole. In: Messerli FH, ed.
Cardiovascular drug therapy: WB Saunders, 1996.
63
17.
Norris RM. Beta blocking drugs. In: Thompson PL, ed. A Coronary Care Manual.
London: Churchill Livingstone, 1997:245-253.
18.
Opie LH, White HD. Nitrates. In: Opie LH, Gersh BG, eds. Drugs for the heart.
Philadelphia: WB Saunders Company, 2000:33-52.
19.
White HD, Gersh BJ, Opie LH. Antithrombotic agents: platelet inhibitors,
anticoagulants and fibrinolytics. In: Opie LH, Gersh BG, eds. Drugs for the heart.
Philadelphia: WB Saunders Company, 2000:273-322.
20.
White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of
stroke.[comment]. New England Journal of Medicine. 2000; 343:317-26.
21.
Ruygrok PN, Muller DW, Serruys PW. Rapamycin in cardiovascular medicine.
Internal Medicine Journal. 2003; 33:103-9.
22.
White HD. Glycoprotein IIb/IIIa non-peptide receptor antagonists: Tirofiban. In:
Cohen M, ed. Handbook of antiplatelet therapy. London: Martin Dunitz, 2003:13348.
64
Cardio-Thoracic Surgery
1.
Barratt-Boyes BG. Homograft aortic valve replacement in aortic incompetence
and stenosis. Thorax 1964; 19:131-150.
2.
Barratt-Boyes BG, Lowe JB, Cole DS, Kelly DT. Homograft valve replacement for
aortic valve disease. Thorax 1965; 20:495-504.
3.
Barratt-Boyes BG. Surgical results in multivalvular heart disease at Green Lane
Hospital. N Z Med J 1965; 64:Suppl-60.
4.
Cole DS. Surgery of obstructive lung disease with bullae. N Z Med J 1965;
64:Suppl.
5.
Clarke CP, Cole DS. The management of spontaneous haemopneumothorax.
Aust N Z J Surg 1966; 35:212-214.
6.
Clarke CP. Experimental studies on the use of diaphragmatic flaps for myocardial
revascularization: preliminary report. Aust N Z J Surg 1967; 37:200-204.
7.
Clarke CP, Kerr AR, Cole DS. The place of surgery in the prophylaxis of
pulmonary embolism. Med J Aust 1967; 1:364-367.
8.
Clarke CP, Allen GL. Traumatic avulsion of the left subclavian artery. Ann Thorac
Surg 1967; 3:154-157.
9.
Clarke CP, Brandt PW, Cole DS, Barratt-Boyes BG. Traumatic rupture of the
thoracic aorta: diagnosis and treatment. Br J Surg 1967; 54:353-358.
10.
Cole DS, . The management of closed chest injury. N Z Med J 1967; 66:356.
11.
Hurley PJ, Lowe JB, Barratt-Boyes BG. Debridement-valvotomy for aortic
stenosis in adults. A follow-up of 76 patients. Thorax 1967; 22:314-319.
12.
Robb D. Animadversions on pleura and lung. Surgery 1967; 61:331-332.
13.
O'Brien KP, Hitchcook GL, Barratt-Boyes B, Lowe JB. Spontaneous aortic cusp
rupture associated with valvular myxomatous transformation. Circulation. 1968;
37:273.
14.
Graham KJ, Barratt-Boyes BG, Cole DS. Catheter emboli to the heart and
pulmonary artery. Br J Surg 1970; 57:184-186.
15.
Graham KJ, Cole DS, Barratt-Boyes BG. The surgical management of ruptured
abdominal aortic aneurysm: a ten-year experience. Aust N Z J Surg 1971;
41:113-116.
16.
Graham KJ, Barratt-Boyes BG, Cole DS. The results of shunt operation for
bleeding varices due to intrahepatic obstruction. Surg Gynecol Obstet 1972;
134:47-50.
17.
Baird D. Resection of a fibromuscular subaortic stenosis in a dog. J Small Amin
Pract 1974; 15:37-41.
18.
Neutze JM, Drakeley MJ, Barratt-Boyes BG. Serum enzymes after cardiac
surgery under profound hypothermia with circulatory arrest and limited
cardiopulmonary bypass. Am Heart J 1974; 88:553-556.
65
19.
Wan SH, Agnew TM, Roche AH, Kerr AR, Graham KG, Brandt PW. Factors
influencing early graft patency after aorto-coronary bypass surgery. Proceedings
10th Signapore-Malaysian Congress of Medicine. 10 1975:30-34.
20.
Partridge JB, Brandt PW, Whitlock RM. The underfilled coronary artery: some
pre- and post-operative observations on recipient arterial quality and left
ventricular function after coronary artery surgery. Clinical Radiology. 1978; 29:58.
21.
Barratt-Boyes BG. Cardiothoracic surgery in the Antipodes: including a report of a
randomized trial of medical and surgical treatment of asymptomatic patients with
severe coronary artery disease; a long-term follow-up of both fresh and antibiotictreated homograft valves; and some observations on glutaraldehyde-preserved
valve tissue. J Thorac Cardiovasc Surg 1979; 78:804-822.
22.
Singh RK, Barratt-Boyes BG, Harris EA. Does pulsatile flow improve perfusion
during hypothermic cardiopulmonary bypass? J Thorac Cardiovasc Surg 1980;
79:827-832.
23.
Barratt-Boyes BG. Advantages and special indications for circulatory arrest
techniques. In: Parezan L, Crupi C, Graham G, eds. Congenital Heart Disease in
the First Thre Months of Life. Bologna: Patron Editore, 1981:461.
24.
Norris RM, Agnew TM, Brandt PW, Graham KJ, Hill DG, Kerr AR, Lowe JB,
Roche AH, Whitlock RM, Barratt-Boyes BG. Coronary surgery after recurrent
myocardial infarction: progress of a trial comparing surgical with nonsurgical
management for asymptomatic patients with advanced coronary disease.
Circulation 1981; 63:785-792.
25.
Smith WM, Neutze JM, Barratt-Boyes BG, Lowe JB. Open mitral valvotomy.
Effect of preoperative factors on result. J Thorac Cardiovasc Surg 1981; 82:738751.
26.
Jonas RA, Barratt-Boyes BG, Kerr AR, Whitlock RM. Late follow-up of the
Braunwald-Cutter valve. Annals of Thoracic Surgery. 1982; 33:554.
27.
McDonald GR, Graham KJ, Barratt-Boyes BG. Aortocaval fistulae: an occasional
cause of congestive cardiac failure. Aust N Z J Surg 1982; 52:573-575.
28.
Neutze J. The cost of cardiac surgery. New Zealand Medical Journal 1982;
95:434-5.
29.
Johnson RN, Neutze JM, Kerr AR, Gillain B. Serum myoglobin concentration as
an index of myocardial damage after cardiac surgery. Int J Cardiol 1983; 4:33-47.
30.
Barratt-Boyes BG, White HD, Agnew TM, Pemberton JR, Wild CJ. The results of
surgical treatment of left ventricular aneurysms. An assessment of the risk factors
affecting early and late mortality. J Thorac Cardiovasc Surg 1984; 87:87-98.
31.
Kerr AR, Roche AH, Rutherford JD, Graham KJ. Coronary artery surgery. N Z
Med J 1984; 97:274.
32.
Matangi MF, Neutze JM, Graham KJ, Hill DG, Kerr AR, Barratt-Boyes BG.
Arrhythmia prophylaxis after aorta-coronary bypass. The effect of minidose
propranolol. J Thorac Cardiovasc Surg 1985; 89:439-443.
33.
Rutherford JD, Whitlock RM, McDonald BW, Barratt-Boyes BG, Kerr AR.
Multivariate analysis of the long-term results of coronary artery bypass grafting
performed during 1976 and 1977. Am J Cardiol 1986; 57:1264-1267.
34.
Barratt-Boyes BG. The timing of operation in valvular insufficiency. J Card Surg
1987; 2:435-452.
66
35.
Neutze JM, White HD. What contribution has cardiac surgery made to the decline
in mortality from coronary heart disease? Br.Med J 1987; 294:405-409.
36.
Osaka S, Barratt-Boyes BG, Brandt PW, Kerr AR, Whitlock RM. Early and late
results of re-operation for coronary artery disease: a 13-year experience. Aust N
Z J Surg 1988; 58:537-541.
37.
Barratt-Boyes BG. Choreoathetosis as a complication of cardiopulmonary bypass.
Ann Thorac Surg 1990; 50:693-694.
38.
Merry AF, Ramage MC, Whitlock RM, Laycock GJ, Smith W, Stenhouse D, Wild
CJ. First-time coronary artery bypass grafting: the anaesthetist as a risk factor.
British Journal of Anaesthesia 1992; 68:6-12.
39.
Barratt-Boyes B. Mistakes in health care. The learning experience in cardiac
surgery. Health care analysis 1993; 1:86-7.
40.
Ruygrok PN, Barratt-Boyes BG, Agnew TM, Coverdale HA, Kerr AR, Whitlock
RM. Aortic valve replacement in the elderly. J Heart Valve Dis 1993; 2:550-557.
41.
Ruygrok PN, Agnew TM, Coverdale HA, Kerr AR, Graham KJ, Whitlock RM.
Coronary artery surgery in the elderly: long-term follow-up. Australian & New
Zealand Journal of Medicine. 1993; 23:489-93.
42.
Agnew TM, Whitlock RM, Neutze JM, Kerr AR. Waiting lists for coronary artery
surgery: can they be better organised? N Z Med J 1994; 107:211-215.
43.
Legget ME, Shaw DP. Fiberoptic cardioscopy under cardiopulmonary bypass:
potential for cardioscopic surgery? Annals of Thoracic Surgery. 1994; 58:222-5.
44.
Ruygrok P, Barratt-Boyes B, Agnew KL, Whitlock R. Long-term follow-up in
elderly patients following allograft aortic valve replacement. Thoraxcenter 1994;
6:8-12.
45.
French JK, Scott DS, Whitlock RML, et al. Late outcome after coronary artery
bypass grafting in patients aged <40 years. Circulation 1995; 92 Suppl:II-14-II-19.
46.
O'Meeghan TJ, Jaffe WM, Raudkivi PJ. Green Lane Hospital experience with
mitral valve repair for prolapse: adverse outcomes for highly symptomatic
patients. J Heart Valve Dis 1997; 6:475-479.
47.
Dixon SR, Ruygrok PN, Agnew TM, Lund M, Aldersley PF, Gibbs HC, Whitlock
RM, Haydock DA, Coverdale HA. Cardiac allograft vasculopathy: the green lane
hospital experience 1987-1998. New Zealand Medical Journal. 1999; 112:417-20.
48.
North RA, Sadler L, Stewart AW, McCowan LM, Kerr AR, White HD. Long-term
survival and valve-related complications in young women with cardiac valve
replacements.[comment]. Circulation. 1999; 99:2669-76.
49.
Seddon ME, French JK, Amos DJ, Ramanathan K, McLaughlin SC, White HD.
Waiting times and prioritization for coronary artery bypass surgery in New
Zealand.[comment]. Heart. 1999; 81:586-92.
50.
Wong SP, Dixon SR, Ruygrok PR, Legget ME. Cardiac surgery in octogenarians-The Green Lane Hospital Experience 1995-1998. Australian & New Zealand
Journal of Medicine. 1999; 29:782-8.
51.
Bridgewater B, Hsee L, Choong C, Whitlock RM, Haydock D. Quality of Life
following coronary artery bypass graft surgery: A compasison between low and
high risk groups 2 years after surgery. Heart Lung and Circulation 2000; 9:A1011.
52.
Neutze JM, Haydock D. Prioritisation and cardiac events while waiting for
coronary bypass surgery in New Zealand. N Z Med J 2000; 113:69-70.
67
53.
Sadler L, McCowan L, White H, Stewart A, Bracken M, North R. Pregnancy
outcomes and cardiac complications in women with mechanical, bioprosthetic
and homograft valves. British Journal of Obstetrics & Gynaecology 2000;
107:245-53.
54.
Choong CK, Smith MD, Haydock DA. Recurrent spontaneous pneumothorax
associated with menstrual cycle: Report of three cases of catamenial
pneumothorax. ANZ Journal of Surgery. 2002; 72:678-9.
55.
Setty SP, Milsom FP, Armstrong G. Asymmetric primary ringless repair of mitral
valve endocarditis: a case report. Journal of Heart Valve Disease. 2002; 11:2925.
56.
Thomson LE, Chen XZ, Greaves SC. Entrapment of mitral chordal apparatus
causing early postoperative dysfunction of a St. June mitra; prosthesis. Americal
Journal of Echocardiography 2002; 15:843-4.
57.
Varghese R, Chen XZ, Doughty RN. Successful repair of self-inflicted stab wound
to the Heart: A case report. Asian Cardiovascular & Thoracic Annals 2003. In
press.
68
General Medicine and General Surgery
1.
Cole DS. Surgery in extracranial cerebrovascular disease. Brit J Surg 1965;
52:892-901.
2.
Jones CT, Troughton WD. Inhibition of the maximum acid output of the stomach
by isopropamide iodide ('Tyrimide'). N Z Med J 1966; 65:758-760.
3.
Yarrow S. Electrical hazards associated with some new medical and surgical
procedures. N Z Med J 1966; 65:21-25.
4.
Clarke CP, Cole DS. Femoro-tibial bypass for peripheral ischaemia. Med J Aust
1968; 2:982-984.
5.
Cole DS, Clarke CP. Femoro-tibial bypass for peripheral ischaemia. N Z Med J
1968:982.
6.
Jones CT, Small C. Intestinal disaccharidase deficiency in adults. N Z Med J
1968; 67:610-613.
7.
Cole DS. Cancer and continuing education. N Z Med J 1969; 69:297-300.
8.
Roche E. Arthur Guyon Purchas. N Z Med J 1970; 71:92-93.
9.
Roche E. Thomas Moore Philson. N Z Med J 1970; 71:90-91.
10.
Ford GR, Agnew TM. Methaemoblobinaemia following prilocaine-local
anaesthesia. New Zealand Medical Journal 1972; 76:104.
11.
Ibbertson HK, Tait JM, Pearl M. Himalayan cretinism. Advances in Experimental
Medical Biology 1972; 30:5169.
12.
Scott AJ, Nicholson GI, Kerr AR. Lincomycin as a cause of pseudomembranous
colitis. Lancet. 1973; 2:1232-4.
13.
Hunter AF. Colonoscopy: a new diagnostic and therapeutic technique. N Z Med J
1976; 84:387-390.
14.
McMyn JK. Spontaneous intramural oesophageal perforation. Australas.Radiol
1977; 21:234-240.
15.
Gupta SM. An evaluation of geriatric service in a public hospital. N Z Med J 1980;
91:147-150.
16.
Opie LH, Muller C, Nathan D, Daries P, Lubbe WF. Evidence for role of cyclic
AMP as second messenger of arrhythmogenic effects of beta-simulation. In:
Hamet P, Sands H, eds. Advances in Cyclic Nucleotide Research. Vol 12. New
York: Raven Press, 1980:63-69.
17.
Lubbe WF, Walkom P, Alexander CJ. Hepatic and splenic haemorrhage as a
complication of toxaemia of pregnancy in a patient with circulating lupus
anticoagulant. N Z Med J 1982; 95:842-844.
18.
Lubbe WF, Walker EB. Chorea gravidarum associated with circulating lupus
anticoagulant: successful outcome of pregnancy with prednisone and aspirin
therapy. Case report. Br J Obstet Gynaecol 1983; 90:487-490.
19.
Lubbe WF. Editorial: Lupus anticoagulant. Lancet 1984; 1:1157-1158.
20.
Lubbe WF, Butler WS, Liggins GC. The lupus-anticoagulant: clinical and obstetric
implications. N Z Med J 1984; 97:398-402.
69
21.
Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Lupus anticoagulant in pregnancy.
Br J Obstet Gynaecol 1984; 91:357-363.
22.
Lubbe WF, Liggins GC. Lupus anticoagulant and pregnancy. Am J Obstet
Gynecol 1985; 153:322-327.
23.
Lubbe WF, Gilchrist AI, Holland RK. Interaction of epinephrine and reduced
extracellular potassium may mediate stress-induced vulnerability to fibrillation in
mammalian heart. In: Beamish RE, Panagia V, Dhalla NS, eds. Pathogenesis of
Stress-induced Heart Disease. Boston: Martinus Nijhoff Publishing, 1985:113120.
24.
Wilsher M, Smeeton WM, Koelmeyer TD, Roche AH. Complete heart block and
bowel infarction secondary to rheumatoid disease. 1985; 44:425-428.
25.
Merry SN, Werry JS, Merry AF, Birchall NM. Malignant neuroleptic syndrome in
an adolescent. J am Acad Child Psychiatry 1986; 5:284-86.
26.
Baker J, Cutfield R, Taylor W. Fructosamine in a diabetic clinic. N Z Med J 1987;
100:733-735.
27.
Kyle C, Baker J, Metcalf P, Johnson R, Norris R. Serum fructosamine as a
screening method for diabetes mellitus in patients with suspected acute
myocardial infarction. Aust N Z J Med 1987; 17:467-471.
28.
Lubbe WF. Low-dose aspirin in prevention of toxaemia of pregnancy. Does it
have a place? Drugs 1987; 34:515-518.
29.
Lubbe WF. Hypertension in pregnancy: whom and how to treat. Br J Clin
Pharmacol 1987; 24 Suppl 1:15S-20S.
30.
Pattison NS, McKay EJ, Liggins GC, Lubbe WF. Anticardiolipin antibodies: their
presence as a marker for lupus anticoagulant in pregnancy. N Z Med J 1987;
100:61-64.
31.
Asherson RA, Lubbe WF. Cerebral and valve lesions in SLE: association with
antiphospholipid antibodies. J Rheumatol 1988; 15:539-543.
32.
Baker J, Metcalf P, Scragg R. Fructosamine concentrations in general population
of Kawerau. Diabetes Care 1988; 11:239-245.
33.
Lubbe WF, Liggins GC. Role of lupus anticoagulant and autoimmunity in
recurrent pregnancy loss. Semin Reproductive Endocrinology. 1988; 6:181-190.
34.
Norris RM. Critique of current therapies of noninsulin-dependent diabetes
mellitus. Prog.Clin Biol Res 1988; 265:151-159.
35.
Lubbe WF. Prevention of preeclampsia by low dose aspirin. N Z Med J 1990;
103:237-238.
36.
Lubbe WF, Butler WS. Acquired defects of coagulation - the lupus anticoagulant.
In: Greer IA, Turpie AGC, Forbes CD, eds. Haemostasis and Thormbosis in
Obstetrics and Gynaecology. London: Chapman and Hall, 1991.
37.
Aylward PE, Wilcox RG, Horgan JH, White HD, Granger CB, Califf RM, Topol EJ.
Relation of increased arterial blood pressure to mortality and stroke in the context
of contemporary thrombolytic therapy for acute myocardial infarction. A
randomized trial. GUSTO-I Investigators. Annals of Internal Medicine. 1996;
125:891-900.
38.
Poole PJ, Caughey DE, Kolbe J, Mercer CJ, Stables SR. Involvement of an
enchondroma in relapsing polychondritis. 1996; 23:186-188.
70
39.
Antonucci T, Whitcomb R, McLain R, Lockwood D, Norris RM. Impaired glucose
tolerance is normalized by treatment with the thiazolidinedione troglitazone.
Diabetes Care 1997; 20:188-193.
40.
Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and
extent of coronary artery disease in women having cardiac
catheterization.[comment]. Annals of Internal Medicine. 1997; 126:32-5.
41.
Sanderson JE, Woo KS, Chung HK, Chan WM, Tse KK, White HD. Endotheliumdependent dilation of the coronary arteries in syndrome X: effects of the cold
pressor test. Cardiology. 1997; 88:414-7.
42.
Richards G. The role of filtration during humidification. Respir.Care Clin N Am
1998; 4:329-339.
43.
Thomson LE, Stewart JT. Ticlopidine induced agranulocytosis managed with
granulocyte colony stimulating factor. New Zealand Medical Journal. 1998;
111:81-2.
44.
Chataline A, Agnew TM, Graham KJ, Kerr AR, Kennedy MP, Luke RA. Blunt
chest trauma and the heart. New Zealand Medical Journal. 1999; 112:334-6.
45.
James P, Ellis CJ, Whitlock RM, McNeil AR, Henley J, Anderson NE. Relation
between troponin T concentration and mortality in patients presenting with an
acute stroke: observational study. BMJ 2000; 320:1502-4.
46.
Wheelahan J, Scott NA, Cartmill R, Marshall V, Morton RP, Nacey J, Maddern
GJ. Minimally invasive laser techniques for prostatectomy: a systematic review.
The ASERNIP-S review group. Australian Safety and Efficacy Register of New
Interventional Procedures-Surgical. British Journal of Urology Int. 2000; 86:80515.
47.
Wheelahan J, Scott N, Marshall V, Morton RP, Nacey J, Maddern GJ. Minimally
invasive non-laser thermal techniques for prostatectomy: a systematic review.
BJU Int. 2000; 86:977-988.
48.
Wong CK, White HD. Dithering over the treatment of diabetics with acute
myocardial infarction.[comment]. European Heart Journal. 2000; 21:1907-9.
49.
Agnew KL, Oliver GF. Neutrophilic fixed drug eruption. Australas.J Dermatol.
2001; 42:200-202.
50.
Aplin CG, Bower C, Finucane K, Sansom JE. Contact allergy to IPPD and
diphenylthiourea in an orthopaedic brace. Contact Dermatitis. 2001; 45:301-2.
51.
Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with
pravastatin: the Prospective Pravastatin Pooling (PPP) Project.[comment].
Circulation. 2001; 103:387-92.
52.
Fink JN, Wallis WE, Haydock DA. Myasthenia gravis with thymoma is more
common in the Maori and Pacific Island populations in New Zealand. Internal
Medicine Journal. 2001; 31:206-10.
53.
Hay KD, Morton RP, Wall CR. Quality of life and nutritional studies in Sjogren's
syndrome patients with xerostomia. N Z Dent.J 2001; 97:128-131.
54.
Rose J, Civil I, Koelmeyer T, Haydock D, Adams D. Ruptured abdominal aortic
aneurysms: clinical presentation in Auckland 1993-1997. ANZ Journal of Surgery.
2001; 71:341-4.
55.
Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of
antiplatelet therapy for prevention of death, myocardial infarction, and stroke in
high risk patients. British Medical Journal 2002; 324:71-86.
71
56.
Gear KJ, Hay KD, Stumpel J. Treatment of parotid ductal stenosis and
concomitant resolution of autonomic symptomatology. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 2002; 94:632-635.
57.
Hay KD, Gear KJ. Xerostomia and you. N Z Dent.J 2002; 98:46-51.
58.
Hay KD, Thomson WM. A clinical trial of the anticaries efficacy of casein
derivatives complexed with calcium phosphate in patients with salivary gland
dysfunction. Oral Surg 2002; 93:271-275.
59.
Lui YY, Woo KS, Wang AY, Yeung CK, Li PK, Chau E, Ruygrok P, Lo YM. Origin
of plasma cell-free DNA after solid organ transplantation. Clinical Chemistry.
2003; 49:495-6.
60.
Sinovich V, Snow J. Protracted superficial Wegener's granulomatosis. Australas.J
Dermatol. 2003; 44:207-214.
72
Heart Valves: Development from GLH
1.
Barratt-Boyes BG. Homograft aortic valve replacement. N Z Med J 1965;
64:Suppl-3.
2.
Barratt-Boyes BG. A method for preparing and inserting a homograft aortic valve.
Br J Surg 1965; 52:847-856.
3.
Cornish CB. Use of freeze-dried aortic valve homografts in aural surgery. 1965;
1:943.
4.
Kelly DT. Myocardial function (studied using angiotensin) after aortic homograft
valve replacement. N Z Med J 1965; 64:Suppl-70.
5.
Barratt-Boyes B. Homograft replacement of aortic valve. Modern Medicine
Australia 1966; 37:14.
6.
Cornish CB, Scott PJ. Freeze -dried aortic valve heterografts in aural surgery.
1966; 2:89-90.
7.
Barratt-Boyes BG. Homograft replacement for aortic valve disease.
Mod.Concepts Cardiovasc Dis 1967; 36:1-6.
8.
Moore PE. Homograft trials in myringoplasty. Pac.Med Surg 1967; 75:175-178.
9.
Barratt-Boyes B, Roche AHG, Cole DS. Aortic homograft valve replacement: A
review of 511 patients with a late follow up extending to 65 months. Journal of
Cardiovasuclar Surgery 1968.
10.
Clarke CP, Barratt-Boyes BG, Sims FH. The fate of preserved homograft
pericardium and autogenous pericardium within the heart. Thorax 1968; 23:111120.
11.
Cornish CB, Scott PJ. Freeze dried heart valves as tympanic grafts. Arch
Otolaryngol. 1968; 88:350-356.
12.
Barratt-Boyes BG, Roche AH, Brandt PW, Smith JC, Lowe JB. Aortic homograft
valve replacement. A long-term follow-up of an initial series of 101 patient.
Circulation 1969; 40:763-775.
13.
Barratt-Boyes BG, Roche AH. A review of aortic valve homografts over a six and
one-half year period. Ann Surg 1969; 170:483-492.
14.
Brandt PW, Roche AH, Barratt-Boyes BG, Lowe JB. Radiology of homograft
aortic valves. Thorax 1969; 24:129-141.
15.
Barratt-Boyes BG. Homograft replacement of the aortic valve. In: Eliakim M,
Neufeld H, eds. Cardiology - current topics and progress. New York: Academic
Press, 1970.
16.
Barratt-Boyes BG. Heart vlave replacement. The medical annual. Bristol: John
Wright, 1970.
17.
Clarkson PM, Barratt-Boyes BG. Bacterial endocarditis following homograft
replacement of the aortic valve. Circulation 1970; 42:987-991.
18.
Barratt-Boyes BG. Long-term follow-up of aortic valvar grafts. Br Heart J 1971;
33:Suppl-5.
19.
Barratt-Boyes BG, Roche A, Agnew TM, Cole D, Kerr A, Monro JL, Lowe JB,
Brandt PW. Homograft Valves. Medical Journal of Australia 1972; Supp 2:38-44.
73
20.
Gavin JB, Herdson PB, Barratt-Boyes BG. The pathology of chemically-sterilized
human heart valve allografts. Pathology 1972; 4:175-183.
21.
Gavin JB, Barratt-Boyes BG, Hitchcock GC, Herdson PB. Histopathology of
"fresh" human aortic valve allografts. Thorax 1973; 28:482-487.
22.
Gavin JB, Herdson PB, Monro JL, Barratt-Boyes BG. Pathology of antibiotictreated human heart valve allografts. Thorax 1973; 28:473-481.
23.
Girinath MR, Gavin JB, Strickett MG, Barratt-Boyes BG. The effects of antibiotics
and storage on the viability and ultrastructure of fibroblasts in canine heart valves
prepared for grafting. Aust N Z J Surg 1974; 44:170-172.
24.
Monro JL, Gavin JB, Barratt-Boyes BG. A comparison of antibiotic-sterilized,
stent-mounted pulmonary and aortic valve allografts in the mitral region of dogs.
Thorax 1974; 29:323-328.
25.
Gavin JB, Seelye ER. Heart valve allografts and bacteraemias of dental origin.
New Zealand Dental Journal. 1976; 72:25-7.
26.
Barratt-Boyes BG, Roche AH, Whitlock RM. Six year review of the results of
freehand aortic valve replacement using an antibiotic sterilized homograft valve.
Circulation 1977; 55:353-361.
27.
Barratt-Boyes BG, Roche A, Heng MB, Rutherford JD. Long-term results using
antibiotic sterilized homograft valves for aortic, mitral or tricuspid replacement. In:
Davila J, ed. Proceedings 2nd Henery Ford Hospital Symposium. New York:
Appleton-Centry-Croft, 1977.
28.
Heng MK, Barratt-Boyes BG, Agnew TM, Brandt PW, Kerr AR, Graham KJ.
Isolated mitral replacement with stent mounted antibiotic treated aortic allograft
valves. Journal of Thoracic & Cardiovascular Surgery. 1977; 74:230.
29.
Thomson FJ, Barratt-Boyes BG. The glutaraldehyde-treated heterograft valve:
some engineering observations. J Thorac Cardiovasc Surg 1977; 74:317-321.
30.
Pohlner PG, Thomson FJ, Hjelms E, Barratt-Boyes BG. Experimental evaluation
of aortic homograft valves mounted on flexible support frames and comparison
with glutaraldehyde-treated porcine valves. J Thorac Cardiovasc Surg 1979;
77:287-293.
31.
Gavin JB, Hjelms E, Barratt-Boyes BG. Histological evaluation of transannular
autografts of pericardium placed in the right ventricular outflow tract of dogs.
Pathology 1981; 13:749-756.
32.
Hjelms E, Pohlner P, Barratt-Boyes BG, Gavin JB. Study of autologous
pericardial patch-grafts in the right ventricular outflow tracts in growing and adult
dogs. J Thorac Cardiovasc Surg 1981; 81:120-123.
33.
Armiger LC. Morphological changes in early myocardial ischaemic injury and
infarction. In: Norris RM, ed. International Seminars in Cardiovascular Medicine.
Edinbugh: Churchill Livingston, 1982:215-231.
34.
Armiger LC, Gavin JB, Barratt-Boyes BG. Histological assessment of orthotopic
aortic valve leaflet allografts:its role in selecting graft pre-treatment. Pathology.
1983; 15:67-73.
35.
Goldstein J, Robinson MC, McDonald GR, Elliott RL, Barratt-Boyes BG.
Monocusp aortic valve replacement in dogs: an experimental model. Aust N Z J
Surg 1983; 53:153-156.
74
36.
Grenadier E, Sahn DJ, Roche AH, Valdes-Cruz LM, Copeland JG Goldberg SJ,
Allen HD. Detection of deterioration or infection of homograft and porcine
xenograft bioprosthetic valves in mitral and aortic positions by two-dimensional
echocardiographic examination. J Am Coll Cardiol 1983; 2:452-459.
37.
Strickett MG, Barratt-Boyes BG, MacCulloch D. Disinfection of human heart valve
allografts with antibiotics in low concentration. Pathology 1983; 15:457-462.
38.
Armiger LC, Thomson RW, Strickett MG, Barratt-Boyes BG. Morphology of heart
valves preserved by liquid nitrogen freezing. 1985; 40:778-786.
39.
Barratt-Boyes BG. The aortic homograft valve: its use as a valve substitute. In:
Yingkai W, Peters RM, eds. International Practie in Cardiothoracic Surgery.
Beijing: Science Press, 1985.
40.
Christie GW, Gavin JB, Barratt-Boyes BG. Graft detachment, a cause of
incompetence in stent-mounted aortic valve allografts. J Thorac Cardiovasc Surg
1985; 90:901-906.
41.
Barratt-Boyes BG, Roche AH, Subramanyan R, Pemberton JR, Whitlock RM.
Long-term follow-up of patients with the antibiotic-sterilized aortic homograft valve
inserted freehand in the aortic position. Circulation 1987; 75:768-777.
42.
Barratt-Boyes BG. Long-term follow up of patients receiving a freehand antibiotic
sterilized homograft aortic valve. In: Rabago G, Colley DA, eds. Heart Valve
Replacement: Current Status & Future Trends. Mount Kisco: Futura Publishing
Company Inc, 1987.
43.
Barratt-Boyes BG, Rutherford JD, Whitlock RM, Pemberton JR. A review of
surgery for acquired tricuspid valve disease, including an assessment of the
stented semilunar homograft valve, and the results of operation for multivalvular
heart disease. Aust N Z J Surg 1988; 58:23-34.
44.
Barratt-Boyes BG. 25 years' clinical experience of allograft surgery - A time for
reflection. In: Yankah AC, ed. Cardaic Valve Allografts 1962-1987: Steinkof
Verlag Darmstadt, 1988.
45.
Jonas RA, Ziemer G, Armiger LC, Britton L, Castaneda AR. Cryopreserved and
fresh valved aortic homograft conduits on a chronic sheep model:
Haemodynamic, angiographic and histological comparisons. In: Yankah AC,
Miller DC, Sommerville J, Hetzer R, Ross DN, Yacoub MH, eds. Cardiac Valve
Allogracfts 192-1987. New York: Springer-Verlag, 1988:65-68.
46.
Jonas RA, Ziemer G, Britton L, Armiger LC. Cryopreserved and fresh antibioticsterilized valved aortic homograft conduits in a long-term sheep model. Journal of
Thoracic & Cardiovascular Surgery. 1988; 96:746-755.
47.
Barratt-Boyes BG. Valvulas aorticas porcinas fijadas a presion cero:
consideraciones teoricas y clinicas. In: Rivera R, ed. Jornadas Internacionales de
Actualizacion Cardiovascular. Aran, 1989.
48.
Jaffe WM, Coverdale HA, Roche AH, Brandt PW, Ormiston JA, Barratt-Boyes
BG. Doppler echocardiography in the assessment of the homograft aortic valve.
Am J Cardiol 1989; 63:1466-1470.
49.
Jaffe WM, Barratt-Boyes BG, Sadri A, Gavin JB, Coverdale HA, Neutze JM. Early
follow-up of patients with the Medtronic Intact porcine valve. A new cardiac
bioprosthesis. J Thorac Cardiovasc Surg 1989; 98:181-192.
50.
Maxwell L, Gavin JB, Barratt-Boyes BG. Uneven host tissue ongrowth and tissue
detachment in stent mounted heart valve allografts and xenografts. Cardiovasc
Res 1989; 23:709-714.
75
51.
Maxwell L, Gavin JB, Barratt-Boyes BG. Differences between heart valve
allografts and xenografts in the incidence and initiation of dystrophic calcification.
Pathology 1989; 21:5-10.
52.
Mayne AS, Christie GW, Smaill BH, Hunter PJ, Barratt-Boyes BG. An
assessment of the mechanical properties of leaflets from four second-generation
porcine bioprostheses with biaxial testing techniques. J Thorac Cardiovasc Surg
1989; 98:170-180.
53.
Barratt-Boyes BG, Haydock D, Macedo T. Aortic valve replacement for active
endocarditis. A comparison of the Allograft valve with prosthetic and bioprosthetic
valves. In: Bodnar E, ed. Surgery for heart valve disease. London: IR Publishers,
1990.
54.
Greaves SC, Barratt-Boyes BG, Neutze JM. The Medtronic Intact Valve: a clinical
follow up extending to 5.5 years, including serial echo-Doppler examinations. In:
Bodnar E, ed. Surgery for heart valve disease. London: ICR Publishers,
1990:316-22.
55.
Jaffe WM, Coverdale HA, Roche AH, Whitlock RM, Neutze JM, Barratt-Boyes
BG. Rest and exercise hemodynamics of 20 to 23 mm allograft, Medtronic Intact
(porcine), and St. Jude Medical valves in the aortic position. J Thorac Cardiovasc
Surg 1990; 100:167-174.
56.
Morris A, Strickett MG, Barratt-Boyes BG. Use of aortic valve allografts from
hepatitis B surface antigen-positive donors. 1990; 49:802-805.
57.
Barratt-Boyes BG, Ko PH, Jaffe WM. The zero pressure fixed medtronic intact
porcine valve: clinical results over a 6-year period, including serial
echocardiographic assessment. J Card Surg 1991; 6:606-612.
58.
Christie GW, Barratt-Boyes BG. On stress reduction in bioprosthetic heart valve
leaflets by the use of a flexible stent. J Card Surg 1991; 6:476-481.
59.
Christie GW, Barratt-Boyes BG. Identification of a failure mode of the antibiotic
sterilized aortic allograft after 10 years: implications for their long-term survival. J
Card Surg 1991; 6:462-467.
60.
Kadoba K, Armiger LC, Sawatari K, Jonas RA. The influence of time from donor
death to graft harvest on conduit function in cryopreserved aortic allografts in
lambs. Circulation 1991; 84 (Suppl III):100-111.
61.
Barratt-Boyes BG. Clinical experience with the zero-pressure-fixed Medtronic
Intact bioprosthetic valve. Eur J Cardiothorac Surg 1992; 6 Suppl 1:S79-S81.
62.
Barratt-Boyes BG, Christie GW, Raudkivi PJ. The stentless bioprosthesis:
surgical challenges and implications for long-term durability. Eur J Cardiothorac
Surg 1992; 6 Suppl 1:S39-S42.
63.
Christie GW. Anatomy of aortic heart valve leaflets: the influence of
glutaraldehyde fixation on function. European Journal of Cardio-Thoracic Surgery.
1992; 6:S25-32; discussion S33.
64.
Christie GW. Computer modelling of bioprosthetic heart valves. European Journal
of Cardio-Thoracic Surgery. 1992; 6:S95-100; discussion S101.
65.
Haydock D, Barratt-Boyes B, Macedo T, Kirklin JW, Blackstone E. Aortic valve
replacement for active infectious endocarditis in 108 patients. A comparison of
freehand allograft valves with mechanical prostheses and bioprostheses. Journal
of Thoracic & Cardiovascular Surgery. 1992; 103:130-9.
76
66.
Sawatari K, Kawata H, Armiger LC, Jonas RA. Growth of composite conduits
utilising longitudinal arterial autograft. Journal of Thoracic & Cardiovascular
Surgery. 1992; 103:47-51.
67.
Barratt-Boyes BG, Jaffe WM, Ko PH, Whitlock RM. The zero pressure fixed
medtronic intact porcine valve: an 8.5 year review. J Heart Valve Dis 1993; 2:604611.
68.
Gross JM, Christie GW. A non-invasive technique to quantify in vitro bioprosthetic
valvular coaptation. ASAIO Journal. 1993; 39:M392-7.
69.
Kadoba K, Armiger LC, Sawatari K, Jonas RA. Mechanical durability of
pulmonary allograft conduits at systemic pressure - Angiographic and histological
study in lambs. Journal of Thoracic & Cardiovascular Surgery. 1993; 105:132141.
70.
Milsom FP, Doty DB. Aortic valve replacement and mitral valve repair with
allograft.[comment]. Journal of Cardiac Surgery. 1993; 8:350-7.
71.
Barratt-Boyes BG, Christie GW. What is the best bioprosthetic operation for the
small aortic root?: allograft, autograft, porcine, pericardial? Stented or unstented?
J Card Surg 1994; 9:158-164.
72.
Barratt-Boyes BG. Aortic allograft valve implantation: freehand or root
replacement? J Card Surg 1994; 9:196-197.
73.
Armiger LC. Viability studies of human valves prepared for use as allografts.
Annals of Thoracic Surgery. 1995; 60:S118-121.
74.
Armiger LC, Christie GW, Barratt-Boyes BG. Biochemical and cellular
characterization of cardiac valve tissue after cryopreservation or antibiotic
preservation. Journal of Thoracic & Cardiovascular Surgery. 1995; 110:282-284.
75.
Armiger LC. Further comments concerning:Biochemical and cellular
characterization of cardia valve tissue after cryopreservation or antibiotic
preservation. Journal of Thoracic & Cardiovascular Surgery. 1995; 110:284.
76.
Christie GW, Barratt-Boyes BG. Mechanical properties of porcine pulmonary
valve leaflets: how do they differ from aortic leaflets? Ann Thorac Surg 1995;
60:S195-S199.
77.
Christie GW, Barratt-Boyes BG. Biaxial mechanical properties of explanted aortic
allograft leaflets. Ann Thorac Surg 1995; 60:S160-S164.
78.
Christie GW, Barratt-Boyes BG. Age-dependent changes in the radial stretch of
human aortic valve leaflets determined by biaxial testing. Ann Thorac Surg 1995;
60:S156-S158.
79.
Myers DJ, Nakaya G, Girardot MN, Christie GW. A comparison between
glutaraldehyde and diepoxide-fixed stentless porcine aortic valves: biochemical
and mechanical characterization and resistance to mineralization. Journal of
Heart Valve Disease. 1995; 4:S98-101.
80.
Haziza F, Papouin G, Barratt-Boyes B, Christie G, Whitlock R. Tears in
bioprosthetic heart valve leaflets without calcific degeneration. Journal of Heart
Valve Disease. 1996; 5:35-9.
81.
Armiger LC, Barratt-Boyes BG. Pre-implantation viability of cryopreserved valves
prepared by the Green Lane Technique. In: Yankah AC, Yacoub MH, Hetzer R,
eds. Cardiac Valve Allografts: science and practice. New York: Springer,
1997:47-57.
77
82.
Haydock DA. Allograft vs Prosthetic aortic valve replacement for active infective
endocarditis. In: Yacoub MH, Yankah AC, Hetzer R, eds. Cardiac Valve
Allografts:Science and Practice, 1997:207-215.
83.
Armiger LC. Post-implantation leaflet cellularity of valve allografts:are donor cells
beneficial or detrimental? Annals of Thoracic Surgery. 1998; 66:S233-235.
84.
Barratt-Boyes BG, Jaffe WM, Whitlock RM. The Medtronic Intact Porcine Valve:
ten-year clinical review. J Thorac Cardiovasc Surg 1998; 116:1005-1014.
85.
Barratt-Boyes BG. On "Aortic Valve Replacement With Biological Substitute". J
Card Surg 1998; 13:9-10.
86.
Barratt-Boyes BG. Tissue valves: a historical perspective. In: Bockeria LA, ed.
History of Cardiovascular Surgery: Moscow Publishing House of Bakoulev
Scientific Centre for Cardiovascular Surgery, 1998:113-8.
87.
Christie GW, Gross JF, Eberhardt CE. Fatigue-induced changes to the biaxial
mechanical properties of glutaraldehyde-fixed porcine aortic valve leaflets.
Seminars in Thoracic & Cardiovascular Surgery. 1999; 11:201-5.
88.
Wong SP, Legget ME, Greaves SC, Barratt-Boyes BG, Milsom FP, Raudkivi PJ.
Early experience with the mosaic bioprosthesis: a new generation porcine valve.
Ann Thorac Surg 2000; 69:1846-1850.
89.
Wong SP, Legget ME, Milsom FP, Raudkivi PJ. Initial experience with the
freestyle stentless aortic bioprosthesis. New Zealand Medical Journal. 2000;
113:266-8.
90.
Wasywich CA, Ruygrok PN, Coverdale HA, West T, Kerr A. Extended follow up
after after allograft aortic valve replacement in elderly patients. Heart Lung and
circulation 2003;12:103-7.
78
Otolaryngology
1.
Roydhouse N. A controlled study of adenotonsillectomy. 1970; 92:611-616.
2.
Melding PS, Goodey RJ, Thorne PR. The use of intravenous lignocaine in the
diagnosis and treatment of tinnitus. J Laryngol.Otol. 1978; 92:115-121.
3.
Melding PS, Goodey RJ. The treatment of tinnitus with oral anticonvulsants. J
Laryngol.Otol. 1979; 93:111-122.
4.
Hillas J, Booth RJ, Somerfield S, Morton R, Avery J, Wilson JD. A comparative
trial of intra-nasal beclomethasone dipropionate and sodium cromoglycate in
patients with chronic perennial rhinitis. Clin Allergy 1980; 10:253-258.
5.
Goodey RJ. Drugs in the treatment of tinnitus. In: Evered D, laurenson G, eds.
Tinnitus. London: Pitman, 1981:262-278.
6.
Dorman EB, Morton RP. Hearing loss in minor head injury. N Z Med J 1982;
95:454-455.
7.
Morton RP. A profile of laryngeal cancer in Auckland 1965-1979. N Z Med J 1982;
95:652-655.
8.
Morton RP, Chapman P. The results of treatment of laryngeal cancer in Auckland
New Zealand 1965-1979. Aust N Z J Surg 1982; 52:418-423.
9.
Ramadan MF, Morton RP, Stell PM, Pharoah PO. Epidemiology of laryngeal
cancer. Clin Otolaryngol. 1982; 7:417-428.
10.
Stell PM, Morton RP. 'Average' survival times after treatment of cancer. Clin
Oncol 1982; 8:293-303.
11.
Campbell IT, Morton RP, Cole JA, Raine CH, Shapiro LM, Stell PM. A
comparison of the effects of intermittent and continuous nasogastric feeding on
the oxygen consumption and nitrogen balance of patients after major head and
neck surgery. Am J Clin Nutr. 1983; 38:870-878.
12.
Morton RP, Missotten FE, Pharoah PO. Classifying cancer of the lip: an
epidemiological perspective. Eur J Cancer Clin Oncol 1983; 19:875-879.
13.
Morton RP. Pharyngeal pseudodiverticulum in an adult. J Laryngol.Otol. 1983;
97:79-83.
14.
Morton RP, Campbell IT. Nutritional support and cancer chemotherapy. Lancet
1983:687.
15.
Morton RP, Stell P, Pharoah PO. Classifying cancer of the middle ear cleft.
Cancer 1983; 53:1612-1617.
16.
Stell PM, Missotten F, Singh SD, Ramadan MF, Morton RP. Mortality after
surgery for hypopharyngeal cancer. Br.J Surg 1983; 70:713-718.
17.
Stell PM, Morton RP, Singh SD. Cervical lymph node metastases: the
significance of the level of the lymph node. Clin Oncol 1983; 9:101-107.
18.
Stell PM, Morton RP, Singh SD. Squamous carcinoma of the head and neck: the
untreated patient. Clin Otolaryngol. 1983; 8:7-13.
19.
Campbell IT, Morton RP. Postoperative feeding patterns and diurnal temperature
rhythms. Ann Rev Chronopharmocol. 1984; 1:291-294.
20.
Morton RP. Current use of chemotherapy for head and neck cancer. J
Laryngol.Otol. 1984; 98:819-828.
79
21.
Morton RP, Davies AD, Baker J, Baker GA, Stell PM. Quality of life in treated
head and neck cancer patients: a preliminary report. Clin Otolaryngol. 1984;
9:181-185.
22.
Morton RP, Stell PM. Cytotoxic chemotherapy for patients with terminal
squamous carcinoma--does it influence survival? Clin Otolaryngol. 1984; 9:175180.
23.
Morton RP, Stell PM, Derrick PP. Epidemiology of cancer of the middle ear cleft.
Cancer 1984; 53:1612-1617.
24.
Morton RP, Stell PM. Supraglottic laryngectomy: a perspective for New Zealand.
Aust N Z J Surg 1984; 54:63-66.
25.
Stell PM, Morton RP. A microprocessor system for the storage and retrieval of
otolaryngological data. J Laryngol.Otol. 1984; 98:1125-1130.
26.
Stell PM, Morton RP. [Functional complications following supraglottal
laryngectomy]. HNO 1984; 32:385-387.
27.
Morton RP, Sellars SL, Sealy R. Computerized staging of cancer of the maxillary
sinus. Int J Biomed.Comput. 1985; 16:191-199.
28.
Morton RP, Pharoah PO, Stell P. The use of a microcomputer for descriptive
epidemiologic research. J Soc Occup.Med 1985; 35:17-21.
29.
Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for
advanced or recurrent squamous cell carcinoma of the head and neck: a
randomised factorial phase III controlled trial. Cancer Chemother.Pharmacol.
1985; 15:283-289.
30.
Gordon AS, Giles ML, Harding DA, Morton RP. Surgery of snoring. J
Laryngol.Otol. 1986; 100:1263-1267.
31.
Morton RP. Snoring in perspective. Clin Otolaryngol. 1986; 11:53-54.
32.
Morton RP, Giles ML. Surgery for pharyngeal pouch. Aust N Z J Surg 1986;
56:77-79.
33.
Morton RP. Sinonasal Cancer in South Africa: a Clinical and Epidemiological
Study. Cape Town: University of Cape Twon, 1986.
34.
Campbell JB, Dorman EB, Helliwell TR, McCormick M, Miles J, Morton RP,
Rugman F, Stell PM, Stoney PJ, Vaughan ED, et al. Factors predicting response
of end stage squamous cell carcinoma of the head and neck to cisplatinum. Clin
Otolaryngol. 1987; 12:167-176.
35.
Campbell JB, Dorman EB, McCormick M, Miles J, Morton RP, Rugman F, Stell
PM, Stoney PJ, Vaughan ED, Wilson JA. A randomized phase III trial of
cisplatinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + 5fluoro-uracil in end-stage head and neck cancer. Acta Otolaryngol. 1987;
103:519-528.
36.
Goodey RJ. Drug therapy in tinnitus. In: Hazell J, ed. Tinnitus. London: Churchill
Livingstone, 1987:176-194.
37.
Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M,
Veevers A, Stell PM. Cisplatin and bleomycin in the treatment of advanced or
recurrent squamous cell carcinoma of the head and neck. A randomized
facultative Phase III controlled study. Sonderb.Strahlenther.Onkol. 1987; 81:141150.
80
38.
Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M,
Veevers A, Stell PM. Cisplatinum und bleomycin fur die behandlung des fortgeschritten oder rezidiviernden plattenepothelikarzionoms an kopf und hals. In:
Sauer R, Scwab C, eds. Kominationstherapie der oropharynx - und
hypopharynxkarziome. Munich: Urban and Schwarzenberg, 1987:141-150.
39.
Morton RP, Dorman EB. Palliative chemotherapy in terminal heand and neck
cancer patients. In: Kerr AK, ed. Scott-Brown's Disease of the Ear, Nose and
Throat. London: Butterworths, 1987.
40.
Willatt DJ, Morton RP, McCormick MS, Stell PM. Staging of maxillary cancer.
Which classification? Ann Otol.Rhinol.Laryngol. 1987; 96:137-141.
41.
Goodey RJ. Drigs in the treatment of tinnitus. In: Kitahara M, ed. Tinnitus,
Pathophysiology and Management. Tokyo: Igaku-Shoin, 1988:64-73.
42.
Gordon AS, Jean-Louis F, Morton RP. Late ear sequelae in cleft palate patients.
Int J Pediatr Otorhinolaryngol. 1988; 15:149-156.
43.
Morton RP, Fielder CP, Dorman EB. Prediction and prevention of fistulae after
major head and neck surgery: a preliminary report. Aust N Z J Surg 1988; 58:951953.
44.
Morton RP, Sellars SL. Laterality of sinonasal cancer and its aetiologic
implications. Clin Otolaryngol. 1988; 13:193-196.
45.
Fielder CP, Morton RP. Wound amylase estimation and the prediction of
pharyngocutaneous fistulae. Clin Otolaryngol. 1989; 14:101-105.
46.
Morton RP. Epidemiology of head and neck cancer: the clinician's contribution.
Clin Otolaryngol. 1989; 14:279-280.
47.
Morton RP. Salivary gland disease. In: Speight T, ed. The Disease Index.
Auckland: Med Pub Co, 1989.
48.
Morton RP, Dorman EB. The lump in the neck of adults. In: Speight T, ed. The
Disease Index. Auckland: Med Pub Co, 1989.
49.
Morton RP, Avery JA. Sinusitis. In: Speight T, ed. The Disease Index. Auckland:
Med Pub Co, 1989.
50.
Campbell IT, Morton RP, Macdonald IA, Judd S, Shapiro L, Stell PM. Comparison
of the metabolic effects of continuous postoperative enteral feeding and feeding
at night only. Am J Clin Nutr. 1990; 52:1107-1112.
51.
Liverpool head and neck oncology group (includes Morton RP, Dorman EB). A
phase III trial of cisplatin, methotrexate, cisplatin + methotrexate, and cisplatin +
5FU in end stage squamous carcinoma of the head and neck. Br J Cancer. 1990;
61:311-315.
52.
McIvor NP, Dorman EB, Morton RP, Gillibrand J, McIntyre, V. Voice rehabilitation
after laryngectomy using primary TE puncture. J Otolaryngol Soc Aust. 1990;
6:295-298.
53.
Morton RP, Mellow CG, Dorman EB. Chest infection following head and neck
surgery: a pilot study. Clin Otolaryngol. 1990; 15:363-366.
54.
Morton RP, Benjamin CS. Nasopharyngeal carcinoma in Auckland: a study of
racial factors. Australas.Radiol 1990; 34:17-18.
55.
Morton RP. Hoarseness. In: Speight T, ed. The Disease INdex. Auckland: Med
Pub Co, 1991.
81
56.
Morton RP, Sillars HA, Benjamin CS. Incidence of 'unsuspected' extranodal head
and neck lymphoma. Clin Otolaryngol. 1992; 17:373-375.
57.
Morton RP. Unsuspected tumors in patients with bilateral nasal polyps. Aust J
Otolaryngol. 1992; 1:134-136.
58.
Morton RP. Tracheotomy: current perspectives. In: Rennie M, ed. Intensive Care
Britain 1992. London: Greycoat, 1992:35-40.
59.
Bartley J. Delayed cerebrospinal rhinorrhoea. Aust N Z J Surg 1993; 63:418.
60.
Borg MF, Benjamin CS, Morton RP, Llewellyn HR. Malignant lympho-epithelial
lesion of the salivary gland: a case report and review of the literature.
Australas.Radiol 1993; 37:288-291.
61.
Morton RP, Bartley JR. Inversion of Zenker's diverticulum: the preferred option.
Head Neck 1993; 15:253-256.
62.
Morton RP. Epidemiology and pre-treatment tumour-related considerations in
supraglottic cancer. In: Devranogulu I, ed. Proceedings, XV World Congress of
ORL & Head and Nexk Surgery. Istanbul: IFOS, 1993:480-483.
63.
Bartley J, Morton RP. Cylindrical cell papilloma: report of a case with 5 year follow
up. Aust J Otolaryngol. 1994; 1:557-559.
64.
Bartley JR, Connew AM. Parental attitudes and postoperative problems related to
paediatric day stay tonsillectomy. N Z Med J 1994; 107:451-452.
65.
Morton RP, Woollons AC, McIvor NP. Nasopharyngeal carcinoma and middle ear
effusion: natural history and the effect of ventilation tubes. Clin Otolaryngol. 1994;
19:529-531.
66.
Morton RP, Ferguson CM, Lambie NK, Whitlock RM. Tumor thickness in early
tongue cancer. Arch Otolaryngol.Head Neck Surg 1994; 120:717-720.
67.
Morton RP, Hitchcock B. A study of second opinions in otolaryngology. Aust J
Otolaryngol. 1994; 1:542-545.
68.
Morton RP, Woollons AC, McIvor NP. Nasopharyngeal carcinoma and middle ear
effusion. Natural history and impact of ventilation tubes. Aust J Otolaryngol. 1994;
1:557-559.
69.
Morton RP, Cheng A, Kreins K, Whitlock RM. Respiratory complications following
major head and neck surgery. Aust J Otolaryngol. 1994; 1:356-358.
70.
Woollons AC, Morton RP. When does middle ear effusion signify nasopharyngeal
cancer? N Z Med J 1994; 107:507-509.
71.
Morton RP. Life-satisfaction in patients with head and neck cancer. Clin
Otolaryngol. 1995; 20:499-503.
72.
Morton RP. Evolution of quality of life assessment in head and neck cancer. J
Laryngol.Otol. 1995; 109:1029-1035.
73.
Morton RP, Witterick IJ. Rationale and development of a quality-of-life instrument
for head-and-neck cancer patients. Am J Otolaryngol. 1995; 16:284-293.
74.
Morton RP, Bartley JR. Simple sublingual ranulas: pathogenesis and
management. J Otolaryngol. 1995; 24:253-254.
75.
Morton RP. Specialist management of middle ear disease in Northern New
Zealand. Aust J Otolaryngol. 1995; 2:129-131.
76.
Morton RP. Quality-of-life measures in head-and-neck cancer: capabilities and
caveats. Curr Oncol. 1995; 2:77-83.
82
77.
Mahadevan M, Morton RP, Thorne P, Giles ML, Gunn R. The importance of
audiometric patterns in sudden sensineural hearing loss. Aust J Otolaryngol.
1996; 2:245-248.
78.
Morton RP, Liavaag PG, McLean M, Freeman JL. Transcervico-mandibulo-palatal
approach for surgical salvage of recurrent nasopharyngeal cancer. Head Neck
1996; 18:352-358.
79.
Morton RP. Antibiotic prophylaxis and head and neck surgery--what about
pulmonary complications? Clin Otolaryngol. 1996; 21:97-98.
80.
Morton RP. Quality of life assessment: integral to clinical practice. Clin
Otolaryngol. 1996; 21:1-2.
81.
Morton RP, McIvor NP. Neoplasms of the hypoharynx. In: Kerr AK, ed. ScottBrown's Disease of the Ear, Nose and Throat. London: Butterworths, 1996.
82.
Morton RP. Laryngeal cancer: quality-of-life and cost-effectiveness. Head Neck
1997; 19:243-250.
83.
Morton RP. Quality of life: current status and future directions. In: Shah J, ed.
Head and Neck Cancer, 1997:119-125.
84.
Morton RP. The Quality of life paradox of bucco-pharyngal cancer. Proceedings,
XVI World congress of ORL & Head and Neck Surgery. Sydney: IFOS, 1997.
85.
Morton RP. Quality of life in head and neck patients. Proceedings, Congress of
International Federation of Head and Neck Oncology Societies. Mumbai, 1997.
86.
Connolly A, Bartley J. 'External' Mustarde suture technique in otoplasty. Clin
Otolaryngol 1998; 23:97-99.
87.
Davison MJ, Morton RP, McIvor NP. Plunging ranula: clinical observations. Head
Neck 1998; 20:63-68.
88.
Morton RP. Salvage surgery for recurrent nasopharyngeal cancer. Clin
Otolaryngol. 1998; 23:397-402.
89.
Porter MJ, McIvor NP, Morton RP, Hindley AC. Audit in the management of T3
fixed-cord laryngeal cancer. Am J Otolaryngol. 1998; 19:360-364.
90.
Rutter MJ, Furneaux CE, Morton RP. Craniofacial resection of anterior skull base
tumours: factors contributing to success. Aust N Z J Surg 1998; 68:350-353.
91.
Bartley J, Fergusson W, Moody A, Wells AU, Kolbe J. Normal adult values,
diurnal variation, and repeatability of nasal nitric oxide measurement. American
Journal of Rhinology. 1999; 13:401-5.
92.
Chaplin JM, Morton RP. A prospective, longitudinal study of pain in head and
neck cancer patients. Head Neck 1999; 21:531-537.
93.
Sigler L, Bartley J, Parr D, Morris A. Maxillary sinusitis caused by medusoid form
of Schizophyllum commune. Journal of Clinical Microbiology. 1999; 37:33953398.
94.
Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC
QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC
QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J
Cancer 2000; 36:1796-1807.
95.
Fraser AG, Morton RP, Gillibrand J. Presumed laryngo-pharyngeal reflux:
investigate or treat? J Laryngol.Otol. 2000; 114:441-447.
96.
McIvor NP, Flint DJ, Gillibrand J, Morton RP. Thyroid surgery and voice-related
outcomes. Aust N Z J Surg 2000; 70:179-183.
83
97.
Morton RP, Chaplin JM. Where are we with clinical outcomes in head and neck
cancer? Curr Opin Otolaryngol. 2000; 8:98-102.
98.
Morton RP. Validation of quality of life measures in head and neck cancer
patients. Aust J Otolaryngol. 2000; 3:479-487.
99.
Morton RP. Surgical management of pharyngeal diverticulum. CME Bull
Otolaryngol Head Neck Surg. 2000; 4:54-57.
100.
Morton RP. Multimodality therpay for advanced head and neck cancer.
Proceedings, 5th International conference on Head and Neck Cancer. San
Francisco, 2000.
101.
Popat S, Liavaag PG, Morton RP, McIvor NP, Irish J, Freeman JL. Epstein Barr
virus genome in nasopharyngeal carcinoma from New Zealand. Head and Neck.
2000; 22:505-508.
102.
Stillman JA, Morton RP, Goldsmith D. Automated electrogustometry: a new
paradigm for the estimation of taste detection thresholds. Clin Otolaryngol. 2000;
25:120-125.
103.
Morton RP. Studies in the Quality of Life of Head and Neck Cancer Patients.
Results of a 2-year Longitudinal Study. St Louis: Triologic Society, St Louis, 2001.
104.
Thompson L, Morton RP, Cuthbertson S, Galler L, McArthur J. Saline installation
prior to endotracheal suctioning in hospitalised adults with an artificial airway.
Cochrane review 2001.
105.
Goldsmith D, West T, Morton RP. HLA associations with nasopharyngeal
carcinoma in Southern Chinese. A Meta-analysis. Clin Otolaryngol. 2002; 27:6167.
106.
Kwok HC, Morton RP, Chaplin JM, McIvor NP, Sillars HA. Quality of life after
parotid and temporal bone surgery for cancer. Laryngoscope 2002; 112:820-833.
107.
Morton RP. Studies in the quality of life of head and neck cancer patients: results
of a two-year longitudinal study and a comparative cross-sectional cross-cultural
survey. Laryngoscope 2003; 113:1091-1103.
108.
Morton RP, Izzard ME. Quality-of-life Outcomes in Head and Neck Cancer
Patients. World J Surg 2003.
109.
Neeff M, Crowder VL, McIvor NP, Chaplin JM, Morton RP. Comparison of the use
of endoscopic and radiologic gastrostomy in a single head and neck cancer unit.
ANZ.J Surg 2003; 73:590-593.
110.
Stillman JA, Morton RP, Hay KD, Ahmad Z, Goldsmith D. Electrogustometry:
strengths, weaknesses, and clinical evidence of stimulus boundaries. Clin
Otolaryngol. 2003; 28:406-410.
84
Paediatric and Congenital Cardiac
1.
Barratt-Boyes BG. Cardiac surgery in infancy. N Z Med J 1965; 64:Suppl-9.
2.
Cant BR. Heart diseases in infancy: an analysis of 500 cases. N Z Med J 1965;
64:Suppl-2.
3.
Kelly DT. Isolated congenital pulmonary incompetence. Br.Heart J 1965; 27:777780.
4.
Kelly DT. Congenital stenosis of pulmonary and aortic valves. Am J Cardiol 1965;
16:750-753.
5.
Lowe JB. Pulmonary stenosis with under-developed right ventricle. N Z Med J
1965; 64:Suppl-3.
6.
Lowe JB. Total anomalous pulmonary venous connection in infancy. N Z Med J
1965; 64:Suppl-6.
7.
Neutze JM. Follow up of high resistance patients after shunt surgery. N Z Med J
1965; 64:Suppl-8.
8.
Neutze JM. Open heart surgery for tetralogy of Fallot. N Z Med J 1965; 64:Suppl20.
9.
Neutze JM. Transposition of the great vessels in infancy. New Zealand Medical
Journal. 1965; 64:Suppl:13-4.
10.
Clarke CP, Barratt-Boyes BG. The cause and treatment of pulmonary edema
after the Mustard operation for correction of complete transposition of the great
vessels. J Thorac Cardiovasc Surg 1967; 54:9-15.
11.
Roche AH. Anomalous origin of the left coronary artery from the pulmonary artery
in the adult. Report of uneventful ligation in two cases. Am J Cardiol 1967;
20:561-565.
12.
Barratt-Boyes BG. The surgery of tetralogy of Fallot, pulmonary atresia with
ventricular septal defect and transposition of the great vessels. Australas Radiol
1968; 12:311-319.
13.
Brandt PW. The radiology of cyanotic congenital heart disease. Australas.Radiol
1968; 12:297-310.
14.
Lowe JB. Cyanotic congenital heart disease. Australas.Radiol 1968; 12:291-297.
15.
Gonzalez-Lavin L, Barratt-Boyes BG. Surgical considerations in the treatment of
ventricular septal defect associated with aortic valvular incompetence. J Thorac
Cardiovasc Surg 1969; 57:422-430.
16.
McMyn JK. Tetralogy of Fallot. Angiocardiographic diagnosis compared with
surgical findings. 1969; 13:36-73.
17.
Richmond DE, Lowe JB, Barratt-Boyes BG. Results of surgical repair of atrial
septal defects in the middle-aged and elderly. Thorax 1969; 24:536-542.
18.
Barratt-Boyes BG. Surgery of transposition of the great vessels in infancy. In:
Eliakim M, Neufeld H, eds. Cardiology - current topics and progress. New York:
Academic Press, 1970.
19.
Barratt-Boyes BG, Simpson M, Neutze JM. Intracardiac surgery in neonates and
infants using deep hypothermia with surface cooling and limited cardiopulmonary
bypass. Circulation 1971; 43:I25-I30.
85
20.
Barratt-Boyes BG. Cardiac surgery in neonates and infants. Circulation 1971;
44:924-925.
21.
Seelye ER, Harris EA, Squire AW, Barratt-Boyes BG. Metabolic effects of deep
hypothermia and circulatory arrest in infants during cardiac surgery. Br J Anaesth
1971; 43:449-459.
22.
Barratt-Boyes BG, Neutze JM, Seelye ER, Simpson M. Complete correction of
cardiovascular malformations in the first year of life. Prog Cardiovasc Dis 1972;
15:229-253.
23.
Barratt-Boyes BG, Nicholls TT, Brandt PW, Neutze JM. Aortic arch interruption
associated with patent ductus arteriosus, ventricular septal defect, and total
anomalous pulmonary venous connection. Total correction in an 8-day-old infant
by means of profound hypothermia and limited cardiopulmonary bypass. J Thorac
Cardiovasc Surg 1972; 63:367-373.
24.
Brandt PW, Clarkson PM, Neutze JM, Barratt-Boyes BG. Left ventricular
cineangiocardiography in endocardial cushion defect (persistent common
atrioventricular canal). Australas Radiol 1972; 16:367-376.
25.
Clarkson PM, Brandt PW, Barratt-Boyes BG, Neutze JM. "Isolated atrial
inversion". Visceral situs solitus, visceroatrial discordance, discordant ventricular
d loop without transposition, dextrocardia: diagnosis and surgical correction. Am J
Cardiol 1972; 29:877-881.
26.
Clarkson PM, Barratt-Boyes BG, Neutze JM, Lowe JB. Results over a ten-year
period of palliation followed by corrective surgery for complete transposition of the
great arteries. Circulation 1972; 45:1251-1258.
27.
Neutze JM. Heart disease in the first year of life. Med J Aust 1972; 2:Suppl-9.
28.
Barratt-Boyes BG, Neutze JM. Primary repair of tetralogy of Fallot in infancy
using profound hypothermia with circulatory arrest and limited cardiopulmonary
bypass: a comparison with conventional two stage management. Ann Surg 1973;
178:406-411.
29.
Barratt-Boyes BG, Neutze JM, Seelye ER, Simpson M. Complete correction of
cardiovascular malformations in the first year of life. In: Friedman W, Lesch M,
Sonnenblick E, eds. Neonatal heart disease. New York: Grune & Stratton, 1973.
30.
Barratt-Boyes BG. Primary definitive intracardiac operations in infants:Tetralogy
of Fallot. In: Kirklin JW, ed. Advances in Cardiovascular Surgery. New york:
Grune & Stratton, 1973.
31.
Barratt-Boyes BG. Primary definitive intracardiac operations in infants: Total
anomolous pulmonary venous connection. In: Kirklin JW, ed. Advances in
Cardiovascular Surgery. New York: Grune & Stratton, 1973.
32.
Barratt-Boyes BG. Profound hypothermia. Complete correction of cardiovascular
malformations in the first two years of life using profound hypothermia. In: BarrattBoyes BG, Neutze JM, Harris EA, eds. Heart disease in infancy:diagnosis and
Surgical Treatment. Edinburgh: Churchill Livingstone, 1973.
33.
Barratt-Boyes BG. Correction of atrioventricular canal defects in infancy using
profound hypothermia. In: Barratt-Boyes BG, Neutze JM, Harris EA, eds. Heart
Disease in Infancy: Diagnosis and Surgical Treatment. Edinburgh: Churchill
Livingstone, 1973.
86
34.
Barratt-Boyes BG, Kerr AR. Tetralogy of Fallot: Surgery of tetralogy of Fallot in
infancy. Comparison of shunt palliation and primary intracardiac repair. In:
Barratt-Boyes BG, Neutze JM, Harris EA, eds. Heart Disease in Infancy:
Diagnosis and Surgical Treatment. Edinburgh: Churchill Livingstone, 1973.
35.
Barratt-Boyes B. New frontiers in cardiovascular surgery: Surgical prospects in
complex cyanotic congenital heart disease. Singapore Medical Journal 1973:179.
36.
Barratt-Boyes B. Profound hypothermia-technical aspects. Singapore Medical
Journal 1973:445.
37.
Brandt PW, Clarkson PM, Barratt-Boyes BG, Neutze JM. An unusual
oesophageal indentation caused by a long tortuous patent ductus arteriosus.
Australas Radiol 1973; 17:394-396.
38.
Clarkson PM. Growth following corrective cardiac operation in early infancy. In:
Barratt-Boyes BG, Neutze JM, Harris EA, eds. Heart Disease in infancy.
Edinburgh: Churchill Livingstone, 1973:75-81.
39.
Clarkson PM. Transposition of the great arteries with ventricular septal defect and
pulmonary stenosis. In: Barratt-Boyes BG, Neutze JM, Harris EA, eds. Heart
Disease in Infancy. Edinburgh: Churchill Livingstone, 1973:280.
40.
Neutze JM, Simpson MM, Seelye ER, Barratt-Boyes BG. Post-operative
management and complications following profound hypothermic surgery.
Singapore Med J 1973; 14:256-259.
41.
Neutze JM, Clarkson PM. Transposition of the Great Arteries. In: Barratt-Boyes
BG, Neutze JM, Harris EA, eds. Heart Disease in Infancy. Edinburgh: Churchill
Livingstone, 1973:266-275.
42.
Simpson MM, Seelye ER. Postoperative care of infants in the first year of life. In:
Barratt-Boyes BG, Neutze JM, Harris EA, eds. Heart Disease in Infancy.
Edinburgh: Churchill Livingstone, 1973:316.
43.
Barratt-Boyes BG. Complete right ventricle outflow obstruction: Complete
correction in infancy. In: Parezan L, Carcassone M, eds. Open Heart Surgery in
Infanct. Milan, 1974.
44.
Barratt-Boyes BG. Simple TGA: Deep hypothermia with partial ECC in TGA. In:
Parezan L, Carcassone M, eds. Open Heart Surgery in Infancy. Milan, 1974.
45.
Barratt-Boyes BG. Complex TGA: TGV and coarctation of the aorta. In: Parezan
L, Carcassone M, eds. Open Heart Surgery in Infancy. Milan, 1974.
46.
Barratt-Boyes BG. Atrioventricular canal: Comparison of the results between
complete correction and palliative operation. In: Parenzan L, Carcassone M, eds.
Open Heart Surgery in Infancy. Milan, 1974.
47.
Barratt-Boyes BG. Profound hypothermia in Infancy. Physical development after
deep hypothermia. In: Parezan L, Carcassone M, eds. Open Heart Surgery in
Infancy. Marseille, 1974.
48.
Barratt-Boyes BG. Results of early correction in infancy: Results after early
correction in infancy. In: Parezan L, Carcassone M, eds. Open Heart Surgery in
Infancy. Marseille, 1974.
49.
Barratt-Boyes BG. Early correction versus palliation: Extracorporeal circulation
and deep hypothermia. In: Parezan L, Carcassone M, eds. Open Heart Surgery in
Infancy. Marseille, 1974.
50.
Clarkson PM, Orgill AA. Continuous murmurs in infants of low birth weight. J
Pediatr 1974; 84:208-211.
87
51.
Elliott RB, Starling MB, Neutze JM. Medical manipulation of the ductus arteriosus.
Lancet 1975; 1:140-142.
52.
Barratt-Boyes BG, Neutze JM, Clarkson PM, Shardey GC, Brandt PW. Repair of
ventricular septal defect in the first two years of life using profound hypothermiacirculatory arrest techniques. Ann Surg 1976; 184:376-390.
53.
Barratt-Boyes BG. The technique of intracardiac repair in infancy using deep
hypothermia with circulatory arrest and limted cardiopulmonary bypass. In:
Lonescu M, Wooler GH, eds. Current Techniques in Extracorporeal Circulation.
London: Butterworths, 1976.
54.
Brandt PW, Calder AL, Barratt-Boyes BG, Neutze JM. Double outlet left ventricle.
Morphology, cineangiocardiographic diagnosis and surgical treatment. American
Journal of Cardiology 1976; 38:897-909.
55.
Clarkson PM, Neutze JM, Wardill JC, Barratt-Boyes BG. The pulmonary vascular
bed in patients with complete transposition of the great arteries. Circulation 1976;
53:539-543.
56.
Clarkson PM, Barratt-Boyles BG, Neutze JM. Late dysrhythmias and
disturbances of conduction following Mustard operation for complete transposition
of the great arteries. Circulation 1976; 53:519-524.
57.
Clarkson PM, Neutze JM, Barratt-Boyles BG, Brandt PW. Late postoperative
hemodynamic results and cineangiocardiographic findings after Mustard atrial
baffle repair for transposition of the great arteries. Circulation 1976; 53:525-532.
58.
Mathur M, Harris EA, Yarrow S, Barratt-Boyes BG. Measurement of cardiac
output by thermodilution in infants and children after open-heart operations. J
Thorac Cardiovasc Surg 1976; 72:221-225.
59.
Starling MB, Neutze JM, Elliott RL, Elliott RB. Studies on the effects of
prostaglandins E1, E2, A1, and A2 on the dustus arteriosus of swine in vivo using
cineangiography. Prostaglandins 1976; 12:355-367.
60.
Barratt-Boyes BG. Corrective surgery for congenital heart disease in infants with
the use of profound hypothermia and circulatory arrest techniques. Aust N Z J
Surg 1977; 47:737-744.
61.
Barratt-Boyes BG, Calder AL. Double outlet ventricle: Classification and surgical
management. In: Davila J, ed. Proceedings 2nd Henry Ford Hospital Symposium.
New York: Appleton-Century-Croft, 1977.
62.
Bass NM, Roche AH, Neutze JM. The role of echocardiography in neonatal and
paediatric cardiological diagnosis. Med J Aust 1977; 1:5-6.
63.
Brandt PW, Calder AL. Cardiac connections: the segmental approach to
radiologic diagnosis in congenital heart disease. Curr.Probl.Diagn Radiol 1977;
7:1-35.
64.
Neutze JM, Starling MB, Elliott RB, Barratt-Boyes BG. Palliation of cyanotic
congenital heart disease in infancy with E-type prostaglandins. Circulation 1977;
55:238-241.
65.
Neutze JM, Rutherford JD, Hurley PJ. Serum digoxin levels in neonates, infants
and children with heart disease. N Z Med J 1977; 86:7-10.
66.
Stanhope JM, Sampson V, Clarkson PM. High density lipoprotein cholesterol and
other serum lipids in a New Zealand biracial adolescent sample: the Wairos
College survey. Lancet 1977; 1:968-970.
88
67.
Barratt-Boyes BG. Technique and results of profound hypothermia surgery in
congential heart disease in infants, Proceedings 10th Anniversary Meeting of the
Japan Society for Hypothermia, 1978.
68.
Bass NM, Roche AH, Brandt PW, Neutze JM. Echocardiography in assessment
of infants with complete d-transposition of great arteries. Br Heart J 1978;
40:1165-1173.
69.
Starling MB, Neutze JM, Elliott RB. Effect of prostaglandins and some methyl
derivatives on the ductus arteriosus. Adv.Prostaglandin Thromboxane Res 1978;
4:335-343.
70.
Starling MB, Neutze JM, Elliott RL, Taylor IM, Elliott RB. The effects of some
methyl prostaglandin derivatives on the ductus arteriosus of swine in vivo.
Prostaglandins Med 1978; 1:267-281.
71.
Whight CM, Barratt-Boyes BG, Calder AL, Neutze JM, Brandt PW. Total
anomalous pulmonary venous connection. Long-term results following repair in
infancy. J Thorac Cardiovasc Surg 1978; 75:52-63.
72.
Calder AL, Barratt-Boyes BG, Brandt PW, Neutze JM. Postoperative evaluation of
patients with tetralogy of Fallot repaired in infancy. Including criteria for use of
outflow patching and radiologic assessment of pulmonary regurgitation. J Thorac
Cardiovasc Surg 1979; 77:704-720.
73.
Starling MB, Neutze JM, Elliott RL. Control of elevated pulmonary vascular
resistance in neonatal swine with prostacyclin (PGI2). Prostaglandins Med 1979;
3:105-117.
74.
Brandt PW, Clarkson PM. The neonatal chest x-ray in congenital heart disease.
In: Valyasevi A, Mekanandha V, eds. Prceedings of the third Asian Congress of
Pediatrics. Bankok: Medical Publisher, 1980:205-212.
75.
Calder AL, Brandt PW, Barratt-Boyes BG, Neutze JM. Variant of tetralogy of
Fallot with absent pulmonary valve leaflets and origin of one pulmonary artery
from the ascending aorta. Am J Cardiol 1980; 46:106-116.
76.
Clarkson PM, MacArthur BA, Barratt-Boyes BG, Whitlock RM, Neutze JM.
Developmental progress after cardiac surgery in infancy using hypothermia and
circulatory arrest. Circulation 1980; 62:855-861.
77.
Hossack KF, Neutze JM, Lowe JB, Barratt-Boyes BG. Congenital valvar aortic
stenosis. Natural history and assessment for operation. Br Heart J 1980; 43:561573.
78.
Neutze JM. The physiological basis of the clinical presentation of congenital heart
disease in infants. Proceedings of the VIII world congress of Cardiology. Oxford:
Exerpta Medica, 1980.
79.
Starling MB, Neutze JM, Elliott RL. Effects of Prostaglandin E1, prostacyclin, and
tolazoline on elevated pulmonary vascular resistance in neonatal swine.
Adv.Prostaglandin Thromboxane Res 1980; 7:755-757.
80.
Clarkson PM, Nicholson MR, Neutze JM, Hutchinson S, Barratt-Boyes BG.
Assessment of late results of surgical repair of coarctation of the aorta with
reference to hypertension. In: Goodman M, ed. Paediatric Cardiology: Churchill
Livingstone, 1981:430-3.
81.
Soljak MA, Kirker JA, Calder AL, Neutze JM. Extensive aneurysm formation in the
mucocutaneous lymph node syndrome. N Z Med J 1981; 94:43-45.
89
82.
Starling MB, Neutze JM, Elliott RL, Elliott RB. Comparative studies on the
hemodynamic effects of prostaglandin E1 prostacyclin, and tolazoline upon
elevated pulmonary vascular resistance in neonatal swine. Prostaglandins Med
1981; 7:349-361.
83.
Clarkson PM, MacArthur BA, Barratt-Boyes BG, Neutze JM, Whitlock RM.
Cardiac surgery in infancy using profound hypothermia and circulatory arrestL
Late developmental progress. In: Becker R, Katz J, Polonius M, Speidl H, eds.
Psychopathological and neurological dysfunction following open-heart surgery.
Berlin: Springer-Verlag, 1982:187-192.
84.
Clarkson PM, Nicholson MR, Barratt-Boyes BG, Neutze JM, Whitlock RM.
Results after repair of coarctation of the aorta beyond infancy: a 10 to 28 year
follow-up with particular reference to late systemic hypertension. Am J Cardiol
1983; 51:1481-1488.
85.
Calder AL, Kirker JA, Neutze JM, Starling MB. Pathology of the ductus arteriosus
treated with prostaglandins: comparisons with untreated cases. Pediatr Cardiol
1984; 5:85-92.
86.
Ishikawa T, Neutze JM, Brandt PW, Barratt-Boyes BG. Hemodynamics following
the Kreutzer procedure for tricuspid atresia in patients under two years of age. J
Thorac Cardiovasc Surg 1984; 88:373-379.
87.
Neutze JM. Long term results after surgery for Tetralogy of Fallot, VII AsianPacific Congress of Cardiology, Bangkok, 1984.
88.
Robinson PJ, Neutze JM, Brandt PW, Hill DG, Anderson RJ, Rutland MD.
Congenital aneurysm of the left atrium: diagnosis and management. Aust N Z J
Med 1984; 14:267-269.
89.
Barratt-Boyes BG. Repair of tetralogy of Fallot in infancy. In: Yingkai W, Peters
RM, eds. International Practice in Cardiothorasic Surgery. Beijing: Science Press,
1985.
90.
Clarkson PM, Brandt PW, Barratt-Boyes BG, Rutherford JD, Kerr AR, Neutze JM.
Prosthetic repair of coarctation of the aorta with particular reference to Dacron
onlay patch grafts and late aneurysm formation. Am J Cardiol 1985; 56:342-346.
91.
Clarkson PM, Brandt PW. Aortic diameters in infants and young children:
normative angiographic data. Pediatr Cardiol 1985; 6:3-6.
92.
Ishikawa T, Brandt PW. Anomalous origin of the left main coronary artery from
the right anterior aortic sinus: angiographic definition of anomalous course. 1985;
55:770-776.
93.
Lubbe WF. Platelets, prostaglandins and recurrent fetal death. Prostglandin
Perspectives 1985; 2:1-2.
94.
Starling MB, Neutze JM, Hill DG, Jagusch M, Cleland JF, Johns A, Elliott RL. The
effects of prostacyclin (PGI2) on haematological and haemodynamic parameters,
and lung histology in puppies undergoing cardiopulmonary bypass surgery with
profound hypothermia. Prostaglandins Leukot Med 1985; 17:11-29.
95.
Calder AL, Robinson PJ, Roche AH. Anatomical and echocardiographic
correlations in the normal heart. Aust N Z J Med 1986; 16:517-527.
96.
Calder AL, Co EE, Sage MD. Coronary arterial abnormalities in pulmonary atresia
with intact ventricular septum. Am J Cardiol 1987; 59:436-442.
97.
Starling MB, Neutze JM. Effects of prostacyclin on cardiopulmonary bypassmediated lung damage using extravascular lung water measurements.
Adv.Prostaglandin Thromboxane Leukot.Res 1987; 17B:1091-1093.
90
98.
Barratt-Boyes BG. Atrioventricular canal defects: terminology in perspectives in
pediatric cardiology. In: Crupi C, Parezan L, Anderson RH, eds. Pediatric Cardiac
Surgery, Volume 2. New York: Futura Publishing Co, 1989.
99.
Barratt-Boyes BG, Neutze JM, Calder AL. The importance of accurate
assessment of pulmonary vascular disease in children with congential heart
disease: a reason why Doppler echocardiography will not replace the need for
preoperative cardaic catheterisation in children. In: Rivera R, ed. Jornadas
internacionales de actualization cardiovascular. Madrid: Aran Ediciones,
1989:303.
100.
Calder AL. Pulmonary venous obstruction in total anomalous pulmonary venous
connection,. In: Crupi C, Parenzan L, Anderson R, eds. New York: Futura
Publishing Co, 1989:130.
101.
Neutze JM, Ishikawa T, Clarkson PM, Calder AL, Barratt-Boyes BG, Kerr AR.
Assessment and follow-up of patients with ventricular septal defect and elevated
pulmonary vascular resistance. Am J Cardiol 1989; 63:327-331.
102.
Barratt-Boyes BG. The role of surgery in congenital heart disease in the year
2000. In: Pongpanich B, ed. Pediatric Cardiology: Elsevier Science Publishers,
1990.
103.
Calder AL. Morphological features in situs ambiguus. In: Crupi C, Parenzan L,
Anderson R, eds. Perspectives in Pediatric Cardiac Surgery. New York: Futura
Publishing Co, 1990:273.
104.
Gentles TL, Clarkson PM, Trenholme AA, Lennon DR, Neutze JM. Kawasaki
disease in Auckland, 1979-1988. N Z Med J 1990; 103:389-391.
105.
Starling MB, Neutze JM. Prostaglandins and extracorporeal circulation.
Prostaglandins Leukot.Essent.Fatty Acids 1990; 40:1-8.
106.
Calder AL, Chan NS, Clarkson PM, Kerr AR, Neutze JM. Progress of patients
with pulmonary atresia after systemic to pulmonary arterial shunts. Ann Thorac
Surg 1991; 51:401-407.
107.
Korula A, Calder AL, Neutze JM. Effects of prostaglandin E1 given in low doses
on the histopathology of the arterial duct. Int J Cardiol 1991; 33:215-222.
108.
Mawson JB, Goel PK, Brandt PW. Klinefelter's syndrome with anomalous origin
of left main coronary artery. 1991; 22:321.
109.
Gentles TL, Calder AL, Clarkson PM, Neutze JM. Predictors of long-term survival
with Ebstein's anomaly of the tricuspid valve. Am J Cardiol 1992; 69:377-381.
110.
Stewart AD, Calder AL, Neutze JM, James AH, Brandt PW. Stenosis of
pulmonary veins in Down syndrome. J Paediatr Child Health 1992; 28:192-195.
111.
Webster MW, Neutze JM, Calder AL. Acute hemodynamic effects of converting
enzyme inhibition in children with intracardiac shunts. Pediatr Cardiol 1992;
13:129-135.
112.
Neutze JM. Controversies in treatment of congential aoritc stenosis and
coarctation of the aorta. In: Hong CY, ed. Recent advances in Cardiology. Seoul:
Korea Medical Publishing Company, 1993.
113.
Ormiston JA, Neutze JM, Calder AL, Hak NS. Percutaneous balloon angioplasty
for early postoperative modified Blalock-Taussig shunt failure. Cathet.Cardiovasc
Diagn 1993; 29:31 -34.
91
114.
Roberts AB, Hampton E, Wilson N. Ultrasound detection of fetal structural
abnormalities in Auckland 1988-9. New Zealand Medical Journal. 1993; 106:4413.
115.
Wilson NJ, Neutze JM. Adult congenital heart disease: principles and
management guidelines--Part I. Aust N Z J Med 1993; 23:498-503.
116.
Wilson NJ, Neutze JM. Adult congenital heart disease: principles and
management guidelines: Part II. Aust N Z J Med 1993; 23:697-705.
117.
Wilson NJ, Neutze JM, Mawson JB, Calder AL. Transcatheter closure of patent
ductus arteriosus in children and adults. N Z Med J 1993; 106:299-301.
118.
Clarkson PM, Wilson NJ, Neutze JM, North RA, Calder AL, Barratt-Boyes BG.
Outcome of pregnancy after the Mustard operation for transposition of the great
arteries with intact ventricular septum. J Am Coll Cardiol 1994; 24:190-193.
119.
Leversha AM, Wilson NJ, Clarkson PM, Calder AL, Ramage MC, Neutze JM.
Efficacy and dosage of enalapril in congenital and acquired heart disease. Arch
Dis Child 1994; 70:35-39.
120.
Wilson NJ, Allen BC, Clarkson PM, Knight DB, Roberts AB, Calder AL. One year
audit of a referral fetal echocardiography service. N Z Med J 1994; 107:258-260.
121.
Peck D, Holland R, Merry A. Paediatric cardiac catheterisation and the laryngel
mask airway. Anaesthesia & Intensive Care. 1995; 23:643.
122.
Wilson NJ, Neutze JM, Rutland MD, Ramage MC. Transthoracic
echocardiography for right ventricular function late after the Mustard operation.
Am Heart J 1996; 131:360-367.
123.
Wilson NJ, Clarkson PM, Barratt-Boyes BG, et al. Long-term outcome after the
Mustard repair for simple transposition of the great arteries. 28-year follow-up. J
Am Coll Cardiol 1998; 32:758-765.
124.
Nomura F, Finucane K, Smith W, Kerr AR. The failing Fontan with atrial flutter: a
successful surgical option. Annals of Thoracic Surgery. 1999; 68:1845-8.
125.
Thomson L, Webster M, Wilson N. Transcatheter closure of a large coronary
artery fistula with the Amplatzer duct occluder. comment. Catheterization &
Cardiovascular Interventions. 1999; 48:188-90.
126.
Tonkin SL, Clarkson PM. A view from New Zealand: comments on the prolonged
QT theory of SIDS causation. Pediatrics 1999; 103:818-819.
127.
Wilson NJ, Occleshaw CJ, O'Donnell CP, Neutze JM, Kerr AR. Subclinical aortic
perforation with the infant double-button patent ductus arteriosus occluder.
comment. Catheterization & Cardiovascular Interventions. 1999; 48:296-8.
128.
Armishaw J, Gentles TL, Calder AL, Raudkivi PJ, Kerr AR. Transposition of the
great arteries: operative outcome in the current era. N Z Med J 2000; 113:456459.
129.
Gentles TL, Sanders SP, Colan SD. Misrepresentation of left ventricular
contractile function by endocardial indexes: clinical implications after coarctation
repair. Am Heart J 2000; 140:585-595.
130.
Neutze JM, Calder AL, Gentles TL, Wilson NJ. Aortic Stenosis. In: Hoffman J,
Moller J, eds. Pediatric Cardiovascular Medicine. New York: Churchill Livingston,
2000:511.
131.
Skinner JR. Contributing author of: Neonatal Formulary. London: BMJ Publishing
Group, 2000.
92
132.
Wernovsky G, Stiles KM, Gauvreau K, et al. Cognitive development after the
Fontan operation. Circulation 2000; 102:883-9.
133.
Baker E, Skinner JR. Cardiology. In: Stroobant J, Field J, eds. Handbook of
Paediatric Investigations. London: Churchill Livingston.;, 2001:310-330.
134.
Barratt-Boyes BG. Surgical treatment of congenital heart disease at Green Lane
Hospital: an historical review. N Z Med J 2001; 114:S4-S9.
135.
Gentles TL, Neutze JM, Caulder AL, Greene ER. Cardiac output measurements
in congenital heart disease: validation of a simple, portable Doppler method. J
Ultrasound Med 2001; 20:365-370.
136.
Gentles TL, Calder AL, Greene DR, Neutze JM. A comparison of Doppler and
Fick cardiac outputs in children with congenital heart disease. J Ultrasound Med
2001; 20:365-70.
137.
Nomura F, Finucane K, Kerr AR. Rare venous connection causes severe
cyanosis after the Fontan operation. Annals of Thoracic Surgery. 2001; 72:21278.
138.
O'Donnell C, Neutze JM, Skinner JR, Wilson NJ. Transcatheter patent ductus
arteriosus occlusion: evolution of techniques and results from the 1990s. J
Paediatr Child Health 2001; 37:451-455.
139.
Porter GF, Gentles TL. Images in clinical medicine. Giant coronary-artery
aneurysm in Kawasaki's disease. N Engl.J Med 2001; 345:98.
140.
Setty SP, Finucane K, Wilson NJ, Beca J, Kerr AR. Stage one Norwood results:
The Green Lane experience. Heart Lung and Circulation 2001; 10:136-141.
141.
Skinner JR. Diagnosis of patent ductus arteriosus. Seminars in neonatology
2001; 6:49-61.
142.
Armstrong D, Battin MR, Knight D, Skinner JR. Staphylococcus aureus
endocarditis in preterm neonates. Am J Perinatol 2002; 19:247-251.
143.
Butler R, Webster MW. Meralgia paresthetica: an unusual complication of cardiac
catheterization via the femoral artery. Catheter.Cardiovasc Interv. 2002; 56:69-71.
144.
Gentles TL, Colan SD. Wall stress misrepresents afterload in children and young
adults with abnormal left ventricular geometry. J Appl.Physiol 2002; 92:10531057.
145.
Heaton P, Wilson N. Fatal Kawasaki disease caused by early occlusive coronary
artery disease. Archives of Disease in Childhood. 2002; 87:145-6.
146.
Hornung TS, Derrick GP, Deanfield JE, Redington AN. Transposition Complexes
in the Adult: A Changing Perspective. Cardiology Clinics of North America 2002;
20:405-420.
147.
Setty SP, Finucane K, Skinner JR, Kerr AR. Extracardiac conduit with a limited
maze procedure for the failing Fontan with atrial tachycardias. Ann Thorac Surg
2002; 74:1992-1997.
148.
Young AA, Cowan BR, Occleshaw CJ, Oxenham HC, Gentles TL. Temporal
evolution of left ventricular strain late after repair of coarctation of the aorta using
3D MR tissue tagging. J Cardiovasc Magn Reson. 2002; 4:233-243.
149.
Cormack B, Wilson NJ, Finucane K, West TM. The Use of Monogen for Pediatric
Postoperative Chylothorax. The Annals of Thoracic Surgery 2003.
93
150.
Hall R, Gentles TL. Adult congenital heart disease. In: Sidebotham D, Merry A,
Legget M, eds. Practical Perioperative Transesophageal Echocardiography.
London: Elsevier, 2003.
151.
Hornung TS. Transposition of the Great Arteries. In: Gatzoulis, Webb, Daubeney,
eds. Diagnosis and Management of Adult Congenital Heart Disease: Churchill
Livingstone, 2003.
152.
James PA, Aftimos S, Skinner JR. Familial mitral valve prolapse associated with
short stature, characteristic face, and sudden death. Am J Med Genet 2003;
119A:32-36.
153.
Shanahan CL, Wilson NJ, Gentles TL, Skinner JR. The influence of measured
versus assumed uptake of oxygen in assessing pulmonary vascular resistance in
patients with a bidirectional Glenn anastomosis. Cardiology in the Young 2003;
13:137-142.
154.
Skinner JR. Echocardiography. In: Forfar JO, Arneil G, C., eds. Textbook of
Paediatrics. London: Churchill Livingstone, 2003:821-830.
155.
Skinner JR. Sudden Infant Death Syndrome. In: Tse H, Lee KL, eds. Clinical
Cardiac Pacing and Electrophysiology, 2003:351-354.
156.
Skinner JR. Neonatal Heart Disease. In: Forfar JO, Arneil GC, eds. Textbook of
Paediatrics. London: Churchill Livingstone, 2003:840-853.
94
Pathology
1.
Gwynne J. Falacies in cancer mortality statistics. 1965; 64:146-151.
2.
Sims FH. Clinical chemistry in New Zealand. N Z Med J 1970; 72:122-125.
3.
MacCulloch D, Cornere BM. A method for bacteriological sampling of surfaces by
direct application of culture media. Journal of Clinical Pathology. 1973; 26:977-8.
4.
MacCulloch D, Prairie J. A comparison of direct and diluted sputum culture
results. New Zealand Medical Journal. 1973; 78:442-3.
5.
Reeve J. Lack of resistance to methicillin and cloxacillin among staphylococci at
Green Lane Hospital. N Z Med J 1973; 77:86-90.
6.
MacCulloch D, Richardson RA, Allwood GK. The penetration of doxycycline,
oxytetracycline and minocycline into sputum. New Zealand Medical Journal.
1974; 80:300-2.
7.
MacCulloch D, Allwood GK. The value of blood culture in the diagnosis of
pneumococcal pneumonia. New Zealand Medical Journal. 1974; 80:168-70.
8.
Lubbe WF, Cadogan ES, Kannemeyer AH. Oesophageal ulceration due to slowrelease potassium in the presence of left atrial enlargement. N Z Med J 1979;
90:377-379.
9.
MacCulloch D, Cornere BM. In-vitro activity of cefoxitin against recent clinical
bacterial isolates. New Zealand Medical Journal. 1979; 89:83-5.
10.
MacCulloch D, Menzies RE. A comparison of the in-vitro activity of piperacillin,
ticarcillin and carbenicillin against Gram-negative bacilli. New Zealand Medical
Journal 1981; 93:93-94.
11.
Lubbe WF, Nguyen T, West EJ. Modulation of myocardial cyclic AMP and
vulnerability to fibrillation in the rat heart. Federation Proceedings 1983; 42:24602464.
12.
Rajan RS, Western J, Barratt-Boyes BG, Woodfield DG. Blood utilisation in open
heart surgery at Green Lane Hospital. N Z Med J 1983; 96:575-577.
13.
Jaffe WM, Wattie WJ, Rutland MD, Lubbe WF. Extensive pulmonary embolism
associated with lupus anticoagulant. N Z Med J 1985; 98:184-185.
14.
Menzies RE, MacCulloch D. Comparison of a beta-lactamase induction test with
a test that detects low-frequency resistance to cefotaxime. Antimicrobial Agents &
Chemotherapy. 1985; 27:672-3.
15.
Menzies RE, Cornere BM, MacCulloch D. Cephalosporin susceptibility of
methicillin-resistant, coagulase-negative staphylococci. Antimicrobial Agents &
Chemotherapy. 1987; 31:42-5.
16.
Singh K, Morris A, Bremner D, MacCulloch D, Lang SD. Clinically significant
Streptococcus anginosus (S.milleri) infection: a review of 186 cases. New
Zealand Medical Journal 1988; 101:813-816.
17.
Menzies RE, Cornere BM, MacCulloch D. Adaptation of methicillin-resistant
Staphylococcus aureus during antibiotic therapy. Journal of Antimicrobial
Chemotherapy. 1989; 23:923-7.
18.
Morris A, Ward C. High incidence of vancomycin-associated leukopenia and
neutropenia in a cardio-thorasic surgical unit. Journal of Infection 1991; 22:217223.
95
19.
Morris A, Guild I. Corynebacterium pseudodiphtherium endocarditis; five case
reports, review and antibiotic susceptibilities of nine strains. Reviews of Infectious
Diseases 1991; 13:887-892.
20.
Boyhan A, Casimir CM, French JK, Teahan CG, Segal AW. Molecular cloning
and characterization of grancalcin, a novel EF-hand calcium-binding protein
abundant in neutrophils and monocytes. Journal of Biological Chemistry. 1992;
267:2928-33.
21.
Cheng AT, Dorman B. Fine needle aspiration cytology: the Auckland experience.
Aust N Z J Surg 1992; 62:368-372.
22.
Lewis BD. Laboratory evaluation of the Glucocard blood glucose test meter. Clin
Chem. 1992; 38:2093-2095.
23.
Baker JR, Zyzak DV, Thorpe SR, Baynes JW. Mechanism of fructosamine assay:
evidence against role of superoxide as intermediate in nitroblue tetrazolium
reduction. Clin Chem. 1993; 39:2460-2465.
24.
Baker JR, Zyzak DV, Thorpe SR, Baynes JW. Chemistry of the fructosamine
assay: D-glucosone is the product of oxidation of Amadori compounds. Clin
Chem. 1994; 40:1950-1955.
25.
Parhami-Seren B, Lynch M, White HD, Reed GL. Mapping the antigenic regions
of streptokinase in humans before and after streptokinase therapy. Molecular
Immunology. 1995; 32:717-24.
26.
Roberts S, Morris A, McIvor NP, Ellis-Pegler R. Chrombacterium vioaceum
infection of the deep tissues of the neck in a traveller to Thailand. Clinical
Infectious Diseases. 1997; 25:334-335.
27.
Theakston E, Morris A, Streat S, Baker B, Woodfield D. Transfusion transmitted
Yersinia enterocolitica infection in New Zealand. Australian & New Zealand
Journal of Medicine. 1997; 27:62-67.
28.
Pottumarthy S, Morris AJ. Detection of decreased penicillin susceptibility in
viridans group streptococci. Pathology. 1998; 30:188-91.
29.
Drinkovic D, Taylor SL, Pottumarthy S, Morris AJ. Prospective vancomycin audit
in Auckland healthcare hospitals. New Zealand Medical Journal. 1999; 112:336-9.
30.
Johnson RN, Baker JR. Analytical error of home glucose monitors: a comparison
of 18 systems. Ann Clin Biochem. 1999; 36 ( Pt 1):72-79.
31.
Pottumarthy S, Morris AJ, Harrison AC, Wells VC. Evaluation of the tuberculin
gamma interferon assay: potential to replace the Mantoux skin test. Journal of
Clinical Microbiology. 1999; 37:3229-32.
32.
Al-Samarrai TH, Zhang N, Lamont IL, Martin L, Kolbe J, Wilsher M, Morris AJ,
Schmid J. Simple and inexpensive but highly discriminating method for computerassisted DNA fingerprinting of Pseudomonas aeruginosa. Journal of Clinical
Microbiology. 2000; 38:4445-52.
33.
Drinkovic D, Wong CG, Taylor SL, Roberts SA, Morris AJ. Pneumococcal
bacteraemia and opportunities for prevention. New Zealand Medical Journal.
2001; 114:326-8.
34.
Graves N, Nicholls TM, Morris AJ. Modeling the costs of hospital-acquired
infections in New Zealand. Infection Control & Hospital Epidemiology. 2003;
24:214-23.
96
35.
Graves N, Nicholls TM, Wong CG, Morris AJ. The prevalence and estimates of
the cumulative incidence of hospital-acquired infections among patients admitted
to Auckland District Health Board Hospitals in New Zealand. Infection Control &
Hospital Epidemiology. 2003; 24:56-61.
97
Physiology
1.
Harris EA. Exercise tolerance tests. N Z Med J 1965; 64:Suppl-6.
2.
Parker R. A simple syringe holder for constant volume injection in dye dilution
studies. N Z Med J 1965; 64:332-333.
3.
Sinclair JD. The measurement of cardiac output. New Zealand Medical Journal.
1965; 64:Suppl:71-2.
4.
Whitlock RM. A means of speaking for patients with cuffed tracheostomy tubes.
British Medical Journal 1967; 26:564-7.
5.
Harris EA, Seelye ER, Squire AW. Oxygen consumption during cardiopulmonary
bypass with moderate hypothermia in man. Br.J Anaesth. 1971; 43:1113-1120.
6.
Harris EA. Accurate analysis of carbon dioxide in oxygen-nitrogen mixtures by
infra-red absorption. Biomed.Eng 1973; 8:66-69.
7.
Harris EA, Hunter ME, Seelye ER, Vedder M, Whitlock RM. Prediction of the
physiological dead-space in resting normal subjects. Clin Sci Mol.Med 1973;
45:375-386.
8.
Harris EA, Kenyon AM, Nisbet HD, Seelye ER, Whitlock RM. The normal
alveolar-arterial oxygen-tension gradient in man. Clin Sci Mol.Med 1974; 46:89104.
9.
Harris EA. An expiratory mixing chamber. Aust J Sports Med. 1975; 7:63.
10.
Harris EA. Physiological limits to performance. N Z Vet.J 1975; 23:255-259.
11.
Harris EA. Letter: Haemoglobin binding curve and oxygen transport. Br.Med J
1975; 3:231.
12.
Liang A, Pulley B, Salive HT, Harris EA. Spirometric standards from 387 healthy
New Zealand children. Aust N Z J Med 1975; 5:260-266.
13.
Bradley CA, Harris EA, Seelye ER, Whitlock RM. Gas exchange during exercise
in healthy people. I. The physiological dead-space volume. 1976; 51:323-333.
14.
Harris EA, Seelye ER, Whitlock RM. Gas exchange during exercise in healthy
people II. Venous admixture. Clin Sci Mol.Med 1976; 51:335-344.
15.
Sinclair JD, Hill PM, Brandt PW. Thoracic and arterial pressures, blood flow and
syncope. N Z Med J 1976; 84:270-272.
16.
Rea HH, Withy SJ, Seelye ER, Harris EA. The effects of posture on venous
admixture and respiratory dead space in health. 1977; 115:571-580.
17.
Rush EC, Neutze JM, Harris EA. Calibration of densitometers for indicator dye
dilution. 1977; 11:263-269.
18.
Harris EA, Seelye ER, Whitlock RM. Revised standards for normal resting deadspace volume and venous admixture in men and women. Clin Sci Mol.Med 1978;
55:125-128.
19.
McKinney RJ, Harris EA. Evaluation of the OSM2 hemoximeter. Cardiovasc Res
1978; 12:630-634.
20.
Rea HH, Harris EA, Seelye ER, Whitlock RM, Withy SJ. The effects of
cardiopulmonary bypass upon pulmonary gas exchange. J Thorac Cardiovasc
Surg 1978; 75:104-120.
98
21.
Macfie AE, Harris EA, Whitlock RM. Transit-time analysis of the forced spirogram
in healthy children and adults. 1979; 46:263-267.
22.
Macfie AE, Harris EA, Whitlock RM. The maximal expiratory flow/volume curve in
197 healthy New Zealanders: a comparison with recent American standards.
1981; 11:517-521.
23.
Rea HH. Lung function changes as a relection of tissue ageing in young adults.
Bull Europ Physiopath Resp 1982; 18:5.
24.
Harris EA, Whitlock RM. Fractional carbon monoxide uptake and "diffusing
capacity" in models of pulmonary maldistribution. Bull Eur Physiopathol.Respir.
1983; 19:427-432.
25.
Harris EA, Whitlock RM. Prediction equations for fractional CO uptake derived
from 50 healthy subjects. Bull Eur Physiopathol.Respir. 1983; 19:433-438.
26.
Tavener SJ, Withy SJ, Harris EA. Response characteristics of a mass
spectrometer. Med Biol Eng Comput. 1984; 22:493-498.
27.
Haresnape AM, Harris EA, Hill P. Taylor laminar dispersion in human airways.
Respiration Physiology. 1985; 59:131.
28.
Buchanan PR, Tavener SJ, Withy SJ, Harris EA. Recovery of ventilation
distributions by gas wash-out of a mechanical pump. Clin Phys Physiol Meas.
1986; 7:237-252.
29.
Harris EA, Buchanan PR, Whitlock RM. Human alveolar gas-mixing efficiency for
gases of differing diffusivity in health and airflow limitation. Clin Sci (Lond) 1987;
73:351-359.
30.
Harris EA. Measurement of dead-space volume. Clin Sci (Lond) 1987; 73:239240.
31.
Ameratunga R, Harris EA. The alveolar carbon monoxide uptake fraction: a
simple, alternative measure of carbon monoxide transfer. Eur Respir.J 1988;
1:115-118.
32.
Harris EA, Whitlock RM. Correction of inert gas washin or washout for gas
solubility in blood. J Appl.Physiol 1988; 65:1598-1603.
33.
Withy S. Computers in cardiology.[comment]. New Zealand Medical Journal.
1989; 102:154-5.
34.
Withy S, Ashton N, Burke N, Hood M, Smith WM. Computer in Cardiology. New
Zealand Medical Journal 1989; 102:154-5.
35.
Fuller GC, Harris EA. Prolonged measurement of respiratory tidal and minute
volumes. Clin Phys Physiol Meas. 1990; 11:143-147.
36.
Fuller GC, Harris EA, Withy SJ. Gas-mixing efficiency in a mathematical model of
the lung. Clin Phys Physiol Meas. 1990; 11:149-158.
37.
Harris EA. Alveolar partial pressures of carbon dioxide and oxygen measured by
a helium washout technique. Thorax 1991; 46:151.
38.
Seear M, Anderson B, Hall R, Hui H. Mathematical model of oxygen transport: a
teaching aid for normal physiology adaptable to extracorporeal oxygenation
circuits. American Journal of Physiology. 1995; 268:S32-9.
39.
Eaton T, Withy S, Garrett JE, Mercer J, Whitlock RM, Rea HH. Spirometry in
primary care practice: the importance of quality assurance and the impact of
spirometry workshops.[comment]. Chest. 1999; 116:416-23.
99
40.
Milivojevic-Poleksic L, Wells AU, Moody A, Fergusson W, Tukuitonga C, Kolbe J.
Spirometric lung volumes in the adult Pacific Islander population: comparison with
predicted values in a European population. Respirology. 2001; 6:247-53.
41.
Schermer T, Eaton TE, Pauwels R, va Weel C. Spirometry in primary care. Is it
good enough to face demands like world COPD Day? Eur Respir J 2003.
100
Politics, GLH History and Health Economics
1.
2.
Cole DS. New medical school for New Zealand. Br.Med J 1965; 5461:585-586.
Pearl M. Kiwi in the Khumbu. New Zealand Medical Journal. 1965; 64:584-8.
3.
Robb D. A council of medical education. N Z Med J 1965; 64:652-654.
4.
Robb D. Surgery in New Zealand. A retrospect and a prospect. Br J Surg 1965;
52:829-835.
5.
Robb D. New medical school--University of Auckland. World Med J 1966; 13:104105.
6.
Robb D. The surgeon among doctors. Surgery 1966; 60:948-949.
7.
Robb D. Paduan predecessors. Surgery 1966; 60:1287-1288.
8.
Robb D. Medicine in China. N Z Med J 1967; 66:183-187.
9.
Roche EH. A chapter in the gradual infiltration of science into medicine. N Z Med
J 1967; 66:594-599.
10.
Robb D. A General Medical Council for Australasia? Med J Aust 1968; 2:11151117.
11.
Cole DS. A single medical college for New Zealand. N Z Med J 1970; 72:191-198.
12.
Hutchinson BR. The history and development of anaesthesia in New Zealand.
Prceedings of the III Asian and Australasian. 1970:494-496.
13.
Robb D. A Pacific-wide view of surgery. Surgery 1970; 67:558-560.
14.
Roche E. Some medical pioneers in New Zealand: Part 2. N Z Med J 1970;
71:90-93.
15.
Roche E. Some medical pioneers in New Zealand, Part 1. 1970; 71:29.
16.
Cole DS. Heart surgery at Green Lane Hospital with a background of work in
experimental animals. N Z Vet.J 1971; 19:131.
17.
Robb D. The pathology of medical practice. N Z Med J 1971; 74:344.
18.
Robb D. An integrated health service. N Z Med J 1971; 74:280.
19.
Robb D. Healing. N Z Med J 1971; 74:101-102.
20.
Coombes AC. Presidential address. N Z Med J 1972; 75:218-221.
21.
Cole DS. Postgraduate medical education: the graduate phase in New Zealand.
N Z Med J 1973; 78:118-124.
22.
Cole DS. The society for Preservation of the Saphenous vein (SPSV). N Z Med J
1973; 77:127.
23.
Hunter A. The personal relationship between doctor and patient. N Z Med J 1973;
78:213-214.
24.
Hutchinson BR. Some highlights in the history of nitrous oxide. New Zealand
Medical Journal. 1973; 77:171-7.
25.
Barratt-Boyes B. Obituary notice - Sir Douglas Robb 1899-1974. Proceedings of
the Royal Society of New Zealand 1974:121.
26.
Newman J. Old age looks at itself. N Z Med J 1974; 80:107-109.
101
27.
Newman J. Letter: Overcoming the doctor shortage: some practical suggestions.
N Z Med J 1975; 82:95-96.
28.
Robb D. Medical education. N Z Med J 1975; 81:154-159.
29.
Robb D. Earlier help for sick doctors. Br Med J 1980; 281:150.
30.
Richmond DE, Mercer CJ. Improving medical meetings. IV--Evaluate for the
future. Br Med J 1983; 287:1450-1451.
31.
Richmond DE, Mercer CJ. Improving medical meetings. III--Diversify the format of
conference sessions. Br Med J 1983; 287:1363-1364.
32.
Neutze J. The health budget. New Zealand Medical Journal 1985; 98:657.
33.
Harris EA. The Cartwright report and consent. N Z Med J 1988; 101:671.
34.
Harris EA. Ignorant consent: a cautionary tale. N Z Med J 1989; 102:383-384.
35.
Harris EA. Ethics committees. N Z Med J 1989; 102:325.
36.
Leslie PN, Hay DR, Horton MB, et al. A standard for ethics
committees.[comment]. New Zealand Medical Journal. 1989; 102:618.
37.
Neutze J. A standard for ethical committees. New Zealand Medical Journal 1989;
102:111.
38.
Yarrow S. How it all started: New Zealand's first open heart operation. N Z Med J
1989; 102:353-355.
39.
Members of the consultant staff Green Lane Hospital. Informed consent:
discussion paper by the NZ Health Council's working party. New Zealand Medical
Journal 1990; 103:348-51.
40.
Armiger L, Gluckman PD, Lubbe WF, Marbrook J, Norris RM, Skinner JR Watkins
WB, White HD, Wiggins P. Medical research in New Zealand. Lancet 1990:1222.
41.
Elliott J, White H. Patients are patients. New Zealand Medical Journal 1990;
103:593.
42.
Harris EA. Medical research. N Z Med J 1990; 103:50.
43.
Harris EA. Ethical committees in practice. N Z Med J 1990; 103:279.
44.
White HD. All patients. New Zealand Medical Journal 1990; 103:593.
45.
Neutze J. What is the real issue? New Zealand Medical Journal 1991; 104:146-7.
46.
White H. Patients and clients. New Zealand Nursing Journal 1991.
47.
Ackland RH, Becroft DM, Fraser AR, Hawke JE, James AG, McKenzie AR,
Neutze JM, Smith WM, Whitlock RM. Resident hospital doctors' strike.[comment].
New Zealand Medical Journal. 1992; 105:43.
48.
Harris EA. Medical ethics and the New World Order. N Z Med J 1992; 105:405407.
49.
Harris EA. Professional conduct? N Z Med J 1992; 105:414.
50.
Harris EA. Commercially sensitive ethics. N Z Med J 1992; 105:501.
51.
Harris EA. Getting the figures right. N Z Med J 1992; 105:272.
52.
Harris EA. Open letter to market-led ministers of health. Health Care Analysis
1992; 1:95.
53.
Hutchinson BR. A brief history of anaesthesia in New Zealand. New Zealand
Medical Journal. 1992; 105:175-7.
102
54.
Morris DS. Surgeons and the International Committee of the Red Cross. Aust N Z
J Surg 1992; 62:170-172.
55.
Neutze J. Health reforms. New Zealand Medical Journal 1992; 105:412.
56.
Harris EA. To market-led Ministers of Health. Health Care Anal. 1993; 1:95-97.
57.
Harris EA. Who shall call the tune? N Z Med J 1993; 106:292.
58.
Mann JI, Crooke M, Fear H, Hay DR, Jackson R, Neutze JM, White HD.
Pharmaceutical sponsorship. New Zealand Medical Journal 1993; 106:318.
59.
Harris EA. Forensic sampling and medical ethics. N Z Med J 1994; 107:138.
60.
Harris EA. Ethical pluralism. N Z Med J 1994; 107:341.
61.
Harris EA. Clinical research, Inc. N Z Med J 1994; 107:440.
62.
Corkill B, Merry A. Long v R: medical manslaughter - the case for change. Law
Talk 1995; 438:9-13.
63.
Harris EA. MRI at south Auckland. N Z Med J 1995; 108:90.
64.
Harris EA. The mirage called choice. Health Care Analysis 1995; 3:185.
65.
Merry AF, Peck DJ. Anaesthetists, errors in drug administration and the law.
1995; 108:185-187.
66.
Merry AF, Corkill B, Blair R. The long case: a case for change. New Zealand
Medical Journal 1995; 108:348.
67.
Merry AF. Manslaughter, common-sense and justice. New Zealand Medical
Association Newsletter 1995:1-2.
68.
Neutze JM, White HD. A direct threat to research in public hospitals. N Z Med J
1995; 108:320-322.
69.
Neutze JM, Webster M, Agnew TM. Core services and cardiac surgery. New
Zealand Medical Journal 1995; 108:133.
70.
Hutchinson BR. Sir Lambert Ormsby--expatriate New Zealander. New Zealand
Medical Journal. 1996; 109:214.
71.
Hutchinson BR. Anson's voyage and scurvy. History, Heritage and Health
Proceedings 4th Biennial Conference of the Australian Society of the History of
Medicine, 1996:249-251.
72.
McCall Smith A, Merry A. Medical accountability and the criminal law: New
Zealand vs The World. Health Care Analysis 1996; 4:45-54.
73.
McCall Smith A, Merry A. Medical manslaughter. Health Care Analysis 1996;
4:229-33.
74.
Neutze J, White HD. Comparing health expenditure. New Zealand Medical
Journal 1996; 109:388.
75.
Merry AF, McCall Smith AA. "Medical manslaughter". 1997; 166:342-343.
76.
Morris D, Merry A, Carew J, Fitzpatrick C, Panting A, Steele G. Visit to Qui Nhon,
Vietnam, by New Zealand Medical team. New Zealand Medical Journal 1997;
110:190-2.
77.
Neutze J, White H. Comparing health expenditure. New Zealand Medical Journal
1997; 110:20.
103
78.
Williams BF, French JK, White HD. Is our method of obtaining consent
appropriate for randomised controlled trials in acute myocardial infarction? New
Zealand Medical Journal 1997; 110:298-299.
79.
Harris EA. The New World Order revisited. N Z Med J 1999; 112:187-189.
80.
Harris EA. Is competition good for medicine? Health Care Anal. 1999; 7:91-98.
81.
Channer KS, French JK, White HD, Richards M. Prioritising waiting lists. Lancet.
2000; 355:1915-16.
82.
Gander PH, Merry AF, Miller MA, Weller J. Hours of work and fatigue related
error: a survey of New Zealand anaesthetists. Anaesth Intensive Care 2000;
28:178-83.
83.
Harris EA. What isn't medical practice? N Z Med J 2000; 113:152.
84.
Merry AF, Davies JM, Maltby JR. Qualitative research in health care. 2000;
84:552-555.
85.
Merry AF, Gorton M. Medical Manslaughter and Other Crimes. In: Dooley B,
Fearnside M, Gorton M, eds. Surgery, Ethics and The Law. Melbourne: Royal
Australasian College of Surgeons, 2000:207-220.
86.
Harris EA. Re-run: what isn't medical practice? N Z Med J 2001; 114:50.
87.
Norris RM. Early days in the Coronary Care Unit. N Z Med J 2001; 114:S14-S16.
88.
Runciman WB, Merry A, McCall Smith A. Improving patients' safety by gathering
information. British Medical Journal 2001; 323:298.
89.
White HD. Ministry of Health Statistics - coronary bypass surgery in New Zealand.
New Zealand Medical Journal 2001; 114:437.
90.
Merry AF, Smith W, Finucane K, Beca J. And now Auckland. New Zealand
Medical Journal 2002; 115:89-90.
91.
Seddon M, Merry A. How safe are our hospitals? New Zealand Medical Journal
2002; 115:1-4.
92.
Runciman WB, Merry AF, Tito F. Error, blame, and the law in health care--an
antipodean perspective. 2003; 138:974-979.
93.
Runciman WB, Merry A. A tragic death: a time to blame or a time to learn?
Journal of Quality and Safety in Healthcare 2003; 12:321-2.
94.
Williams BF, French JK, White HD, Investigators ftH-CS. Informed consent during
the clinical emergency of acute myocardial infarction (HERO-2 consent
substudy): a prospective observational study. Lancet 2003; 361:918-922.
104
Respiratory
Asthma
1.
Sinclair JD. The response of asthmatics to bronchodilator aerosols. New Zealand
Medical Journal. 1966; 65:524-7.
2.
Gebbie T, Harris EA, O'Donnell TV, Spears GF. Multicentre, short-term
therapeutic trial of disodium cromoglycate, with and without prednisone, in adults
with asthma. Br Med J 1972; 4:576-580.
3.
Swinburn PD. Asthma in adult patients. N Z Med J 1978; 88:204-207.
4.
Liang A, Macfie AE, Harris EA, Whitlock RM. Transit-time analysis of the forced
expiratory spirogram during clinical remission in juvenile asthma. 1979; 34:194199.
5.
Swinburn PD, Sexton M. Inhaled bronchodilators: a comparison of different
methods of inhaling. N Z Med J 1981; 94:340.
6.
Jackson RT, Beaglehole R, Rea HH, Sutherland DC. Mortality from asthma: a
new epidemic in New Zealand. British Medical Journal 1982; 285:771-4.
7.
Keating G, Mitchell EA, Jackson R, Beaglehole R, Rea H. Trends in sales of
drugs for asthma in New Zealand, Australia, and the United Kingdom, 1975-81.
British Medical Journal 1984; 289:348-51.
8.
Sutherland DC, Beaglehole R, Fenwick J, Jackson RT, Mullins P, Rea HH. Death
from asthma in Auckland: circumstances and validation of causes. New Zealand
Medical Journal. 1984; 97:845-8.
9.
Sears MR, O'Donnell TV, Rea HH. Asthma mortality and socioeconomic status.
New Zealand Medical Journal. 1985; 98:765.
10.
Sears MR, Rea HH, Beaglehole R, Gillies AJ, Holst PE, O’Donnell TV, Rothwell
RP, Sutherland DC. Asthma mortality in New Zealand: a two year national study.
New Zealand Medical Journal. 1985; 98:271-5.
11.
Swinburn PD. Post viral bronchitis and asthma. N Z Med J 1985; 98:192-193.
12.
Rea HH, Scragg R, Jackson R, Beaglehole R, Fenwick J, Sutherland DC. A casecontrol study of deaths from asthma. Thorax. 1986; 41:833-9.
13.
Sears MR, Rea HH, Rothwell RP, O’Donnell TV, Holst PE, Gillies AJ, Beaglehole
R. Asthma mortality: comparison between New Zealand and England. British
Medical Journal 1986; 293:1342-5.
14.
Sears MR, Rea HH, de Boer G, et al. Accuracy of certification of deaths due to
asthma. A national study. American Journal of Epidemiology. 1986; 124:1004-11.
15.
Sears MR, Rea HH, Fenwick J, Beaglehole R, Gillies AJ, Holst PE, O’Donnell TV,
Rothwell RP, Sutherland DC. Deaths from asthma in New Zealand. Archives of
Disease in Childhood 1986; 61:6-10.
16.
Beaglehole RD, Jackson RT, Sears MR, Rea HH. Asthma mortality in New
Zealand: a review with some policy implications. New Zealand Medical Journal
1987; 100:231-4.
17.
Karalus NC, Harrison AC. Inhaled high-dose beclomethasone in chronic asthma.
New Zealand Medical Journal. 1987; 100:306-8.
105
18.
Rea HH, Sears MR, Beaglehole R, et al. Lessons from the national asthma
mortality study: circumstances surrounding death. New Zealand Medical Journal.
1987; 100:10-3.
19.
Rothwell RP, Rea HH, Sears MR, Beaglehole R, Gillies AJ, Holst PE, O’Donnell
TV. Lessons from the national asthma mortality study: deaths in hospital. New
Zealand Medical Journal. 1987; 100:199-202.
20.
Sears MR, Rea HH. Patients at risk for dying of asthma: New Zealand
experience. Journal of Allergy & Clinical Immunology. 1987; 80:477-81.
21.
Sears MR, Rea HH, Beaglehole R. Asthma mortality: a review of recent
experience in New Zealand. Journal of Allergy & Clinical Immunology. 1987;
80:319-25.
22.
Sears MR, Rea HH. Asthma mortality: comparison between New Zealand and
England. British Medical Journal 1987; 294:646.
23.
Sears MR, Rea HH, Fenwick J, et al. 75 deaths in asthmatics prescribed home
nebulisers. British Medical Journal Clinical Research Ed.. 1987; 294:477-80.
24.
Asher MI, Pattemore PK, Harrison AC, Mitchell AC, Mitchell EA, Rea HH, Stewart
AW, Woolcock AJ. International comparison of the prevalence of asthma
symptoms and bronchial hyperresponsiveness. American Review of Respiratory
Disease. 1988; 138:524-9.
25.
Garrett JE, Mulder J, Wong-Toi H. Characteristics of asthmatics using an urban
accident and emergency department. New Zealand Medical Journal. 1988;
101:359-61.
26.
Garrett JE, Mulder J, Veale A. Trends in the use of an urban accident and
emergency department by asthmatics. New Zealand Medical Journal. 1988;
101:253-5.
27.
Jackson R, Sears MR, Beaglehole R, Rea HH. International trends in asthma
mortality: 1970 to 1985.[comment]. Chest. 1988; 94:914-8.
28.
Garrett JE, Mulder J, Wong-Toi H. Reasons for racial differences in A & E
attendance rates for asthma. New Zealand Medical Journal. 1989; 102:121-4.
29.
McClellan VE, Garrett JE. Attendance failure at Middlemore Hospital asthma
clinic. New Zealand Medical Journal. 1989; 102:211-3.
30.
Mitchell EA, Stewart AW, Pattemore PK, Asher MI, Harrison AC, Rea HH.
Socioeconomic status in childhood asthma. International Journal of Epidemiology.
1989; 18:888-90.
31.
Pattemore PK, Asher MI, Harrison AC, Mitchell EA, Rea HH, Stewart AW. Ethnic
differences in prevalence of asthma symptoms and bronchial
hyperresponsiveness in New Zealand schoolchildren. Thorax. 1989; 44:168-76.
32.
Bai TR. Abnormalities in airway smooth muscle in fatal asthma. 1990; 141:552557.
33.
McClellan VE, Garrett JE. Asthma and the employment experience. New Zealand
Medical Journal. 1990; 103:399-401.
34.
Pattemore PK, Asher MI, Harrison AC, Mitchell EA, Rea HH, Stewart AW. The
interrelationship among bronchial hyperresponsiveness, the diagnosis of asthma,
and asthma symptoms.[comment]. American Review of Respiratory Disease.
1990; 142:549-54.
35.
Bai TR. Abnormalities in airway smooth muscle in fatal asthma. A comparison
between trachea and bronchus. 1991; 143:441-443.
106
36.
Garrett JE, Turner P. The severity of asthma in relation to beta agonist
prescribing.[comment]. New Zealand Medical Journal. 1991; 104:39-40.
37.
Kuitert LM, Harrison AC. Pneumocystis carinii pneumonia as a complication of
methotrexate treatment of asthma. Thorax. 1991; 46:936-7.
38.
Rea HH, Garrett JE, Mulder J, Chapman KR, White JG, Rebuck AS. Emergency
room care of asthmatics: a comparison between Auckland and Toronto. Annals of
Allergy. 1991; 66:48-52.
39.
Taylor GH, Rea HH, McNaughton S, Smith L, Mulder J, Asher MI, Mitchell EA,
Seelve E, Stewart AW. A tool for measuring the asthma self-management
competency of families. Journal of Psychosomatic Research. 1991; 35:483-91.
40.
Bai TR, Mak JC, Barnes PJ. A comparison of beta-adrenergic receptors and in
vitro relaxant responses to isoproterenol in asthmatic airway smooth muscle. Am
J Respir.Cell Mol.Biol 1992; 6:647-651.
41.
McNaughton S, Smith L, Rea HH. The management of childhood asthma:
attendance and school performance. New Zealand Journal of Education Studies
1993; 28:155-164.
42.
Rea HH, Robinson D, Egglestone D. Effect of physical conditioning programme
on fitness and disease severity in asthmatics. New Zealand Medical Journal
1993.
43.
Richards GN, Kolbe J, Fenwick J, Rea HH. Demographic characteristics of
patients with severe life threatening asthma: comparison with asthma
deaths.[comment]. Thorax. 1993; 48:1105-9.
44.
Garrett J, Fenwick JM, Taylor G, Mitchell E, Rea H. Peak expiratory flow meters
(PEFMs)--who uses them and how and does education affect the pattern of
utilisation?[comment]. Australian & New Zealand Journal of Medicine. 1994;
24:521-9.
45.
Garrett J, Fenwick JM, Taylor G, Mitchell E, Stewart J, Rea H. Prospective
controlled evaluation of the effect of a community based asthma education centre
in a multiracial working class neighbourhood. Thorax. 1994; 49:976-83.
46.
Kolbe J, Garrett J, Vamos M, Rea HH. Influences on trends in asthma morbidity
and mortality: the New Zealand experience. Chest. 1994; 106:211S-215S.
47.
Garrett J, Kolbe J, Richards G, Whitlock T, Rea H. Major reduction in asthma
morbidity and continued reduction in asthma mortality in New Zealand: what
lessons have been learned?[comment]. Thorax. 1995; 50:303-11.
48.
Garrett JE. Manual of Asthma Management. In: O'Byrne P, Thomson NC, eds.
Hospital Practice, 1995:791-804.
49.
Kolbe J, Fitzgerald JM, Mackem PT. Near fatal asthma: A New Zaland
perspective. Proceedings of a Workshop on Near Fatal Asthma. Can Respir J
1995; 2:113-126.
50.
Richards G, Kolbe J, Fenwick J, Rea H. The effects of privet exposure on asthma
morbidity. New Zealand Medical Journal. 1995; 108:96-9.
51.
Wilsher ML, Kolbe J. Association of Mycoplasma pneumoniae antigen with initial
onset of bronchial asthma.[comment]. American Journal of Respiratory & Critical
Care Medicine. 1995; 151:579-80.
52.
Garrett JE, Lanes SF, Kolbe J, Rea HH. Risk of severe life threatening asthma
and beta agonist type: an example of confounding by severity.[comment]. Thorax.
1996; 51:1093-9.
107
53.
Garrett JE, Kolbe J. Near-fatal asthma in South Australia: descriptive features
and medication use.[comment]. Australian & New Zealand Journal of Medicine.
1996; 26:487-9.
54.
Kolbe J, Vamos M, Fergusson W, Elkind G, Garrett J. Differential influences on
asthma self-management knowledge and self-management behavior in acute
severe asthma. Chest. 1996; 110:1463-8.
55.
Kolbe J, Vamos M, James F, Elkind G, Garrett J. Assessment of practical
knowledge of self-management of acute asthma.[comment]. Chest. 1996; 109:8690.
56.
Kolbe J, Richards G, Mercer-Fenwick J, Rea H. Relationship of non-specific
airway hyperresponsiveness (AHR) to measures of peak expiratory flow (PEF)
variability. Australian & New Zealand Journal of Medicine. 1996; 26:59-65.
57.
Rea HH, Garrett JE, Lanes SF, Birmann BM, Kolbe J. The association between
asthma drugs and severe life-threatening attacks.[comment]. Chest. 1996;
110:1446-51.
58.
Garret JE, Lanes S, Rea H, Kolbe J. Fenoterol asthma deaths and asthma
severity: counfounding or confusion. Thorax. 1997; 52:750-752.
59.
Garrett J, Williams S, Wong C, Holdaway D. Application of asthma action plans to
childhood asthma: a national survey. New Zealand Medical Journal. 1997;
110:308-10.
60.
Garrett JE. Health service accessibility and deaths from asthma.[comment].
Thorax. 1997; 52:205-6.
61.
Garrett JE. Combined anticholinergic therapy in the management of acute
asthma. Respirology. 1997; 2:S17-8.
62.
Garrett JE, Town GI, Rodwell P, Kelly AM. Nebulized salbutamol with and without
ipratropium bromide in the treatment of acute asthma. Journal of Allergy &
Clinical Immunology. 1997; 100:165-70.
63.
Kolbe J, Vamos M, Fergusson W. Socio-economic disadvantage, quality of
medical care and admission for acute severe asthma. Australian & New Zealand
Journal of Medicine. 1997; 27:294-300.
64.
Mitchell EA, Stewart AW, Rea HH, McNaughton S, Taylor G, Smith LT, Asher MI,
Mulder J, Seelye ER. Measuring morbidity from asthma in children. New Zealand
Medical Journal. 1997; 110:3-6.
65.
Walls C, Crane J, Gillies J, Wilsher M, Wong C. Occupational asthma and other
nonasbestos occupational respiratory diseases notified between 1993 and 1996.
New Zealand Medical Journal. 1997; 110:246-9.
66.
Garrett J, Williams S, Wong C, Holdaway D. Treatment of acute asthmatic
exacerbations with an increased dose of inhaled steroid. Archives of Disease in
Childhood. 1998; 79:12-7.
67.
Kolbe J, Fergusson W, Garrett J. Rapid onset asthma: a severe but uncommon
manifestation. Thorax. 1998; 53:241-7.
68.
Kolbe J, Vamos M, Fergusson W, Elkind G. Determinants of management errors
in acute severe asthma. Thorax 1998; 53:14-20.
69.
Lanes SF, Garrett JE, Wentworth CE, 3rd, Fitzgerald JM, Karpel JP. The effect of
adding ipratropium bromide to salbutamol in the treatment of acute asthma: a
pooled analysis of three trials.[comment]. Chest. 1998; 114:365-72.
108
70.
Garrett J, Kolbe J. Hospital Practice. In: O'Byrne P, Thompson, eds. Manual of
Asthma Management: WB Saunders, 1999:631-42.
71.
Kolbe J. Asthma education, action plans, psychosocial issues and adherence.
Canadian Respiratory Journal. 1999; 6:273-80.
72.
Vamos M, Kolbe J. Psychological factors in severe chronic asthma. Australian &
New Zealand Journal of Psychiatry. 1999; 33:538-44.
73.
Eaton T, Garrett J, Milne D, Frankel A, Wells AU. Allergic bronchopulmonary
aspergillosis in the asthma clinic. A prospective evaluation of CT in the diagnostic
algorithm.[comment]. Chest. 2000; 118:66-72.
74.
Kolbe J, Fergusson W, Vamos M, Garrett J. Case-control study of severe life
threatening asthma (SLTA) in adults: demographics, health care, and
management of the acute attack.[comment]. Thorax. 2000; 55:1007-15.
75.
Walls C, Crane J, Gillies J, Wilsher M, Wong C. Occupational asthma cases
notified to OSH from 1996 to 1999. New Zealand Medical Journal. 2000; 113:4912.
76.
Kolbe J. Prevention of Death in Asthma. International Review of Asthma 2001;
3:62-71.
77.
Snell G, Peacock M, Garrett J. Lung Volume Reduction Surgery (LVRS). Internal
Medicine Journal 2001; 31:112-115.
78.
Baldwin DR, Gannon P, Bright P, Newton DT, Robertson A, Venables K, Graneek
B, Barker RD, Cartier A, Malo JL, Wilsher M, Pantin CF, Burge PS. Interpretation
of occupational peak flow records: level of agreement between expert clinicians
and Oasys-2. Thorax. 2002; 57:860-4.
79.
Kolbe J, Fergusson W, Vamos M, Garrett J. Case-control study of severe life
threatening asthma (SLTA) in adults: psychological factors. Thorax. 2002;
57:317-22.
80.
Kolbe J. Psychosocial influences on adherence to self-management plans.
Disease Management and Health Outcomes 2002; 10:551-570.
81.
Kolbe J. Prevention of Asthma Attacks. In: Barnes P, ed. Practical issues in
asthman management, 2002.
82.
Hughes R, Goldkorn A, Masoli M, Weatherall M, Burgess C, Beasley R. Use of
isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment
of severe asthma in adults: randomised placebo-controlled trial. Lancet 2003;
361:2114-2117.
83.
Main J, Moss-Morris R, Booth R, Kaptein AA, Kolbe J. The use of reliever
medication in asthma: the role of negative mood and symptom reports. Journal of
Asthma. 2003; 40:357-65.
109
Respiratory
COPD
1.
Sinclair JD. The progress of pulmonary deficiency in emphysema. Brit J Tuberc
1955; 49:157-165.
2.
Sinclair JD. The effect of obesity on obstructive lung disease. New Zealand
Medical Journal. 1965; 64:Suppl:83-4.
3.
Swinburn PD. Chronic bronchitis and emphysema. N Z Med J 1980; 91:221-223.
4.
Harrison AC. Further considerations in managing the respiratory cripple. New
Zealand Medical Journal. 1982; 95:660-1.
5.
Harrison AC. Comprehensive management of the respiratory cripple: basic
principles. New Zealand Medical Journal. 1982; 95:270-1.
6.
Sivakumaran P, Garrett JE. The prescription of domicilary long-term oxygen
therapy in Auckland.[comment]. New Zealand Medical Journal. 1996; 109:439-42.
7.
Young P, Dewse M, Fergusson W, Kolbe J. Respiratory rehabilitation in chronic
obstructive pulmonary disease: predictors of nonadherence. European
Respiratory Journal. 1999; 13:855-9.
8.
Young P, Dewse M, Fergusson W, Kolbe J. Improvements in outcomes for
chronic obstructive pulmonary disease (COPD) attributable to a hospital-based
respiratory rehabilitation programme. Australian & New Zealand Journal of
Medicine. 1999; 29:59-65.
9.
Eaton TE, Grey C, Garrett JE. An evaluation of short-term oxygen therapy: the
prescription of oxygen to patients with chronic lung disease hypoxic at discharge
from hospital. Respiratory Medicine. 2001; 95:582-7.
10.
Eaton T, Garrett JE, Young P, Fergusson W, Kolbe J, Rudkin S, Whyte K.
Ambulatory oxygen improves quality of life of COPD patients: a randomised
controlled study. European Respiratory Journal. 2002; 20:306-12.
11.
Lewis CA, Eaton TE, Fergusson W, Whyte KF, Garrett JE, Kolbe J. Home
overnight pulse oximetry in patients with COPD: more than one recording may be
needed. Chest. 2003; 123:1127-33.
12.
Lewis CA, Eaton TE, Young P, Fergusson W, Kolbe J. Short-burst oxygen
therapy is ineffective both before and after exercise in patients with severe
COPD. European Respiratory Journal. 2003.
110
Respiratory
Tuberculosis
1.
Kerr AR. TB and Polynesians. New Zealand Medical Journal. 1972; 76:295.
2.
Swinburn PD. Tuberculosis in Auckland. N Z Med J 1973; 78:520-525.
3.
Brett W, Harrison AC, Breed MC, Brett A. Tuberculosis at Green Lane Hospital
1980-1982. New Zealand Medical Journal. 1986; 99:705-8.
4.
Harrison AC. Control of nosocomial tuberculosis in New Zealand: a window into
hospital occupational health? New Zealand Medical Journal. 1987; 100:349-52.
5.
Isaacs RD, Nicholson GI, Holdaway IM. Miliary tuberculosis with hypercalcaemia
and raised vitamin D concentrations. Thorax 1987; 42:555-556.
6.
Karalus NC. Contact screening procedures for tuberculosis in Auckland. N Z Med
J 1988; 101:45-49.
7.
Samarasinghe D, Hawken M, Harrison AC. Intermittent supervised treatment of
tuberculosis at Green Lane Hospital, 1987-8. New Zealand Medical Journal.
1992; 105:243-5.
8.
Bradley A, Rea HH. Drug resistant tuberculosis in Auckland 1988-92. New
Zealand Medical Journal 1994; 167:99-101.
9.
McNaughton H, Morris S, Kolbe J. The risk of tuberculous infection in hospital
medical staff. Australian & New Zealand Journal of Medicine. 1994; 24:312-3.
10.
Harrison AC, Calder L. New guidelines for tuberculosis control in New Zealand.
NZ Public Health Report., 1996:89-91.
11.
Cameron RJ, Harrison AC. Multidrug resistant tuberculosis in Auckland 1988-95.
New Zealand Medical Journal. 1997; 110:119-22.
12.
Sivakumaran P, Harrison AC, Marschner J, Martin P. Ocular toxicity from
ethambutol: a review of four cases and recommended precautions.[comment].
New Zealand Medical Journal. 1998; 111:428-30.
13.
Harrison AC, Jayasundera T. Mycobacterial cervical adenitis in Auckland:
diagnosis by fine needle aspirate. New Zealand Medical Journal. 1999; 112:7-9.
14.
Harrison A, Calder L, Karalus N, Martin P, Kennedy M, Wong C. Tuberculosis in
immigrants and visitors. New Zealand Medical Journal. 1999; 112:363-5.
15.
Wilsher ML, Hagan C, Prestidge R, Wells AU, Murison G. Human in vitro immune
responses to Mycobacterium tuberculosis.[comment]. Tubercle & Lung Disease.
1999; 79:371-7.
16.
Calder L, Hampton L, Prentice D, Reeve M, Vaughan A, Vaughan R, Harrison A,
Voss L, Morris AJ, Singh H, Koberstein V. A school and community outbreak of
tuberculosis in Auckland. New Zealand Medical Journal. 2000; 113:71-4.
17.
Pottumarthy S, Wells VC, Morris AJ. A comparison of seven tests for serological
diagnosis of tuberculosis. Journal of Clinical Microbiology. 2000; 38:2227-31.
18.
Harrison AC, Calder L. Guidelines for tuberculosis control in New Zealand, 2003.
Wellington: Ministry of Health, 2002.
111
19.
Harrison AC. Awarness, clinical features and early diagnosis of tuberculosis. In:
Harrison AC, Calder L, eds. Guidelines for tuberculosis control in New Zealand.
Wellington: Ministry of Health, 2002.
20.
Harrison AC. Clinical investigation and assessment of tuberculosis. In: Harrison
AC, Caulder L, eds. Guidelines for tuberculosis control in New Zealand.
Wellington: Ministry of Health, 2002.
21.
Harrison AC. M Tuberculosis, TB medicines and monitoring. In: Harrison AC,
Calder L, eds. Guidelines for tuberculosis control in New Zealand. Wellington:
Ministry of Health, 2002.
22.
Harrison AC. Treatment of tuberculosis. In: Harrison AC, Calder L, eds.
Guidelines for tuberculosis control in New Zealand. Wellington: Ministry of health,
2002.
23.
Harrison AC. Treatment of tuberculosis in special clinical circumstances. In:
Harrison AC, Calder L, eds. Guidelines for tuberculosis control in New Zealand.
Wellington: Ministry of Health, 2002.
24.
McWilliams T, Wells AU, Harrison AC, Lindstrom S, Cameron RJ, Foskin E.
Induced sputum and bronchoscopy in the diagnosis of pulmonary tuberculosis.
Thorax. 2002; 57:1010-4.
25.
Morris A, Harrison AC. Non-tuberculous mycobacteria (NTM). In: Harrison AC,
Calder L, eds. Guidelines for tuberculosis control in New Zealand. Wellington:
Ministry of Health, 2002.
26.
Paterson A, McEnnis V, Martin P, Calder L, Harrison AC. Infection control in
tuberculosis. In: Harrison AC, Calder L, eds. Guidelines for tuberculosis control in
New Zealand. Wellington: Ministry of Health, 2002.
112
Respiratory
Cystic fibrosis/bronchiectasis/diffuse
parenchymal disease
1.
Ogilvie CA, Haresnape AM, Harris EA. Apparatus for bronchial challenge with
cold air. Med Biol Eng Comput. 1983; 21:235-238.
2.
Kolbe J, Caughey D, Rainer S. Sulphasalazine-induced sub-acute hypersensitivity pneumonitis. Respiratory Medicine. 1994; 88:149-52.
3.
Kolbe J. Cystic Fibrosis. The Disease Index: Medical Publishing Co Ltd, 1995.
4.
Wilsher ML, Hallowes M, Birchall NM. Gamma/delta T lymphocytes in the blood
of patients with sarcoidosis. Thorax. 1995; 50:858-62.
5.
Kolbe J, Wells AU. Bronchiectasis: a neglected cause of respiratory morbidity and
mortality. Respirology. 1996; 1:221-5.
6.
Wilsher ML, Hallowes M, Birchall NM. Gamma/delta cells in tissue from patients
with sarcoidosis. Thorax. 1996; 51:1123-6.
7.
Wilsher ML, Gurley AM. Transtracheal aspiration using rigid bronchoscopy and a
rigid needle for investigating mediastinal masses. Thorax. 1996; 51:197-9.
8.
Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM, du Bois RM.
Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to
extent of disease on computed tomography. Arthritis Rheum. 1997; 40:12291236.
9.
Wilsher ML, Kolbe J, Morris AJ, Welch DF. Nosocomial acquisition of
Burkholderia gladioli in patients with cystic fibrosis.[comment]. American Journal
of Respiratory & Critical Care Medicine. 1997; 155:1436-40.
10.
Eaton TE, Lambie N, Wells AU. Bronchiectasis following colectomy for Crohn's
disease.[comment]. Thorax. 1998; 53:529-31.
11.
Eaton TE, Lambie N, Wells AU. Bronchiectasis following colectomy for Crohn's
disease. 1998; 53:529-531.
12.
Hansell DM, Milne DG, Wilsher ML, Wells AU. Pulmonary sarcoidosis:
morphologic associations of airflow obstruction at thin-section CT. Radiology.
1998; 209:697-704.
13.
Harms HK, Matouk E, Tournier G, von der Hardt H, Weller PH, Romano L,
Heijerman HG, FitzGerald MX, Richard D, Strandvik B, Kolbe J, Kraemer R,
Michalsen H. Multicenter, open-label study of recombinant human DNase in
cystic fibrosis patients with moderate lung disease. DNase International Study
Group. Pediatric Pulmonology. 1998; 26:155-61.
14.
Wells A. High resolution computed tomography in sarcoidosis: a clinical
perspective. Sarcoidosis.Vasc.Diffuse.Lung Dis 1998; 15:140-146.
15.
Wells A. Clinical usefulness of high resolution computed tomography in
cryptogenic fibrosing alveolitis. Thorax 1998; 53:1080-1087.
16.
Wells AU. Computed tomographic imaging of bronchiolar disorders. Curr Opin
Pulm.Med 1998; 4:85-92.
17.
Wilsher ML, Veale AG. Medical thoracoscopy in the diagnosis of unexplained
pleural effusion. Respirology. 1998; 3:77-80.
113
18.
Wilsher ML, Menzies RE, Croxson MC. Mycobacterium tuberculosis DNA in
tissues affected by sarcoidosis. Thorax. 1998; 53:871-4.
19.
Wilsher ML. Seasonal clustering of sarcoidosis presenting with erythema
nodosum. European Respiratory Journal. 1998; 12:1197-9.
20.
Cameron RJ, Kolbe J, Wilsher ML, Lambie N. Bronchiolitis obliterans organising
pneumonia associated with the use of nitrofurantoin.[comment]. Thorax. 2000;
55:249-51.
21.
Kolbe J, Wells A, Ram FS. Inhaled steroids for bronchiectasis. Cochrane
Database of Systematic Reviews. 2000:CD000996.
22.
McWilliams TJ, Wilsher ML, Kolbe J. Cystic fibrosis diagnosed in adult patients.
New Zealand Medical Journal. 2000; 113:6-8.
23.
Moody A, Fergusson W, Wells A, Bartley J, Kolbe J. Increased nitric oxide
production in the respiratory tract in asymptomatic pacific islanders: an
association with skin prick reactivity to house dust mite. Journal of Allergy &
Clinical Immunology. 2000; 105:895-9.
24.
Roberts HR, Wells AU, Milne DG, Rubens MB, Kolbe J, Cole PJ, Hansell DM.
Airflow obstruction in bronchiectasis: correlation between computed tomography
features and pulmonary function tests. Thorax. 2000; 55:198-204.
25.
Casey P, Garrett J, Eaton T. Allergic bronchopulmonary aspergillosis in a lung
transplant patient successfully treated with nebulized amphotericin. Journal of
Heart & Lung Transplantation. 2002; 21:1237-41.
26.
Eaton TE, Weiner Miller P, Garrett JE, Cutting GR. Cystic fibrosis transmembrane
conductance regulator gene mutations: do they play a role in the aetiology of
allergic bronchopulmonary aspergillosis? Clinical & Experimental Allergy. 2002;
32:756-61.
27.
Kolbe J. Drug use in cyctic fibrosis. Modern Medicine 2003.
28.
Kolbe J. Adult cystic fibrosis. In: Gibson P, ed. Evidenced-based respiratory
medicine: BMJ Books, 2003.
29.
Kolbe J. Bronchiectasis. In: Gibson P, ed. Evidenced-based respiratory medicine:
BMJ Books, 2003.
114
Respiratory
Lung Cancer/pleural/sleep
1.
Hinds JR, Hitchcock GC. Adenocarcinoma of the lung. Thorax 1969; 24:10-17.
2.
House AJ, Thomson KR. Evaluation of a new transthoracic needle for biopsy of
benign and malignant lung lesions. AJR Am J Roentgenol. 1977; 129:215-220.
3.
Shevland JE, House AJ, Rea HH. Computed tomographic assessment of the
mediastinum in patients with lung cancer. Australasian Radiology. 1983; 27:2405.
4.
Frankish PD, Kolbe J. Thoracic empyema due to Streptococcus milleri: four
cases. New Zealand Medical Journal. 1984; 97:849-51.
5.
Harrison AC. The management of non-small cell lung cancer. New Zealand
Medical Journal. 1985; 98:142-4.
6.
Garrett JE, Breed MC. Changes in outcome for patients with bronchial carcinoma:
the Green Lane Hospital experience. New Zealand Medical Journal. 1986;
99:455-8.
7.
Harvey VJ, Kolbe J. The management of small cell lung cancer. New Zealand
Medical Journal. 1986; 99:104-6.
8.
Garrett JE. Lung Cancer. The Disease Index: Medical Publishing Company Ltd,
1989:267-9.
9.
Walker EB, Frith RW, Harding DA, Cant BR. Uvulopalatopharyngoplasty in
severe idiopathic obstructive sleep apnoea syndrome. Thorax 1989; 44:205-208.
10.
Wong CA, Wilsher ML. Treatment of exogenous lipoid pneumonia by whole lung
lavage. Australian & New Zealand Journal of Medicine. 1994; 24:734-5.
11.
Roche DH, Wilsher ML, Gurley AM. Transtracheal needle aspiration. Diagnostic
Cytopathology. 1995; 12:106-12.
12.
Wilsher M. Recent advances in the management of tracheobronchial obstruction.
New Zealand Medical Journal. 1995; 108:215-6.
13.
Wilsher ML, Gurley ML. Transtracheal fine needle aspiration using the rigid
needle in the diagnosis of lung cancer. Thorax 1995; 51:197-199.
14.
Sivakumaran P, Wilsher ML. Microfilarial pleural effusion associated with
adenocarcinoma. Australian & New Zealand Journal of Medicine. 1997; 27:341.
15.
Baldwin DR, Kolbe J, Troy K, Belcher J, Gibbs H, Frankel A, Eaton T, Christmas
T, Veale A. Comparative clinical and physiological features of Maori, Pacific
Islanders and Europeans with sleep related breathing disorders. Respirology.
1998; 3:253-60.
16.
Lee YC, McCrystal MR, Christmas TI. Chemotherapy for small cell lung
carcinoma: the Greenlane Hospital experience 1993-1995. New Zealand Medical
Journal. 1998; 111:451-2, 453-4.
17.
Whyte KF. Home nocturnal ventilation for chronic respiratory failure--a proven
treatment? New Zealand Medical Journal. 1998; 111:155-6.
18.
Lee YC, Knox BS, Garrett JE. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra
21-1) in the differentiation of malignant and benign pleural effusions. Australian &
New Zealand Journal of Medicine. 1999; 29:765-9.
115
19.
Lindstrom ST, Kolbe J. Community acquired parapneumonic thoracic empyema:
predictors of outcome. Respirology. 1999; 4:173-9.
20.
Coltman R, Taylor DR, Whyte K, Harkness M. Craniofacial form and obstructive
sleep apnea in Polynesian and Caucasian men. Sleep. 2000; 23:943-50.
21.
Hancox RJ, Whyte KF, Baxter JM. Home ventilation: the Green Lane Hospital
experience. New Zealand Medical Journal. 2000; 113:500-3.
22.
Baguley BC, Marshal ES, Christmas TI. Cultures of surgical material from lung
cancers: a kinetic approach. Lung Cancer Series: Methods in molecular medicine:
Humana Press, 2001.
23.
Brant A, Eaton T. Serious complications with talc slurry pleurodesis. Respirology.
2001; 6:181-5.
24.
Cornere MM, Fergusson W, Kolbe J, Christmas TI. Characteristics of patients
with lung cancer under the age of 45 years: a case control study. Respirology.
2001; 6:293-6.
25.
Anderson FE, Kingshott RN, Taylor DR, Jones DR, Kline LR, Whyte KF. A
randomized crossover efficacy trial of Oral CPAP (Oracle) compared with nasal
CPAP in the management of obstructive sleep apnea. Sleep 2003; 26.
26.
Lee YC, Baumann MH, Maskell NA, Waterer GW, Eaton TE, Davies RJ, Heffner
JE, Light RW. Survey of pulmonologists on pleurodesis practice for malignant
pleural effusions in five English speaking countries. Chest 2003 in press
116
Respiratory
General
1.
Grant IW, Harris EA. Respiratory Medicine. In: Davidson, ed. The Principles and
Practice of Medicine. Edinburgh: Livingstone, 1964.
2.
Harris EA. The respiratory effects of hypnotics and cough suppressants. N Z Med
J 1965; 64:Suppl-5.
3.
Harris EA. Respiratory failure with normal lungs. N Z Med J 1967; 66:351-353.
4.
Harris EA. Respiratory section. In: Passmore, Robson, eds. A Companion to
Medical Studies - Vol I. Edinburgh: Blackwell, 1968.
5.
Harris EA. Respiratory Pharmacology. In: Passmore, Robson, eds. A Companion
to Medical Studies - Vol II. Edinburgh: Blackwell, 1968.
6.
Harris EA. Clinical chest medicine. In: Passmore, Robson, eds. A Companion to
Medical Studies - Vol II. Edinburgh: Blackwell, 1968.
7.
Glass WI, Harris EA, Whitlock RM. Phosgene poisoning: case report. 1971;
74:386-389.
8.
Doak PB, Becroft DM, Harris EA, et al. Pneumocystis carinii pneumonia-transplant lung. 1973; 42:59-71.
9.
Gupta SM, Johnston WH. Apical pulmonary disease in ankylosing spondylitis. N Z
Med J 1978; 88:186-188.
10.
House AJ. Biopsy techniques in the investigation of diseases of the lung,
mediastinum, and chest wall. Radiol Clin North Am 1979; 17:393-412.
11.
Childs WJ, Mercer CJ, Lubbe WF. Psittacosis: a clinical spectrum in New
Zealand. N Z Med J 1980; 92:3-6.
12.
Jagusch MF, Roberts RM, Rea HH, Priestley DR. Human pulmonary dirofilariasis.
New Zealand Medical Journal. 1984; 97:556-8.
13.
Isaacs RD, Wattie WJ, Wells AU, Rea HH, Bai TR. Massive haemoptysis as a
late consequence of pulmonary irradiation. Thorax. 1987; 42:77-8.
14.
Kolbe J. Respiratory Failure. In: Wilson JD, ed. Drug Use in Respiratory Disease:
ADIS press, 1987:151-174.
15.
Wallace RH, Kolbe J. Fibreoptic bronchoscopy and bronchoalveolar lavage in the
investigation of the immunocompromised lung. New Zealand Medical Journal.
1992; 105:215-7.
16.
Karalus NC, Garrett JE, Lang SD, Scott WG. A clinical and economic comparison
of Roxithromycin 150mg twice daily vs Amoxycillin 500mg/Clavulinic Acid 125mg
three times daily for the teatment of lower respiratory tract infections in General
Practice. Drug Investigations 1994; 8:179-90.
17.
Sage D, Kolbe J. The High Risk Parturient: Respiratory Disease. In: Zundert V,
Ostheimer, eds. Pain Relief and Anaesthesia in Obstetrics: Churchill Livingstone,
1994.
18.
Karalus NC, Garrett JE, Lang SD, et al. Roxithromycin 150 mg b.i.d. versus
amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower
respiratory tract infections in general practice. Infection. 1995; 23:S15-20.
117
19.
Lee YC, Milne D, Rea HH. Pulmonary alveolar microlithiasis: an alternative
diagnosis to miliary tuberculosis. Australian & New Zealand Journal of Medicine.
1997; 27:336-7.
20.
Scanlon N, Wilsher M, Kolbe J. Imipenem induced dental staining. Australian &
New Zealand Journal of Medicine. 1997; 27:190.
21.
Wilsher M. Endobronchial Nd-Yag laser therapy at Green Lane Hospital. New
Zealand Medical Journal. 1998; 111:347-9.
22.
Garrett JE. Anticholinergics in the Upper and Lower Airways. In: Spector S, ed.
Lung Biology in Health and Disease, 1999:73-86.
23.
Eaton T, Rudkin S, Garrett JE. The clinical utility of arterialized earlobe capillary
blood in the assessment of patients for long-term oxygen therapy.[comment].
Respiratory Medicine. 2001; 95:655-60.
24.
Baldwin DR, Eaton T, Kolbe J, Christmas T, Milne D, Mercer J, Steele E, Garrett
J, Wilsher ML, Wells AU. Management of solitary pulmonary nodules: how do
thoracic computed tomography and guided fine needle biopsy influence clinical
decisions? Thorax. 2002; 57:817-22.
25.
Hughes RJ, Hopkins R, Hill S, et al. The incidence of venous thromboembolism in
low to moderate risk long distance air travellers; The NZATT Study. Lancet 2003.
118
Rheumatic Heart Disease
1.
Smith HJ, Neutze JM, Roche AH, Agnew TM, Barratt-Boyes BG. The natural
history of rheumatic aortic regurgitation and the indications for surgery. Br Heart J
1976; 38:147-154.
2.
Stanhope JM, Clarkson PM, Mangan AJ, Swindells JC, Frankish JD. Rheumatic
fever in New Zealand: the Wairoa College survey design and response rate. N Z
Med J 1976; 84:186-189.
3.
Frankish JD, Stanhope JM, Martin DR, Clarkson PM, Leslie PN, Langley RB.
Rheumatic fever and streptococci: the Wairoa College study. N Z Med J 1978;
87:33-38.
4.
Smith WM. An appraisal of rheumatic valvular disease in Western Samoa.
Australian & New Zealand Journal of Medicine. 1979; 9:560-5.
5.
Stanhope JM, Clarkson PM, Philipp R. Rheumatic fever: clinical and laboratory
manifestations in a New Zealand community. N Z Med J 1979; 90:369-372.
6.
Stanhope JM, Clarkson PM. Diagnostic criteria of rheumatic fever in a New
Zealand community. Aust N Z J Med 1981; 11:234-242.
7.
Neutze JM, Clarkson PM. Rheumatic fever: an unsolved problem in New
Zealand. N Z Med J 1984; 97:591-593.
8.
Neutze JM. Rheumatic fever. In: Weatherall DJ, ed. Oxford textbook of medicine.
Oxford: Oxford University Press, 1986.
9.
Neutze JM. Rheumatic fever and rheumatic heart disease in the western Pacific
region. N Z Med J 1988; 101:404-406.
10.
Neutze JM. WHO Study Group on Rheumatic Fever and Rheumatic Heart
Disease. Geneva: World Health Organization, 1988.
11.
Neutze JM, Clarkson PM. The current status of rheumatic fever and rheumatic
heart disease. In: Pongpanich B, Sueblinvong V, Vongprateep C, eds. Pediatric
Cardiology.;: Exerpta Medica.;, 1990.
12.
International Rheumatic Fever Study Group (includes Clarkson PM, Neutze JM).
Allergic reactions to long-term benzathine penicillin prophylaxis for rheumatic
fever. Lancet 1991:1308-1310.
13.
North DA, Heynes RA, Lennon DR, Neutze J. Analysis of costs of acute
rheumatic fever and rheumatic heart disease in Auckland. New Zealand Medical
Journal. 1993; 106:400-3.
14.
Abernethy M, Bass N, Sharpe N, et al. Doppler echocardiography and the early
diagnosis of carditis in acute rheumatic fever. Australian & New Zealand Journal
of Medicine. 1994; 24:530-5.
15.
Neutze JM, North DA, Heynes RA, Lennon DR. Rheumatic heart disease. New
Zealand Medical Journal 1994; 107:67.
16.
Wilson NJ, Neutze JM. Echocardiographic diagnosis of subclinical carditis in
acute rheumatic fever. Int J Cardiol 1995; 50:1-6.
17.
Neutze JM. The cardiac aspects of rheumatic fever. In: Weatherall DJ,
Ledingham JGG, Warrell DA, eds. Oxford textbook of medicine. New York:
Oxford UNiversity Press, 1996.
119
18.
Wilson NJ, Voss LM, Neutze JM, Ameratunga R, Lennon DR. The natural history
of acute rheumatic fever to one year in the echocardiographic era. In: Imai Y,
Momma K, eds. Proceedings of the 2nd world congress of pediatric cardiology
and cardiac surgery. New York: Futura Publishing Co, 1997.
19.
Neutze JM. Cardiac aspects of rheumatic fever. In: Ledingham JGG, Warrell DA,
eds. Concise Oxford textbook of medicine. Oxford: Oxford University Press,
2000:114.
20.
Gentles TL, Colan SD, Wilson NJ, Biosa R, Neutze JM. Left ventricular
mechanics during and after acute rheumatic fever: contractile dysfunction is
closely related to valve regurgitation. J Am Coll Cardiol 2001; 37:201-207.
21.
Voss LM, Wilson NJ, Neutze JM, Whitlock RM, Ameratunga RV, Cairns LM,
Lennon DR. Intravenous immunoglobulin in acute rheumatic fever: a randomized
controlled trial. Circulation 2001; 103:401-406.
22.
Wong SP, French RA, Bolson EA, Legget ME, Sheehan FH. Morphology of the
Rheumatic Mitral Regurgitant Valve by Three-Dimensional Echocardiography.
American Heart Journal 2001; 142:897-907.
120
Subject Headings and Key Words for CD Rom
Books and Theses……………………………………..………………. GLHBOOK
Early Years 1942-1960s (Compiled by Pat Clarkson)…….……………. GLHEY
Anaesthesia and Perfusion…………………….…….…..……………. GLHanaes
Adult Cardiology
Arrhythmias, Electophysiology and Pacing………..…..………… GLHAEP
Cardiac transplantation……………………….……….…………… GLHHTx
Coronary artery disease……………………….….…...………….. GLHCAD
General cardiology…………………………….….……………..GLHCARDg
Inherited cardiac diseases (includes
surgery for HCM)………………………………………………GLHinDIS
Interventional cardiac catheterisation …………………….…………GLHcc
Imaging (Includes echocardiography,
cineangiography, MRI, nuclear, CT)…………..…………..GLHIMAGE
Drugs and therapeutics …………………………….……………GLHDRUG
Cardio-Thoracic Surgery…………………………………...……………..GLHCTS
General Medicine/Surgery…………………………..............…………..GLHGEN
Heart Valves: Development from GLH…………......………………….GLHValve
Otolaryngology………………………………..…….…..…………….……GLHENT
Paediatric and Congenital Cardiac………….….………..…..………….GLHPCC
Pathology………………………..…………..……………………………GLHPATH
Physiology…………………………………………..…..………………..GLHPHYS
Politics, History and Health Economics (Includes the Harris/
Neutze/Merry/White advocacy letters……………..………………GLHPOL
Respiratory
Asthma……………………………………..……………………….GLHASTH
COPD……………………………………………...….……………GLHCOPD
Tuberculosis ………………………………..…….……..……………. GLHTb
Cystic fibrosis/bronchiectasis/
diffuse parenchymal disease………………………………GLHCYS
Lung Cancer/pleural/sleep……………..…..………………GLHCAN/PL/SL
General …………………………………………………………...GLHRESPg
Rheumatic Heart Disease (adult and paediatric)……….…………….. GLHRHD
Book chapters and internet publications are indexed with Journals
121